<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2025.1520482</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Active ingredients of traditional Chinese medicine inhibit NOD-like receptor protein 3 inflammasome: a novel strategy for preventing and treating heart failure</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lin</surname>
<given-names>Ruifang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yu</surname>
<given-names>Yunfeng</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1823978"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Du</surname>
<given-names>Lixin</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2924388"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ding</surname>
<given-names>Zehui</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Ziyan</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2012726"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes" corresp="yes">
<name>
<surname>Wei</surname>
<given-names>Jiaming</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2797922"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes" corresp="yes">
<name>
<surname>Guo</surname>
<given-names>Zhihua</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2882298"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>College of Chinese Medicine, Hunan University of Chinese Medicine</institution>, <addr-line>Changsha, Hunan</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Hunan Key Laboratory of Colleges and Universities of Intelligent TCM Diagnosis and Preventive Treatment of Chronic Diseases, Hunan University of Chinese Medicine</institution>, <addr-line>Changsha</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>First Clinical College of Chinese Medicine, Hunan University of Chinese Medicine</institution>, <addr-line>Changsha, Hunan</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>College of Pharmacy, Hunan University of Chinese Medicine</institution>, <addr-line>Changsha, Hunan</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Xing Zhang, National University of Singapore, Singapore</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Youhua Wang, Shanghai University of Traditional Chinese Medicine, China</p>
<p>Xing Luo, Harbin Medical University, China</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Jiaming Wei, <email xlink:href="mailto:004916@hnucm.edu.cn">004916@hnucm.edu.cn</email>; Zhihua Guo, <email xlink:href="mailto:004294@hnucm.edu.cn">004294@hnucm.edu.cn</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>24</day>
<month>01</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>16</volume>
<elocation-id>1520482</elocation-id>
<history>
<date date-type="received">
<day>31</day>
<month>10</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>06</day>
<month>01</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Lin, Yu, Du, Ding, Wang, Wei and Guo</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Lin, Yu, Du, Ding, Wang, Wei and Guo</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Heart failure (HF) has emerged as a significant global public health challenge owing to its high rates of morbidity and mortality. Activation of the NOD-like receptor protein 3 (NLRP3) inflammasome is regarded as a pivotal factor in the onset and progression of HF. Therefore, inhibiting the activation of the NLRP3 inflammasome may represent a promising therapeutic approach for preventing and treating HF. The active ingredients serve as the foundation for the therapeutic effects of traditional Chinese medicine (TCM). Recent research has revealed significant advantages of TCM active ingredients in inhibiting the activation of the NLRP3 inflammasome and enhancing cardiac structure and function in HF. The study aimed to explore the impact of NLRP3 inflammasome activation on the onset and progression of HF, and to review the current advancements in utilizing TCM active ingredients to inhibit the NLRP3 inflammasome for preventing and treating HF. This provides a novel perspective for the future development of precise intervention strategies targeting the NLRP3 inflammasome to prevent and treat HF.</p>
</abstract>
<abstract abstract-type="graphical" id="abs001">
<title>Graphical Abstract</title>
<p>
<graphic xlink:href="fimmu-16-1520482-g004.tif" position="anchor"/>
</p>
</abstract>
<kwd-group>
<kwd>NLRP3</kwd>
<kwd>inflammasome</kwd>
<kwd>heart failure</kwd>
<kwd>active ingredient</kwd>
<kwd>traditional Chinese medicine</kwd>
</kwd-group>
<contract-num rid="cn001">82174343, 82405372</contract-num>
<contract-sponsor id="cn001">National Natural Science Foundation of China<named-content content-type="fundref-id">10.13039/501100001809</named-content>
</contract-sponsor>
<counts>
<fig-count count="3"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="188"/>
<page-count count="28"/>
<word-count count="11583"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Inflammation</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Heart failure (HF) is the terminal stage of the progression of diverse functional or organic cardiovascular diseases, characterized by impaired ventricular filling and ejection capacity, with prevalent risk factors including hypertension, myocardial infarction, and myocardial disease (<xref ref-type="bibr" rid="B1">1</xref>). Epidemiological studies have indicated a global total of &gt; 64 million patients with HF, with a prevailing trend toward a younger age of onset (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>). HF has emerged as a significant public health issue, posing risks to human health and escalating societal burden (<xref ref-type="bibr" rid="B2">2</xref>). Currently, the standard pharmacological interventions for HF management include angiotensin receptor-neprilysin inhibitors, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, sodium-glucose co-transporter 2 inhibitors, beta blockers, aldosterone receptor antagonists, and diuretics (<xref ref-type="bibr" rid="B4">4</xref>). Although they ameliorate HF to a certain extent, uncertainties persist concerning their long-term effects, and the potential adverse events associated with long-term medication are concerning. Therefore, there is an urgent need to develop safe and effective therapeutic strategies. HF is a clinical syndrome encompassing a range of complex pathological processes, including myocardial inflammation, myocardial fibrosis, myocardial hypertrophy, impaired angiogenesis, abnormal cardiac electrical signal conduction, energy metabolism disorders, and abnormal cardiomyocyte apoptosis (<xref ref-type="bibr" rid="B5">5</xref>&#x2013;<xref ref-type="bibr" rid="B9">9</xref>). The activation of the NOD-like receptor protein 3 (NLRP3) inflammasome plays a crucial role in driving these pathological changes (<xref ref-type="bibr" rid="B5">5</xref>&#x2013;<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B10">10</xref>). As an intracellular multiprotein complex, persistent or excessive activation of the NLRP3 inflammasome serves as a critical driver of both the onset and progression of HF, with the extent of its activation being strongly correlated with disease severity and patient prognosis (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>). Therefore, inhibiting the activation of the NLRP3 inflammasome holds promise as a novel breakthrough in the prevention and treatment of HF.</p>
<p>Traditional Chinese medicine (TCM) has been recognized as a promising therapeutic strategy for HF, owing to its ability to effectively reverse adverse cardiac remodeling, lower rehospitalization and mortality rates, and enhance the quality of life of patients (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>). The active ingredients of TCM are the material basis for its therapeutic effects and constitute the focal point of research on TCM. Relevant studies have indicated that the active ingredients of TCM can mitigate the onset and progression of HF by inhibiting the NLRP3 inflammasome (<xref ref-type="bibr" rid="B15">15</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>). Thus, this study summarizes the role of NLRP3 inflammasome activation in the onset and progression of HF, as well as the current research on the use of TCM active ingredients to prevent and treat HF through targeted inhibition of the NLRP3 inflammasome, aiming to provide insights for future basic research and novel drug development.</p>
</sec>
<sec id="s2">
<label>2</label>
<title>NLRP3 inflammasome</title>
<sec id="s2_1">
<label>2.1</label>
<title>Structure of the NLRP3 inflammasome</title>
<p>The innate immune system is the first line of defense in the human body. Innate immune cells activate inflammasome by recognizing pathogen-associated molecular patterns and damage-associated molecular patterns via pattern recognition receptors, subsequently initiating inflammatory responses (<xref ref-type="bibr" rid="B12">12</xref>). The NLRP3 inflammasome is the most widely and intensively studied inflammasome and is a multiprotein complex comprising the NLRP3 protein, apoptosis speck-like protein containing a caspase recruitment domain (ASC), and caspase-1 precursor (pro-caspase-1) (<xref ref-type="bibr" rid="B12">12</xref>) (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>). NLRP3 acts as a sensor and consists of a central NACHT domain, a leucine-rich repeat (LRR) domain at the carboxyl-terminal (C-terminal), and a pyrin domain (PYD) at the amino-terminal (N-terminal). The NACHT domain primarily facilitates NLRP3 protein oligomerization and contains an adenosine triphosphatase active site, enabling the regulation of NLRP3 protein activity through adenosine triphosphate (ATP) hydrolysis (<xref ref-type="bibr" rid="B18">18</xref>). The LRR domain mediates protein&#x2013;protein interactions and plays a crucial role in NLRP3 inflammatory signaling by recognizing and interacting with both exogenous and endogenous molecules (<xref ref-type="bibr" rid="B19">19</xref>). PYD recruits downstream effector signaling molecules that trigger inflammasome assembly (<xref ref-type="bibr" rid="B20">20</xref>). ASC functions as an adaptor with two domains: the N-terminal PYD and the C-terminal caspase activation and recruitment domain (CARD) (<xref ref-type="bibr" rid="B21">21</xref>). The PYD of ASC corresponds to the homotypic PYD of NLRP3 proteins, which mediates the interaction between ASC and NLRP3 proteins (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>). The CARD of ASC is responsible for binding pro-caspase-1 (<xref ref-type="bibr" rid="B21">21</xref>). Pro-caspase-1 functions as an effector and comprises three domains: the N-terminal CARD, central large catalytic subunit domain p20, and C-terminal small catalytic subunit domain p10 (<xref ref-type="bibr" rid="B22">22</xref>). The CARD of pro-caspase-1 is responsible for interactions with the CARD of ASC (<xref ref-type="bibr" rid="B22">22</xref>). Subsequently, p20 and p10 facilitate the cleavage of the interleukin-1&#x3b2; precursor (pro-IL-1&#x3b2;) and interleukin-18 precursor (pro-IL-18) into mature forms of IL-1&#x3b2; and IL-18.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Structure of the NLRP3 inflammasome.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1520482-g001.tif"/>
</fig>
<p>When an organism encounters an external stimulus, NLRP3 interacts with the PYD of ASC via its PYD. The CARD of ASC recruits and binds to the CARD of pro-caspase-1, triggering self-cleavage of pro-caspase-1 to yield active caspase-1. Caspase-1 cleaves pro-IL-1&#x3b2; and pro-IL-18 to generate mature IL-1&#x3b2; and IL-18, thus initiating an inflammatory response (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>).</p>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>Mechanism of NLRP3 inflammasome activation</title>
<p>Three distinct pathways exist for NLRP3 inflammasome activation: canonical NLRP3, non-canonical NLRP3, and alternative NLRP3 inflammasome activation (<xref ref-type="bibr" rid="B23">23</xref>) (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>).</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Three pathways and related mechanisms of NLRP3 inflammasome activation.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1520482-g002.tif"/>
</fig>
<sec id="s2_2_1">
<label>2.2.1</label>
<title>Canonical NLRP3 inflammasome activation</title>
<p>Canonical activation of the NLRP3 inflammasome involves two distinct processes: priming and activation (<xref ref-type="bibr" rid="B24">24</xref>). The priming phase involves transcriptional regulation and posttranslational modifications of NLRP3. Recognition of pathogen-associated molecular patterns or damage-associated molecular patterns by the corresponding pattern recognition receptors (<xref ref-type="bibr" rid="B25">25</xref>&#x2013;<xref ref-type="bibr" rid="B27">27</xref>) triggers nuclear factor-&#x3ba;B (NF-&#x3ba;B) translocation and transcription, leading to increased expression of NLRP3, pro-IL-1&#x3b2;, and pro-IL-18 within the nucleus. Furthermore, priming signals trigger posttranslational modifications of NLRP3, including phosphorylation (<xref ref-type="bibr" rid="B28">28</xref>), ubiquitination (<xref ref-type="bibr" rid="B29">29</xref>), alkylation (<xref ref-type="bibr" rid="B30">30</xref>), S-nitrosylation (<xref ref-type="bibr" rid="B31">31</xref>), acetylation (<xref ref-type="bibr" rid="B32">32</xref>), and sumoylation (<xref ref-type="bibr" rid="B33">33</xref>), all of which are crucial for modulating the activation or inhibition of NLRP3. During the activation phase, NLRP3 responds to activating stimuli, subsequently initiating the assembly of the NLRP3 inflammasome, activation of caspase-1, and processing pro-IL-1&#x3b2; and pro-IL-18. This process ultimately produces proinflammatory cytokines IL-1&#x3b2; and IL-18, which are subsequently secreted into the extracellular space to trigger an inflammatory response.</p>
<p>Previous studies agree that the stimulus signals for NLRP3 inflammasome activation include potassium ion (K<sup>+</sup>) efflux (<xref ref-type="bibr" rid="B34">34</xref>), chloride ion (Cl<sup>-</sup>) efflux (<xref ref-type="bibr" rid="B35">35</xref>), mitochondrial dysfunction (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>), endoplasmic reticulum stress (<xref ref-type="bibr" rid="B38">38</xref>), trans-Golgi network catabolism (<xref ref-type="bibr" rid="B39">39</xref>), and the release of tissue protease B from damaged lysosomes (<xref ref-type="bibr" rid="B40">40</xref>). Remarkably, the interplay between some of these stimuli complicates the activation phase of NLRP3 (<xref ref-type="bibr" rid="B41">41</xref>).</p>
</sec>
<sec id="s2_2_2">
<label>2.2.2</label>
<title>Non-canonical NLRP3 inflammasome activation</title>
<p>Non-canonical activation of the NLRP3 inflammasome primarily relies on the mediation of human caspase-4/5 or mouse caspase-11. CARDs of caspase-4/5/11 directly recognize lipopolysaccharides (LPS) from gram-negative bacteria, prompting their oligomerization of caspase-4/5/11 (<xref ref-type="bibr" rid="B42">42</xref>&#x2013;<xref ref-type="bibr" rid="B44">44</xref>). This leads to the cleavage of GSDMD into its active form, GSDMD-NT, which in turn induces pyroptosis by creating pores in the cytoplasmic membrane (<xref ref-type="bibr" rid="B42">42</xref>&#x2013;<xref ref-type="bibr" rid="B44">44</xref>). Notably, while inducing pyroptosis, caspase-4/5/11 do not directly cleave pro-IL-1&#x3b2; (<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B46">46</xref>). They are required to indirectly promote the cleavage of pro-IL-1&#x3b2; and the release of IL-1&#x3b2; through NLRP3-dependent activation of caspase-1 (<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B46">46</xref>). Research has revealed that caspase-4/5/11 can trigger the release of mitochondrial reactive oxygen species (mtROS) and mitochondrial DNA (mtDNA) by enhancing the pore-forming capability of GSDMD in the mitochondria, thereby contributing to the activation of the NLRP3 inflammasome (<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B48">48</xref>). The orphan receptor Nur77 is activated upon binding to LPS and mtDNA (<xref ref-type="bibr" rid="B48">48</xref>). Subsequently, Nur77 interacts with NLRP3, triggering activation of the NLRP3 inflammasome (<xref ref-type="bibr" rid="B48">48</xref>). After LPS stimulation, caspase-4/5/11 trigger intracellular K<sup>+</sup> efflux, one of the pathways by which caspase-4/5/11 mediates NLRP3 inflammasome activation (<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B49">49</xref>). Furthermore, the activated caspase-11 triggers the cleavage of pannexin-1 channels, leading to the release of ATP into the extracellular environment (<xref ref-type="bibr" rid="B50">50</xref>). Subsequently, the P2X7 receptor (P2X7R) responds to extracellular ATP, triggering the assembly of NLRP3 inflammasome and the release of IL-1&#x3b2; (<xref ref-type="bibr" rid="B50">50</xref>). The scaffold structural domain of pro-caspase-11 facilitates the activation of NLRP3 through interaction with the LRRs&#xa0;and PYD of NLRP3 (<xref ref-type="bibr" rid="B51">51</xref>). Intriguingly, this activation is mediated by the co-induction of live gram-negative bacterial mRNA and LPS (<xref ref-type="bibr" rid="B51">51</xref>). In addition to LPS, oxidized phospholipids (oxPAPC) serve as endogenous ligands for caspase-11 (<xref ref-type="bibr" rid="B52">52</xref>). It induces the oligomerization of caspase-11 by binding to its catalytic domain in dendritic cells, thereby promoting the assembly of the NLRP3 inflammasome and inflammation (<xref ref-type="bibr" rid="B52">52</xref>). Nevertheless, indications suggest that oxPAPC exerts an anti-inflammatory effect as it can diminish the non-canonical activation of the macrophage NLRP3 inflammasome and dampen the inflammatory response through competitive binding of LPS to caspase-4 and caspase-11 (<xref ref-type="bibr" rid="B53">53</xref>). Consequently, further investigations are warranted to explore the potential divergent effects of oxPAPCs on non-canonical NLRP3 inflammasome activation across different cell types.</p>
</sec>
<sec id="s2_2_3">
<label>2.2.3</label>
<title>Alternative NLRP3 inflammasome activation</title>
<p>In contrast to the previously mentioned activation pathways, the alternative activation pathway requires only one step to activate the NLRP3 inflammasome and lacks the features of canonical and non-canonical NLRP3 inflammasome activation, such as K<sup>+</sup> efflux, pyroptosis, or pyroptosome formation (<xref ref-type="bibr" rid="B54">54</xref>). This activation pathway exhibits species specificity and has been identified exclusively in human and porcine monocytes (<xref ref-type="bibr" rid="B54">54</xref>). Research revealed that toll-like receptor (TLR) 4 in human monocytes triggered the NLRP3 inflammasome through the TRIF/RIPK1/FADD/caspase-8 signaling pathway upon stimulation by LPS, eliminating the need for a secondary signal for mediation (<xref ref-type="bibr" rid="B54">54</xref>). Tumor necrosis factor-&#x3b1; (TNF-&#x3b1;), a closely associated cytokine in psoriasis, selectively induces the initiation of the NLRP3 inflammasome through the TNFR/caspase-8 pathway even without an initial signal (<xref ref-type="bibr" rid="B55">55</xref>). Apolipoprotein C3 (ApoC3), an endogenous mediator, selectively triggers activation of the NLRP3 inflammasome in human monocytes (<xref ref-type="bibr" rid="B56">56</xref>). This process involves the formation of heterodimers between TLR2 and TLR4, initiating a pathway dependent on SCIMP/Lyn/Syk for calcium influx and ROS production, leading to caspase-8 activation and ultimately triggering activation of the NLRP3 inflammasome (<xref ref-type="bibr" rid="B56">56</xref>).</p>
</sec>
</sec>
</sec>
<sec id="s3">
<label>3</label>
<title>Role of NLRP3 inflammasome activation in the onset and progression of HF</title>
<p>Upon systematically reviewing studies on NLRP3 inflammasome activation in HF, we discovered that its activation promotes the onset&#xa0;and progression of HF by exacerbating multiple crucial pathophysiological processes. These pathological changes include myocardial inflammatory injury, adverse myocardial fibrosis, pathological myocardial hypertrophy, inhibited angiogenesis, abnormal cardiac electrical signal conduction, disturbed cardiac energy metabolism, and abnormal cardiomyocyte apoptosis (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>). Among these processes, myocardial inflammatory injury stands as a central nexus, where chronic inflammation not only directly harms the myocardium but also has the potential to initiate a cascade of events that worsen other pathological alterations in HF. Notably, the activation of the NLRP3 inflammasome involves the modulation of multiple signaling pathways, which are pivotal in mediating the aforementioned pathological processes (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Role of NLRP3 inflammasome activation in the onset and progression of HF.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" rowspan="2" align="left">Effects</th>
<th valign="middle" rowspan="2" align="left">Targets or related signal pathways</th>
<th valign="top" colspan="2" align="center">Models</th>
<th valign="middle" rowspan="2" align="center">References</th>
</tr>
<tr>
<th valign="top" align="center">
<italic>In vivo</italic>
</th>
<th valign="top" align="center">
<italic>In vitro</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" rowspan="20" align="left" style="background-color:#ffffff">Exacerbate myocardial inflammatory injury</td>
<td valign="top" align="left" style="background-color:#ffffff">mTOR&#x2191;, NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>Lipid emulsion and LADCA ligation-induced HF model</td>
<td valign="top" align="left" style="background-color:#ffffff">a. CD4<sup>+</sup> T cells<break/>PMA/Ionomycin Mixture and IL-2-induced cell inflammation model<break/>b. THP-1 macrophages<break/>LPS and ATP-induced cell inflammation model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B59">59</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Hsp90, SGT1&#x2191;, Drp1&#x2191;, NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male Wistar rats<break/>LCA ligation-induced HF model</td>
<td valign="top" align="left" style="background-color:#ffffff">NRVMs<break/>LPS and nigericin/ATP-induced cell inflammation model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B60">60</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">P2X7R/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male CD1 mice<break/>LCA ligation-induced AMI model</td>
<td valign="top" align="left" style="background-color:#ffffff">HL-1 cells<break/>LPS and nigericin/ATP-induced cell inflammation model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B61">61</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">TLR4/MyD88/NF-&#x3ba;B/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LADCA ligation-induced MI model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B62">62</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male CD-1 mice<break/>LCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B63">63</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">MicroRNA-148a&#x2193;, TXNIP/TLR4/NF-&#x3ba;B/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">SD rats<break/>LADCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">NRCMs<break/>H/R-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B64">64</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">AMPK&#x2193;, NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>Langendorff perfusion-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">NRVMs<break/>H/R-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B65">65</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">SIRT1&#x2193;, Akt/PDH/ROS/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">C57BL/6J WT, SIRT1-KO and PDH E1&#x3b1;-KO mice<break/>LADCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B66">66</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">MARCH2&#x2193;, PGAM5/MAVS/NLRP3 &#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6J WT and MARCH2-KO mice<break/>LADCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">HL-1cells and NMCMs<break/>H/R-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B67">67</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">TAOK1&#x2193;, YAP&#x2193;, TEAD&#x2193;, NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">SD rats<break/>DOX intraperitoneal injection-induced HF model</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells<break/>IL-17-induced cell inflammation model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B69">69</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6J mice<break/>DOX intraperitoneal injection-induced HF model</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells<break/>DOX-induced cell toxicity model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B68">68</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">FTO&#x2193;, TLR4/NF-&#x3ba;B/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Serum samples from healthy volunteers and HF patients</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells<break/>DOX-induced cell toxicity model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B71">71</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">TLR4/MyD88/NF-&#x3ba;B/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Blood samples from healthy volunteers, atrial fibrillation patients and HF patients</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B70">70</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">NOX1&#x2191;, NOX4&#x2191;, Drp1&#x2191;, NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Female and male C57BL/6J WT, NLRP3-KO, and caspase-1-KO mice<break/>DOX intraperitoneal injection-induced DCM model</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells and NRVCs<break/>DOX-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B72">72</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">a. Male C57Bl/6 mice<break/>TAC-induced HF model<break/>b. Male Dahl salt-sensitive rats<break/>High-salt diet-induced HF model</td>
<td valign="top" align="left" style="background-color:#ffffff">Human cardiomyocytes and murine macrophages<break/>LPS-induced cell inflammation model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B74">74</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">CaMKII&#x3b4;/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Female and male CaMKII&#x3b4; floxed and CaMKII&#x3b4;-KO mice<break/>TAC-induced cardiac pressure overload model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B75">75</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">CaMKII&#x3b4;/NF-&#x3ba;B/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male CaMKII&#x3b4; floxed, CaMKII&#x3b4; -KO and NLRP3-KO mice<break/>Ang II intraperitoneal injection-induced hypertension model</td>
<td valign="top" align="left" style="background-color:#ffffff">AMVMs and NRVMs<break/>Ang II-induced cell hypertension model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B76">76</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">a. Male SD rats<break/>Monocrotaline subcutaneous injection induced-PAH models<break/>b. Male SD rats<break/>Sugen-5416 ubcutaneous injection combined with H/R induced-PAH models<break/>c. Male SD rats<break/>Pulmonary artery banding induced-HF models<break/>d. RV tissue from healthy volunteers and HF patients</td>
<td valign="top" align="left" style="background-color:#ffffff">NRCMs and peripheral blood mononuclear cells (from rats treated with Monocrotaline) co-cultivation</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B78">78</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">SD rats<break/>a. Monocrotaline intraperitoneal injection induced-PAH model<break/>b. LPS intraperitoneal injection induced-acute right ventricular failure model</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells and BMDMs<break/>LPS-induced cell inflammation model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B79">79</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">IL-30&#x2193;, NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6 WT and IL-30-KO mice<break/>Cecum ligation and puncture induced-myocardial dysfunction model</td>
<td valign="top" align="left" style="background-color:#ffffff">BMDMs<break/>LPS-induced cell inflammation model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B77">77</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="14" align="left" style="background-color:#ffffff">Aggravate adverse myocardial fibrosis</td>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6 mice<break/>LCA ligation-induced myocardial infarction model</td>
<td valign="top" align="left" style="background-color:#ffffff">CFs<break/>Hypoxia-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B86">86</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">TLR4/MyD88/NF-&#x3ba;B/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6J mice<break/>LADCA ligation-induced MI model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B87">87</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">CaSR&#x2191;, Beclin-1&#x2191;, LC3-II/I&#x2191;, NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male Wistar rats<break/>LADCA ligation-induced MI model</td>
<td valign="top" align="left" style="background-color:#ffffff">Peritoneal macrophages (from MI model rats)</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B88">88</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">NF-&#x3ba;B&#x2191;, NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male Dahl salt-sensitive rats<break/>High-salt diet-induced HF model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B89">89</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">NF-&#x3ba;B/NLRP3 &#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6J mice<break/>Aortic banding-induced cardiac pressure overload model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B90">90</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">SGK1/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male B6/129S mice<break/>Ang II subcutaneous permeabilization-induced hypertension model</td>
<td valign="top" align="left" style="background-color:#ffffff">BMDMs and MCFs<break/>LPS and Ang II-induced cell inflammation model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B85">85</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">IMD<sub>1-53</sub>/cAMP/PKA&#x2193;, IRE1&#x3b1;/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>Ang II subcutaneous injection-induced myocardial fibrosis model</td>
<td valign="top" align="left" style="background-color:#ffffff">NRCFs<break/>Ang II-simulated fibrosis model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B91">91</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">CTRP3&#x2193;, P2X7R/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male WKY rats and SHRs<break/>Hypertension model</td>
<td valign="top" align="left" style="background-color:#ffffff">NRCFs<break/>Ang II-simulated fibrosis model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B92">92</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Lp-PLA2/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6J mice<break/>Ang II subcutaneous permeabilization-induced hypertension model</td>
<td valign="top" align="left" style="background-color:#ffffff">BMDMs and RCFs<break/>LPS and Ang II-induced cell inflammation model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B84">84</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Female C57BL6/J mice<break/>High-fat diet and Ang II-induced HF model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B93">93</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3/TGF-&#x3b2;/Smad4&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6J mice<break/>TAC-induced pathological cardiac remodeling</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B94">94</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">AGTR1/NLRP3/TGF-&#x3b2;1&#x2191;, AQP1&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LADCA ligation-induced HF model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B95">95</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">nNOS&#x2193;, TLR4/NLRP3&#x2191;, TGF-&#x3b2;1/IL-1&#x3b2;&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male 129sv mice<break/>ISO subcutaneous injection-induced left ventricular fibrosis model</td>
<td valign="top" align="left" style="background-color:#ffffff">HCFs<break/>LPS and ATP-induced cell inflammation model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B96">96</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3/ROS/TGF-&#x3b2;/R-Smad&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL6 WT, NLRP3-KO, ASC-KO, and caspase-1-KO mice<break/>Ang II subcutaneous permeabilization -induced cardiac fibrosis model</td>
<td valign="top" align="left" style="background-color:#ffffff">a. CFs<break/>AngII or TGF-&#x3b2;-simulated fibrosis model<break/>b. Peritoneal macrophages<break/>LPS and ATP-induced cell inflammation model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B97">97</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="8" align="left" style="background-color:#ffffff">Intensify pathological myocardial hypertrophy</td>
<td valign="top" align="left" style="background-color:#ffffff">Trim31&#x2193;, NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male and female C57BL/6N WT, Trim31 floxed and Trim31-KO mice<break/>ISO subcutaneous injection-induced HF model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B99">99</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">GRK2&#x2191;, Nrf2&#x2193;, NLRP3&#x2191;, OS&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells<break/>ISO-induced cell hypertrophy model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B102">102</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">RAGE/NF-&#x3ba;B/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells<break/>Ang II-induced cell hypertrophy model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B103">103</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">PRMT5&#x2193;, E2F-1/NF-&#x3ba;B/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>TAC-induced cardiac hypertrophy model</td>
<td valign="top" align="left" style="background-color:#ffffff">AC16 cells and HCMs<break/>Ang II-induced cell hypertrophy model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B104">104</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Sema4D/MAPK/NF-&#x3ba;B/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6 mice<break/>TAC-induced cardiac hypertrophy model</td>
<td valign="top" align="left" style="background-color:#ffffff">NRCMs<break/>Ang II-induced cell hypertrophy model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B105">105</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2191;, Calcineurin&#x2191;, MAPK&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6J mice<break/>TAC-induced pathological cardiac remodeling model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B94">94</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">ROS/NLRP3/caspase-1&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male F344 rats<break/>SiNPs intratracheal instillation-induced pathological cardiac hypertrophy model</td>
<td valign="top" align="left" style="background-color:#ffffff">CMs and AC16 Cells<break/>SiNPs-simulated hypertrophy model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B106">106</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">SNO-MLP/TLR3/RIP3/NF-&#x3ba;B/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">a. Male SHRs, WKY rats, C57BL/6 WT mice<break/>TAC coarctation-induced pathological cardiac remodeling model<break/>b. Myocardial samples from patients undergoing heart valve replacement surgery</td>
<td valign="top" align="left" style="background-color:#ffffff">NRCMs<break/>Ang II or phenylephrine-induced cell hypertrophy model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B107">107</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="2" align="left" style="background-color:#ffffff">Inhibite angiogenesis</td>
<td valign="top" align="left" style="background-color:#ffffff">ROS/TXNIP/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6 mice<break/>LADCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">NMCMs and CMECs<break/>Hypoxia/hypoglycemic and normoxia/normal-glucose-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B10">10</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">MicroRNA-495&#x2193;, NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6 mice<break/>LADCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">CMECs (from MI/R mice)</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B111">111</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="10" align="left" style="background-color:#ffffff">Disturb cardiac electrical signal conduction</td>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">a. Blood and left and right ventricular myocardial tissue samples from healthy volunteers and HF patients<break/>b. Male Dsg2 gene mutation and WT mice<break/>Knockout of the Dsg2 Gene in Cardiomyocytes-induced arrhythmogenic right ventricular cardiomyopathy model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B6">6</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6 mice<break/>TAC-induced HF model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B115">115</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">WT and MD1-KO mice<break/>Uninephrectomy combined with d-aldosterone perfusion and high-salt diet-induced HF model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B117">117</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">P2X7R/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LADCA ligation-induced HF model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B118">118</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">SOX2-OT/microRNA-2355-3p/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SPF SD rats<break/>Aortic coarctation and constant current stimulation of left carotid sympathetic nerve node-induced HF-VA model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B116">116</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2191;, CaMKII&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male Dahl salt-sensitive rats<break/>High-salt diet-induced HF model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B119">119</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">P2X7R/NLRP3/IL-1&#x3b2;&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LCA ligation-induced AMI model</td>
<td valign="top" align="left" style="background-color:#ffffff">Macrophages<break/>a. LPS and IFN&#x2010;&#x3b3;-induced M1 macrophage polarization model<break/>b. IL-4-induced M2 macrophage polarization model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B120">120</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Camk2n1&#x2193;, CaMKII&#x3b4;/p38 MAPK/JNK/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male WT and Camk2n1-KO mice<break/>LADCA ligation-induced MI model</td>
<td valign="top" align="left" style="background-color:#ffffff">MCFs and NMVMs<break/>Hypoxia-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B121">121</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3/IL-1&#x3b2;/p38 MAPK&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LADCA ligation-induced MI model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B123">123</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3/caspase-1/IL-1&#x3b2;/p38&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LADCA ligation-induced MI model</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells<break/>Hypoxia-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B122">122</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="4" align="left" style="background-color:#ffffff">Disturb cardiac energy metabolism</td>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2191;, CD36&#x2193;, CPT1&#x3b2;&#x2193;, GLUT4&#x2193;, p-PDH&#x2191;, AKT&#x2191;, AMPK&#x3b1;&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6J mice<break/>High-fat diet and TAC-induced HF model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B7">7</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2191;, RISK&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">Isolated hearts (from male Wistar rats)<break/>Langendorff perfusion-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B127">127</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6J WT and NLRP3-KO mice<break/>Ang II osmotic minipump-induced cardiomyopathy model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B125">125</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">ROS/NF-kB/TXNIP/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">SD rats<break/>High-fat diet and streptozotocin intraperitoneal injection-induced diabetic cardiomyopathy model</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells<break/>High glucose-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B126">126</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="6" align="left" style="background-color:#ffffff">Exacerbate cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">MicroRNA-30a-5p&#x2191;, SIRT1&#x2193;, NF-&#x3ba;B/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>Aortic coarctation-induced HF model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B8">8</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">CaSR/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">a. Blood samples from healthy volunteers and AMI patients<break/>b. Male Wistar rats<break/>Coronary artery ligation-induced AMI model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B132">132</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">ZNF561-AS1/microRNA-223-3p/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male Kunming mice<break/>MI model</td>
<td valign="top" align="left" style="background-color:#ffffff">HCMs<break/>Hypoxic-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B133">133</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3/caspase-1&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LADCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells<break/>H/R-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B134">134</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">lncRNA HULC&#x2193;, microRNA-377-5p/NLRP3/caspase-1/IL-1&#x3b2;&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Neonatal SD rats<break/>LADCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells<break/>H/R-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B135">135</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">STING/IRF3/NLRP3&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57/B6 mice<break/>LPS intraperitoneal injectione-induced cardiomyopathy model</td>
<td valign="top" align="left" style="background-color:#ffffff">NRCMs and H9c2 cells<break/>LPS-induced cell inflammation model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B136">136</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>&#x2191; indicates activation; &#x2193; indicates inhibition.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Signaling pathways regulating NLRP3 inflammasome activation in HF: <bold>(A)</bold> Signaling pathway exacerbating myocardial inflammatory injury. <bold>(B)</bold> Signaling pathway aggravating adverse myocardial fibrosis. <bold>(C)</bold> Signaling pathway intensifying pathological myocardial hypertrophy. <bold>(D)</bold> Signaling pathway inhibiting angiogenesis. <bold>(E)</bold> Signaling pathway disturbing cardiac electrical signal conduction. <bold>(F)</bold> Signaling pathway disturbing cardiac energy metabolism. <bold>(G)</bold> Signaling pathway exacerbating cardiomyocyte apoptosis. &#x2191; indicates activation; &#x2193; indicates inhibition.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1520482-g003.tif"/>
</fig>
<sec id="s3_1">
<label>3.1</label>
<title>Exacerbate myocardial inflammatory injury</title>
<p>An appropriate inflammatory response serves as a protective mechanism that eliminates harmful stimuli and repairs damaged tissues (<xref ref-type="bibr" rid="B57">57</xref>). However, excessive or prolonged inflammation escalates the risk of cardiac dysfunction and adverse cardiac remodeling (<xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B58">58</xref>).</p>
<p>In the cardiac tissues of HF rats, increased NLRP3-positive spots, caspase-1 shear activation, and elevated levels of mature IL-1&#x3b2; were accompanied by a heightened inflammatory response (<xref ref-type="bibr" rid="B59">59</xref>, <xref ref-type="bibr" rid="B60">60</xref>). These findings suggest that the NLRP3 inflammasome plays a contributory role in the development of myocardial inflammation in HF (<xref ref-type="bibr" rid="B59">59</xref>, <xref ref-type="bibr" rid="B60">60</xref>). During acute myocardial infarction (AMI), dying heart myocytes initiate the assembly of the NLRP3 inflammasome by activating P2X7R via ATP release (<xref ref-type="bibr" rid="B61">61</xref>). This process amplifies cardiac inflammation, leads to further loss of functional myocardium, and even results in HF (<xref ref-type="bibr" rid="B61">61</xref>). Following myocardial infarction (MI), myocardial injury triggers the activation of the NLRP3 inflammasome, which exacerbates the myocardial inflammatory response, leading to enlargement of the&#xa0;infarct and worsening of cardiac dysfunction (<xref ref-type="bibr" rid="B62">62</xref>). Nicorandil pretreatment decreased NLRP3 inflammasome activation by inhibiting the TLR4/myeloid differentiation primary response protein 88 (MyD88)/NF-&#x3ba;B pathway, thereby alleviating the detrimental effects of MI on the heart (<xref ref-type="bibr" rid="B62">62</xref>). Activation of the NLRP3 inflammasome plays a crucial role in promoting myocardial ischemia/reperfusion (MI/R) injury (<xref ref-type="bibr" rid="B63">63</xref>). MI/R injury results in decreased microRNA-148a expression in myocardial cells, which increases the expression of thioredoxin-interacting protein (TXNIP) (<xref ref-type="bibr" rid="B64">64</xref>). Subsequently, TXNIP activates the TLR4/NF-&#x3ba;B/NLRP3 signaling pathway, promoting the release of inflammatory factors IL-1&#x3b2; and IL-18, thereby increasing inflammatory cell death in myocardial cells, leading to more extensive myocardial damage and worsening of cardiac function (<xref ref-type="bibr" rid="B64">64</xref>). Furthermore, studies have revealed that signaling pathways including adenosine 5&#x2032;-monophosphate (AMP)-activated protein kinase (AMPK) (<xref ref-type="bibr" rid="B65">65</xref>), silent information regulator of transcription (SIRT) 1/serine/threonine protein kinase B (Akt)/pyruvate dehydrogenase (PDH)/ROS (<xref ref-type="bibr" rid="B66">66</xref>), and E3 ubiquitin ligase membrane-associated RING finger protein 2 (MARCH2)/phosphoglycerate mutase 5 (PGAM5)/mitochondrial anti-viral-signaling protein (MAVS) (<xref ref-type="bibr" rid="B67">67</xref>) contribute to the exacerbation of cardiac inflammatory injury by activating the NLRP3 inflammasome, thereby exacerbating adverse cardiac outcomes caused by MI/R.</p>
<p>Activation of the NLRP3 inflammasome is a pivotal factor contributing to increased inflammatory damage in the non-ischemic myocardium. Activation of the NLRP3 inflammasome led to increased cardiomyocyte pyroptosis and reduced proliferative capacity in the doxorubicin (DOX)-induced HF model, collectively exacerbating the pathogenic progression of HF (<xref ref-type="bibr" rid="B68">68</xref>, <xref ref-type="bibr" rid="B69">69</xref>). Mechanistically, activation of the TLR4/MyD88/NF-&#x3ba;B signaling pathway serves as an upstream event that triggers the activation of the NLRP3 inflammasome, thereby exacerbating cardiomyocyte pyroptosis and myocardial inflammation in DOX-induced HF (<xref ref-type="bibr" rid="B70">70</xref>, <xref ref-type="bibr" rid="B71">71</xref>). Myocardial tissues from patients with dilated cardiomyopathy (DCM) exhibit aberrant NLRP3 inflammasome activation and pronounced pyroptosis, which are correlated with diminished cardiac function (<xref ref-type="bibr" rid="B72">72</xref>). In a DOX-induced DCM mouse model, DOX triggered the hyperactivation of the NLRP3 inflammasome by upregulating NOX1 and NOX4 expression and activating dynamin-related protein 1 (Drp1)-dependent mitochondrial fragmentation (<xref ref-type="bibr" rid="B72">72</xref>). This process exacerbates cardiomyocyte pyroptosis and contributes to the progression of cardiac dysfunction (<xref ref-type="bibr" rid="B72">72</xref>). Macrophages play a pivotal role in the regulation of cardiac inflammation (<xref ref-type="bibr" rid="B73">73</xref>). In the HF state, the activation of the NLRP3 inflammasome in myocardial tissue promotes macrophage infiltration into the heart (<xref ref-type="bibr" rid="B74">74</xref>). Mechanistic study has demonstrated that cardiomyocytes activate NLRP3 through the calmodulin-regulated kinase &#x3b4; (CaMKII&#x3b4;) signaling pathway, promoting the release of pro-inflammatory cytokines IL-1&#x3b2;, IL-18, and IL-6, as well as the production of monocyte chemotactic protein-1 (MCP-1) and macrophage inflammatory protein 1&#x3b1; (<xref ref-type="bibr" rid="B75">75</xref>). These factors synergistically promote macrophage migration to myocardial tissue, thereby further amplifying cardiac inflammation (<xref ref-type="bibr" rid="B75">75</xref>). Furthermore, activation of myocardium-specific CaMKII&#x3b4; can also mediate the activation of the NLRP3 inflammasome through the NF-&#x3ba;B pathway, leading to increased macrophage recruitment to the damaged myocardium and exacerbating the cardiac inflammatory cascade (<xref ref-type="bibr" rid="B76">76</xref>). Interestingly, macrophages demonstrate two pro-inflammatory effects, pyroptosis and pro-inflammatory polarization, upon recruitment to the heart (<xref ref-type="bibr" rid="B77">77</xref>&#x2013;<xref ref-type="bibr" rid="B79">79</xref>). In pulmonary arterial hypertension (PAH)-induced right ventricular failure, there was a significant increase in the number of macrophages within the right ventricle, accompanied by an elevated expression of the NLRP3 inflammasome in these macrophages (<xref ref-type="bibr" rid="B78">78</xref>). The elevated expression of the NLRP3 inflammasome not only promoted macrophage pyroptosis, but also drove macrophages toward a pro-inflammatory M1-type phenotype (<xref ref-type="bibr" rid="B78">78</xref>). This shift exacerbated the inflammatory response in the right ventricle, contributing to further deterioration of right ventricular dysfunction (<xref ref-type="bibr" rid="B78">78</xref>). Additionally, cardiomyocyte NLRP3-dependent pyroptosis further stimulates macrophage polarization toward a pro-inflammatory M1 phenotype in myocardial tissues through the release of pro-inflammatory cytokines and MCP-1 (<xref ref-type="bibr" rid="B79">79</xref>). Similarly, in sepsis-induced cardiac inflammatory injury and dysfunction, macrophage pyroptosis in cardiac tissues, along with the polarization of Ly6Chigh macrophages, is positively regulated by NLRP3 complex activation (<xref ref-type="bibr" rid="B77">77</xref>). These studies confirm that activation of the NLRP3 inflammasome exacerbates the cardiac inflammatory cascade by promoting macrophage recruitment to the heart and stimulating macrophage pyroptosis and pro-inflammatory polarization.</p>
</sec>
<sec id="s3_2">
<label>3.2</label>
<title>Aggravate adverse myocardial fibrosis</title>
<p>Myocardial fibrosis is characterized by abnormal proliferation and differentiation of cardiac fibroblasts (CFs) and excessive accumulation and abnormal distribution of the extracellular matrix (ECM). Myocardial fibrosis is a critical reparative response aimed at maintaining cardiac integrity after myocardial injury (<xref ref-type="bibr" rid="B80">80</xref>). However, excessive myocardial fibrosis results in diminished myocardial compliance and cardiac diastolic and systolic dysfunction, serving as a pivotal pathological foundation for the onset and progression of HF (<xref ref-type="bibr" rid="B81">81</xref>, <xref ref-type="bibr" rid="B82">82</xref>).</p>
<p>Myofibroblasts play a crucial role as mediator cells in the progression of myocardial fibrosis (<xref ref-type="bibr" rid="B83">83</xref>). They induce cardiac fibrous scar formation and dysfunction by synthesizing significant quantities of ECM and collagen, secreting pro-fibrotic cytokines, and expressing &#x3b1;-smooth muscle actin (&#x3b1;-SMA) (<xref ref-type="bibr" rid="B83">83</xref>). IL-1&#x3b2; was identified as a key mediator in promoting the proliferation and differentiation of CFs into myofibroblasts, indicating that NLRP3 inflammasome activation is an important factor mediating the progression of myocardial fibrosis (<xref ref-type="bibr" rid="B84">84</xref>, <xref ref-type="bibr" rid="B85">85</xref>). MI leads to a notable upregulation in the expression of fibrotic markers in myocardial tissues, including collagen I, collagen III, and &#x3b1;-SMA (<xref ref-type="bibr" rid="B86">86</xref>). Importantly, the degree of NLRP3 inflammasome activation is positively correlated with the severity of myocardial fibrosis (<xref ref-type="bibr" rid="B86">86</xref>). Myocardial ischemia triggered the activation of the TLR4/MyD88/NF-&#x3ba;B signaling pathway, which facilitated the assembly and activation of the NLRP3 inflammasome, thereby exacerbating cardiac inflammation (<xref ref-type="bibr" rid="B87">87</xref>). The progression of inflammation enhances fibrosis, resulting in increased cardiac stiffness and reduced cardiac pumping function (<xref ref-type="bibr" rid="B87">87</xref>). The expression of calcium-sensitive receptor (CaSR) is elevated in myocardial tissue following MI (<xref ref-type="bibr" rid="B88">88</xref>). CaSR exacerbates both inflammation and fibrosis post-MI by activating the autophagy/NLRP3 inflammasome pathway (<xref ref-type="bibr" rid="B88">88</xref>).</p>
<p>In pressure overload-induced HF, the activation of the NLRP3 inflammasome was identified as a critical factor driving the progression of myocardial fibrosis (<xref ref-type="bibr" rid="B89">89</xref>). Mechanistically, chronic stress overload initiates the activation of the NF-&#x3ba;B/NLRP3 inflammasome pathway (<xref ref-type="bibr" rid="B90">90</xref>). This pathway amplifies the aberrant activation of cardiac fibroblasts and promotes the over-synthesis of collagen associated with fibrosis, thereby fueling the adverse progression of cardiac fibrosis (<xref ref-type="bibr" rid="B90">90</xref>). Administration of angiotensin II (Ang II) induced myocardial fibrosis in mice, as indicated by the excessive deposition of collagen fibers, elevated expression levels of transforming growth factor-&#x3b2; (TGF-&#x3b2;) and connective tissue growth factor, along with NLRP3 inflammasome activation in cardiac tissues and heightened IL-1&#x3b2; secretion (<xref ref-type="bibr" rid="B85">85</xref>). Notably, treatment with MCC950 successfully reversed these pathological alterations (<xref ref-type="bibr" rid="B85">85</xref>). Inositol-requiring enzyme 1&#x3b1; (IRE1&#x3b1;) acted as a sensor of endoplasmic reticulum stress, capable of triggering NLRP3 inflammasome activation, thereby exacerbating the progression of myocardial fibrosis (<xref ref-type="bibr" rid="B91">91</xref>). The endogenous cardiovascular protective peptide, intermedin<sub>1-53</sub> (IMD<sub>1-53</sub>), had the ability to reduce the expression of IRE1&#x3b1; through the activation of the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) pathway, leading to the inhibition of NLRP3 inflammasome activation and mitigation of Ang II-induced cardiac fibrosis (<xref ref-type="bibr" rid="B91">91</xref>). Reduced expression of C1q/TNF-related protein-3 (CTRP3) in myocardial tissue is linked to the advancement of cardiac fibrosis (<xref ref-type="bibr" rid="B92">92</xref>). The restoration of CTRP3 expression ameliorated Ang II-induced myocardial fibrosis by inhibiting the P2X7R/NLRP3 inflammasome pathway to reduce &#x3b1;-SMA, collagen I/III, and matrix metallopeptidase (MMP) 2/9 expression (<xref ref-type="bibr" rid="B92">92</xref>).</p>
<p>TGF-&#x3b2; is a central signaling pathway in the promotion of fibrosis. In HF, activation of the NLRP3 inflammasome is considered a significant factor in the upregulation of TGF-&#x3b2; gene expression in the cardiac tissue (<xref ref-type="bibr" rid="B93">93</xref>). Specifically, the activated NLRP3 inflammasome promotes the advancement of cardiac fibrosis by triggering the TGF-&#x3b2;/Smad4 signaling pathway to enhance the expression levels of collagen type I, collagen type III, MMP-2, MMP-9, and &#x3b1;-SMA (<xref ref-type="bibr" rid="B94">94</xref>). Further study has demonstrated that Ang II receptor type 1 (AGTR1) accelerates myocardial fibrosis progression by activating the NLRP3 inflammasome and enhancing the production of TGF-&#x3b2;1 (<xref ref-type="bibr" rid="B95">95</xref>). Concurrently, activation of the TLR4 receptor also triggers NLRP3 inflammasome activation, initiating a signaling cascade that enhances the pro-fibrotic effects of the TGF-&#x3b2;1/IL-1&#x3b2; axis, promotes cardiac myofibroblast differentiation, increases interstitial collagen deposition, and ultimately exacerbates fibrosis (<xref ref-type="bibr" rid="B96">96</xref>). Additionally, a study revealed the mitochondrial localization of NLRP3 in CFs and demonstrated that NLRP3 is involved in the development of cardiac fibrosis by enhancing mitochondrial ROS production, promoting activation of the TGF-&#x3b2;/R-Smad pathway, and facilitating CF differentiation (<xref ref-type="bibr" rid="B97">97</xref>).</p>
</sec>
<sec id="s3_3">
<label>3.3</label>
<title>Intensify pathological myocardial hypertrophy</title>
<p>Pathological myocardial hypertrophy is an adaptive response of the heart to prolonged pressure or increased volume overload. Nevertheless, as myocardial hypertrophy advances to a certain level, it can exert significant adverse effects on the cardiac structure and function, thereby increasing the risk of HF (<xref ref-type="bibr" rid="B98">98</xref>).</p>
<p>In the context of cardiac remodeling, the activation of the NLRP3 inflammasome promotes not only cardiac inflammation and fibrosis but also aggravates pathological myocardial hypertrophy, consequently exacerbating symptoms of HF (<xref ref-type="bibr" rid="B99">99</xref>). Elevated levels of G protein-coupled receptor kinase 2 (GRK2) were identified in hypertrophied myocardial tissue (<xref ref-type="bibr" rid="B100">100</xref>, <xref ref-type="bibr" rid="B101">101</xref>). Mechanistically, GRK2 promotes the activation of the NLRP3 inflammasome and induces oxidative stress (OS) by downregulating the expression of nuclear factor erythroid-2-related factor 2 (Nrf2), thereby exacerbating isoproterenol (ISO)-induced pathological cardiac hypertrophy (<xref ref-type="bibr" rid="B102">102</xref>). The receptor for advanced glycation endproducts (RAGE) participated in Ang II-induced pathological cardiomyocyte hypertrophy by activating the NF-&#x3ba;B/NLRP3/IL-1&#x3b2; pathway (<xref ref-type="bibr" rid="B103">103</xref>). Under pressure overload, there is a reduction in protein arginine methyltransferase 5 (PRMT5) expression in hypertrophic myocardial tissues. Low PRMT5 expression triggered the activation of the E2F-1/NF-&#x3ba;B signaling pathway, leading to the activation of the NLRP3 inflammasome that promotes maladaptive cardiac hypertrophy induced by transverse aortic constriction (TAC) or Ang II (<xref ref-type="bibr" rid="B104">104</xref>). The overexpression of Sema4D contributed to pressure overload-induced cardiac hypertrophy (<xref ref-type="bibr" rid="B105">105</xref>). It promotes the assembly and activation of NLRP3 complexes by activating the mitogen-activated protein kinase (MAPK)/NF-&#x3ba;B signaling pathway, thereby exacerbating TAC-induced pathological cardiac hypertrophy and dysfunction (<xref ref-type="bibr" rid="B105">105</xref>). Elevated levels of calcineurin and MAPK phosphorylation were observed in the TAC surgery group of pressure-overloaded mice (<xref ref-type="bibr" rid="B94">94</xref>). In contrast, MCC950 ameliorates pathological cardiac hypertrophy and enhances cardiac function by inhibiting calcineurin expression and the MAPK signaling pathway (<xref ref-type="bibr" rid="B94">94</xref>). Silica nanoparticles (SiNPs) contributed to the exacerbation of cardiac hypertrophy (<xref ref-type="bibr" rid="B106">106</xref>). SiNPs worsen myocardial hypertrophy by inducing cardiomyocyte pyroptosis via activation of the ROS/NLRP3/caspase-1 signaling pathway (<xref ref-type="bibr" rid="B106">106</xref>). Transfection of cardiomyocytes with si-NLRP3 or the caspase-1 inhibitor VX-765 limited SiNP-induced pathological cardiac hypertrophy (<xref ref-type="bibr" rid="B106">106</xref>). S-nitrosylated muscle LIM protein (SNO-MLP) expression is markedly elevated in patients and animals with myocardial hypertrophy (<xref ref-type="bibr" rid="B107">107</xref>). This upregulation primarily facilitated the interaction between TLR3 and receptor-interacting protein kinase&#xa0;3&#xa0;(RIP3), thus initiating activation of the NF-&#x3ba;B/NLRP3 inflammasome pathway, ultimately fostering the progression of myocardial hypertrophy (<xref ref-type="bibr" rid="B107">107</xref>).</p>
</sec>
<sec id="s3_4">
<label>3.4</label>
<title>Inhibite angiogenesis</title>
<p>Angiogenesis generates new blood vessels from existing capillaries or capillary post-veins. When the heart is exposed to ischemic and hypoxic stimuli, angiogenesis enhances its blood supply, thereby mitigating damage and preserving cardiac function resulting from ischemia and hypoxia (<xref ref-type="bibr" rid="B108">108</xref>, <xref ref-type="bibr" rid="B109">109</xref>). However, the progression of cardiac pathological remodeling inhibits angiogenesis, resulting in decreased microvascular density and ultimately leading to HF (<xref ref-type="bibr" rid="B109">109</xref>).</p>
<p>Coronary microvessel rarefaction and decreased blood flow reserve have been identified as the primary drivers of diastolic dysfunction in patients with HF with a preserved ejection fraction (HFpEF) (<xref ref-type="bibr" rid="B9">9</xref>). Moreover, decreased cardiac microvascular density is intricately linked to NLRP3 inflammasome activation (<xref ref-type="bibr" rid="B110">110</xref>). Phosphorylation of microfibrillar-associated protein 4 (MAP4) downregulates the expression of angiogenic markers, such as CD31, CD34, VEGFA, VEGFR2, ANG2, and TIE2 (<xref ref-type="bibr" rid="B110">110</xref>). Mechanistically, MAP4 inhibited angiogenesis via NLRP3 inflammasome activation, leading to reduced cardiac microvessel density (<xref ref-type="bibr" rid="B110">110</xref>). Endothelial cells (ECs) serve as primary effector cells in cardiac angiogenesis, and any damage to or aberrant apoptosis of these cells significantly affects their capacity for cardiac angiogenesis. During MI/R injury, microvascular endothelial cells (CMECs) mediated interactions between TXNIP and NLRP3 by generating excessive ROS (<xref ref-type="bibr" rid="B10">10</xref>). This action subsequently escalates the activation level of the NLRP3 inflammasome, exacerbating damage to cardiac microvascular endothelial cells (<xref ref-type="bibr" rid="B10">10</xref>). In ischemia-reperfused myocardial tissues, there was a reduction in microRNA-495 expression, which facilitates the activation of the NLRP3 inflammasome, worsening inflammatory damage and apoptosis in CMECs (<xref ref-type="bibr" rid="B111">111</xref>). Conversely, elevating the expression of microRNA-495 or suppressing the NLRP3 gene decreases apoptosis and enhances the proliferation of CMECs by shifting the cell population from the G0/G1 phase to the S phase (<xref ref-type="bibr" rid="B111">111</xref>). This observation implies that the suppression of NLRP3 inflammasome activation may facilitate the repair and angiogenesis of cardiac microvessels. SIRT3 deficiency resulted in&#xa0;diminished expression of hypoxia-inducible factor-2&#x3b1;, VEGF, and angiopoietin-1, leading to decreased angiogenesis and subsequently&#xa0;causing coronary microvessel rarefaction and cardiac diastolic dysfunction (<xref ref-type="bibr" rid="B112">112</xref>). Trimethylamine N-oxide (TMAO) induces vascular inflammation by suppressing SIRT3 expression and superoxide dismutase 2 (SOD2) activity in endothelial cells, subsequently triggering mtROS/NLRP3 inflammasome signaling (<xref ref-type="bibr" rid="B113">113</xref>). Therefore, SIRT3 deficiency may impede coronary microvascular angiogenesis by activating the NLRP3 inflammasome.</p>
</sec>
<sec id="s3_5">
<label>3.5</label>
<title>Disturb cardiac electrical signal conduction</title>
<p>Ventricular arrhythmias (VAs) are common triggers and causes of death in HF (<xref ref-type="bibr" rid="B114">114</xref>). The cardiac electrical conduction system is crucial for maintaining normal heart function, and conduction abnormalities are the underlying precursors of arrhythmias.</p>
<p>Numerous studies have established that the activation of the NLRP3 inflammasome is a key factor in disrupting the electrical signaling in the heart and inducing malignant arrhythmias, particularly in the context of HF (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B115">115</xref>&#x2013;<xref ref-type="bibr" rid="B119">119</xref>). The activation of the NLRP3 inflammasome not only enhances myocardial inflammatory responses but also promotes the development of cardiac hypertrophy and fibrosis, creating a pro-arrhythmic environment (<xref ref-type="bibr" rid="B115">115</xref>). Additionally, NLRP3 inflammasome activation results in changes to myocyte ion channel functions, including a reduced expression of ion channel proteins such as Kv4.2, KChIP2, and Cav1.2, which affect the timing and morphology of cardiac action potentials and contribute to the development and maintenance of arrhythmias (<xref ref-type="bibr" rid="B115">115</xref>). Simultaneously, sympathetic nervous hyperactivity contributes to an increased susceptibility to HF-related ventricular arrhythmias due to NLRP3 inflammasome activation (<xref ref-type="bibr" rid="B117">117</xref>, <xref ref-type="bibr" rid="B118">118</xref>). In particular, the activation of the NLRP3 inflammasome exacerbates cardiac sympathetic hyperactivity by promoting the release of the proinflammatory cytokine IL-1&#x3b2;, and this inflammatory-neural interaction results in altered electrophysiological properties of the heart, such as prolongation of the action potential duration and shortening of the effective refractory period, which increases the risk of ventricular arrhythmias (<xref ref-type="bibr" rid="B117">117</xref>, <xref ref-type="bibr" rid="B118">118</xref>). In the myocardial tissues of rats with HF-related ventricular arrhythmias (VAs-HF), there was a notable increase in the expression of SOX2-overlapping transcript (SOX2-OT) and NLRP3 (<xref ref-type="bibr" rid="B116">116</xref>). Furthermore, silencing of the SOX2-OT gene reduced NLRP3 inflammasome activation levels by regulating microRNA-2355-3p, thus alleviating HF symptoms and diminishing VAs (<xref ref-type="bibr" rid="B116">116</xref>). In HFpEF, the activation of the NLRP3 inflammasome facilitates the development of atrial fibrillation through the promotion of atrial fibrosis, by prolonging the atrial action potential duration, increasing the dispersion of action potential duration, and activating inflammation-associated signaling pathways (<xref ref-type="bibr" rid="B119">119</xref>). Following MI, P2X7R facilitates the upregulation of nerve growth factor, tyrosine hydroxylase, and growth-associated protein 43 by mediating the activation of the NLRP3/IL-1&#x3b2; pathway, thereby fostering sympathetic sprouting (<xref ref-type="bibr" rid="B120">120</xref>). This cascade leads to altered cardiac electrophysiological characteristics and an increased susceptibility to arrhythmias (<xref ref-type="bibr" rid="B120">120</xref>). After MI, the expression of Camk2n1 is markedly reduced in the infarct border zone, leading to the activation of the CaMKII&#x3b4;/p38 MAPK/C-Jun N-terminal kinase (JNK)/NLRP3 inflammasome signaling pathway (<xref ref-type="bibr" rid="B121">121</xref>). This exacerbates myocardial fibrosis and increases the vulnerability to premature ventricular contractions, tachycardia, and ventricular fibrillation (<xref ref-type="bibr" rid="B121">121</xref>). Connexin 43 (Cx43) is a key regulator of cardiac electrical signal conduction (<xref ref-type="bibr" rid="B122">122</xref>, <xref ref-type="bibr" rid="B123">123</xref>). The activation of the NLRP3 inflammasome within the&#xa0;myocardial infarct zone diminishes the expression of Cx43 in myocardial tissue, resulting in compromised intercellular communication and heightened vulnerability to VAs (<xref ref-type="bibr" rid="B122">122</xref>, <xref ref-type="bibr" rid="B123">123</xref>). Conversely, restoring the expression of Cx43 in the heart by inhibiting the NLRP3/IL-1&#x3b2;/p38 MAPK pathway helps enhance cardiac conduction function and decrease the heart&#x2019;s susceptibility to VAs (<xref ref-type="bibr" rid="B122">122</xref>, <xref ref-type="bibr" rid="B123">123</xref>).</p>
</sec>
<sec id="s3_6">
<label>3.6</label>
<title>Disturb cardiac energy metabolism</title>
<p>The heart, as an organ with high energy and oxygen demands, relies on homeostasis of its energy metabolism as the foundational mechanism for maintaining the stability of the cardiac tissue structure and internal environment (<xref ref-type="bibr" rid="B124">124</xref>). The myocardial energy metabolism relies heavily on mitochondrial oxidative phosphorylation. When mitochondria are damaged, myocardial energy substrate utilization is altered, leading to decreased cardiac energy production and lactic acid build-up, which in turn affects cardiac energy metabolism and cardiomyocyte survival and accelerates the malignant progression of HF (<xref ref-type="bibr" rid="B124">124</xref>).</p>
<p>A complex interplay exists between NLRP3 inflammasome activation and myocardial energy metabolism disruption. Mitochondrial dysfunction is the trigger for the activation of the NLRP3 inflammasome (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>), while the activation of the NLRP3 inflammasome further impairs mitochondrial function and homeostasis (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B125">125</xref>&#x2013;<xref ref-type="bibr" rid="B127">127</xref>). In an obesity-associated HF model, overactivation of the NLRP3 inflammasome results in an imbalance between cardiac energy supply and demand, as evidenced by decreased fatty acid utilization and increased reliance on glycolysis and glucose oxidation in cardiomyocytes, thereby triggering cardiac metabolic reprogramming (<xref ref-type="bibr" rid="B7">7</xref>). This metabolic transition was concomitant with the downregulation of genes associated with mitochondrial energy transfer and respiratory pathways, consequently intensifying the advancement of HF (<xref ref-type="bibr" rid="B7">7</xref>). During MI/R injury, the inhibition of the NLRP3 inflammasome activates the reperfusion injury salvage kinase (RISK) pathway, subsequently enhancing the expression of markers associated with mitochondrial biogenesis and energy metabolism, such as mitochondrial transcription factor A, nuclear respiratory factor-1, and mitochondrial creatine kinase (<xref ref-type="bibr" rid="B127">127</xref>). These findings suggest an association between disturbed myocardial energy metabolism and the formation of the NLRP3 inflammasome complex during MI/R injury, indicating that inhibition of NLRP3 inflammasome activation contributes to the improvement of cardiac energy metabolism, thereby enhancing the resistance of cardiomyocytes to ischemic and hypoxic injury (<xref ref-type="bibr" rid="B127">127</xref>). In the Ang II-induced cardiomyopathy model, increased NLRP3 inflammasome activity was accompanied by decreased mtDNA copy number, reduced ATP synthase activity, increased ROS production, as well as mitochondrial structural alterations, including swelling, disordered matrix organization, and fragmentation (<xref ref-type="bibr" rid="B125">125</xref>). The knockdown of the NLRP3 gene mitigated Ang II-induced mitochondrial structural and functional damage, as well as alleviated cardiac dysfunction (<xref ref-type="bibr" rid="B125">125</xref>). In rats with diabetic cardiomyopathy, cardiomyocyte mitochondria exhibit swelling and matrix disorders, along with activation of the NLRP3 inflammasome (<xref ref-type="bibr" rid="B126">126</xref>). Silencing of the NLRP3 gene aided in restoring mitochondrial structure and reducing glycogenolysis and lipid accumulation in cardiomyocytes, suggesting an enhancement in cardiomyocyte energy metabolism (<xref ref-type="bibr" rid="B126">126</xref>).</p>
</sec>
<sec id="s3_7">
<label>3.7</label>
<title>Exacerbate cardiomyocyte apoptosis</title>
<p>Cardiomyocyte apoptosis is a type of programmed cell death that is genetically regulated (<xref ref-type="bibr" rid="B128">128</xref>). Cardiomyocytes, which are primary cardiac cells, are responsible for contraction (<xref ref-type="bibr" rid="B129">129</xref>). Excessive apoptosis of cardiomyocytes is a significant contributor to the structural alterations and functional deterioration of the heart. Moreover, it is a crucial driver of HF onset and progression (<xref ref-type="bibr" rid="B130">130</xref>, <xref ref-type="bibr" rid="B131">131</xref>).</p>
<p>During the pathological progression of HF, the overactivation of NLRP3 exerts a pro-apoptotic effect on cardiomyocytes (<xref ref-type="bibr" rid="B8">8</xref>). Mechanistically, microRNA-30a-5p activates the NF-&#x3ba;B/NLRP3 signaling cascade by targeting SIRT1, thereby exacerbating cardiomyocyte apoptosis (<xref ref-type="bibr" rid="B8">8</xref>). CaSR expression is markedly elevated in the neutrophils of patients and rats with AMI (<xref ref-type="bibr" rid="B132">132</xref>). This upregulation facilitated NLRP3 inflammasome activation, release of IL-1&#x3b2; through the PLC-IP3 pathway, and calcium release from the endoplasmic reticulum (<xref ref-type="bibr" rid="B132">132</xref>). IL-1&#x3b2; interacted with the IL-1 receptor on cardiomyocytes, leading to an increase in Bax expression and caspase-3 cleavage, while decreasing Bcl2 expression, thereby effectively promoting cardiomyocyte apoptosis (<xref ref-type="bibr" rid="B132">132</xref>). In the myocardial tissue of MI mice, the expression of the long noncoding RNA zinc finger protein 561 antisense RNA 1 (ZNF561-AS1) is significantly upregulated (<xref ref-type="bibr" rid="B133">133</xref>). This upregulation leads to the inhibition of cardiomyocyte proliferation and augmentation of cardiomyocyte apoptosis via activation of the microRNA-223-3p/NLRP3 inflammasome pathway (<xref ref-type="bibr" rid="B133">133</xref>). During MI/R injury, activation of the NLRP3 inflammasome results in increased cardiomyocyte apoptosis through the upregulation of Bax protein expression and downregulation of Bcl2 expression (<xref ref-type="bibr" rid="B134">134</xref>). In myocardial tissues injured by ischemia reperfusion, the expression of long noncoding RNA highly up-regulated in liver cancer (lncRNA HULC) is downregulated (<xref ref-type="bibr" rid="B135">135</xref>). The decrease in lncRNA HULC expression results in heightened microRNA-377-5p activity, triggering the NLRP3/caspase-1/IL-1&#x3b2; signaling pathway (<xref ref-type="bibr" rid="B135">135</xref>). This cascade amplifies caspase-3 and cleaved-caspase-3 expression, ultimately worsening cardiomyocyte apoptosis (<xref ref-type="bibr" rid="B135">135</xref>). In a mouse model of cardiomyopathy, STING activation triggers the activation of the NLRP3 inflammasome by enhancing the phosphorylation and intranuclear translocation of IRF3 (<xref ref-type="bibr" rid="B136">136</xref>). This process elevates the ratios of Bax/Bcl-2 and C-Caspase3/T-Caspase3, leading to an increase in cardiomyocyte apoptosis (<xref ref-type="bibr" rid="B136">136</xref>).</p>
</sec>
</sec>
<sec id="s4">
<label>4</label>
<title>TCM active ingredients in preventing and treating HF by inhibiting the NLRP3 inflammasome</title>
<p>Active ingredients are fundamental to the efficacy of TCM. Existing studies have revealed that active ingredients in TCM exert positive regulatory effects on key pathological processes of HF by inhibiting the NLRP3 inflammasome. In particular, these active ingredients are effective in ameliorating myocardial inflammation, adverse myocardial fibrosis, pathological myocardial hypertrophy, angiogenesis, cardiac electrical signal conduction, cardiac energy metabolism, and reducing abnormal cardiomyocyte apoptosis (<xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>). Further analysis revealed that these active ingredients, with the potential to prevent and treat HF, are primarily found in flavonoids and their glycosides, terpenes and their glycosides, phenolic acids, quinones, and phenylpropanoids (<xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>).</p>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Mechanisms of active ingredients in TCM regulating the NLRP3 inflammasome in HF.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" rowspan="2" colspan="2" align="center">Active ingredients</th>
<th valign="middle" rowspan="2" align="center">Mechanisms</th>
<th valign="middle" rowspan="2" align="center">Effects</th>
<th valign="top" colspan="2" align="center">Models</th>
<th valign="top" rowspan="2" align="center">References</th>
</tr>
<tr>
<th valign="top" align="center">
<italic>In Vivo</italic>
</th>
<th valign="top" align="center">
<italic>In Vitro</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" rowspan="16" align="left" style="background-color:#ffffff">Flavonoids and their glycosides</td>
<td valign="top" rowspan="4" align="left" style="background-color:#ffffff">Astragaloside IV</td>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2193;, GDF15&#x2193;, CRP&#x2193;, IL1RL1&#x2193;, MCP-1&#x2193;, PDH&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation, fibrosis and hypertrophy, and improve cardiac energy metabolism</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6N mice<break/>High-fat diet and administration of N-&#x3c9;-Nitro-L-Arginine methyl ester induced-HF model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B17">17</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">ROS/NLRP3/caspase-1/GSDMD&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation, fibrosis and hypertrophy</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SPF C57BL/6J mice<break/>LADCA ligation-induced MI model</td>
<td valign="top" align="left" style="background-color:#ffffff">BMDMs<break/>LPS-induced cell inflammation model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B137">137</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">LC3II&#x2191;, p62&#x2193;, ROS/NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and hypertrophy</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>Abdominal aortic constriction-induced cardiac hypertrophy model</td>
<td valign="top" align="left" style="background-color:#ffffff">RCMs<break/>Mechanical stretch-induced cell hypertrophy model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B138">138</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">SIRT1&#x2191;, NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6J mice<break/>DOX intraperitoneal injection-induced myocardial toxicity model</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells<break/>DOX-induced cell toxicity model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B139">139</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Phloretin</td>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3/caspase-1/IL-1&#x3b2;/p38&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and fibrosis, and improve electrical signal conduction.</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LADCA ligation-induced MI model</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells<break/>Hypoxia-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B122">122</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Scutellarin</td>
<td valign="top" align="left" style="background-color:#ffffff">Akt&#x2191;, mTORC1/NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LADCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells<break/>OGD/R-cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B140">140</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="3" align="left" style="background-color:#ffffff">Hydroxylsafflower yellow A</td>
<td valign="top" align="left" style="background-color:#ffffff">AMPK&#x2191;, mTOR/NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LADCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B143">143</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">AMPK&#x2191;, NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation, improve energy metabolism, and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells<break/>H/R-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B142">142</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3/caspase-1/GSDMD&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate endothelial inflammation</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">HUVECs<break/>OGD/R-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B141">141</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Formononetin</td>
<td valign="top" align="left" style="background-color:#ffffff">ROS/TXNIP/NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LADCA ligation and release-Induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">NRCMs<break/>LPS and nigericin-induced cell inflammation model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B144">144</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="2" align="left" style="background-color:#ffffff">Luteolin</td>
<td valign="top" align="left" style="background-color:#ffffff">TLR4/NF-&#x3ba;B/NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LADCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells<break/>H/R-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B145">145</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">SIRT1&#x2191;, NLRP3/NF-&#x3ba;B&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and improve electrical signal conduction</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LADCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B146">146</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Biochanin A</td>
<td valign="top" align="left" style="background-color:#ffffff">TLR4/NF-kB/NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LADCA ligation and Release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B147">147</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Irisin</td>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation, fibrosis and hypertrophy</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6J mice<break/>TAC-induced cardiac hypertrophy model</td>
<td valign="top" align="left" style="background-color:#ffffff">CMs<break/>Ang-II-induced cell hypertrophy model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B148">148</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Amentoflavone</td>
<td valign="top" align="left" style="background-color:#ffffff">STING/NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation, fibrosis and hypertrophy, and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6J mice<break/>DOX intraperitoneal injection-induced myocardial toxicity model</td>
<td valign="top" align="left" style="background-color:#ffffff">ventricular CMs, MDA-MB-231 cells and MCF-7 cells<break/>DOX-induced cell toxicity model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B149">149</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Calycosin</td>
<td valign="top" align="left" style="background-color:#ffffff">SIRT1&#x2191;, NLRP3&#x2193;, OS&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and fibrosis, and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male Kunming mice<break/>DOX intraperitoneal injection-induced myocardial toxicity model</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells<break/>DOX-induced cell toxicity model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B150">150</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="20" align="left" style="background-color:#ffffff">Terpenoids and their glycosides</td>
<td valign="top" align="left" style="background-color:#ffffff">Gentiopicroside</td>
<td valign="top" align="left" style="background-color:#ffffff">Nrf2&#x2191;, NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">SD rats<break/>LADCA ligation-induced AMI model</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells<break/>H/R-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B151">151</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="2" align="left" style="background-color:#ffffff">Celastrol</td>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and fibrosis, improve electrical signal conduction, and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LCA ligation induced-HF model</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells<break/>Hypoxia-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B16">16</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and fibrosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LADCA ligation-induced MI model</td>
<td valign="top" align="left" style="background-color:#ffffff">NRCFs<break/>LPS and ATP-induced cell inflammation model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B152">152</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="2" align="left" style="background-color:#ffffff">Muscone</td>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3/IL-1&#x3b2;/p38 MAPK&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and fibrosis, and improve electrical signal conduction</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LADCA ligation-induced MI model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B123">123</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">ROS&#x2193;, NF-&#x3ba;B&#x2193;, NLRP3 &#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6J mice<break/>LADCA ligation-induced MI model</td>
<td valign="top" align="left" style="background-color:#ffffff">BMDMs<break/>Starvation and LPS-induced cell inflammation model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B153">153</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="2" align="left" style="background-color:#ffffff">Oridonin</td>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and fibrosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6 mice<break/>LCA ligation-induced MI model</td>
<td valign="top" align="left" style="background-color:#ffffff">BMDMs<break/>LPS-induced cell inflammation model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B154">154</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">OS&#x2193;, NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6 mice<break/>LADCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B155">155</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="2" align="left" style="background-color:#ffffff">Sweroside</td>
<td valign="top" align="left" style="background-color:#ffffff">CaMKII&#x3b4;/ROS/NF-&#x3ba;B/NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation, fibrosis and hypertrophy</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6 N mice<break/>TAC and Ang II perfusion induced-HF model</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells, AC16 cells and NRCMs<break/>Ang II-induced cell hypertrophy model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B156">156</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Keap1&#x2193;, Nrf2&#x2191;, OS&#x2193;, NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation</td>
<td valign="top" align="left" style="background-color:#ffffff">
<bold>-</bold>
</td>
<td valign="top" align="left" style="background-color:#ffffff">a. Myocardial tissue (from male Wistar rats)<break/>O<sub>2</sub>-saturated Krebs&#x2013;Henseleit solution-induced MI/R model<break/>b. H9c2 cells<break/>H/R-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B157">157</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Geniposide</td>
<td valign="top" align="left" style="background-color:#ffffff">AMPK&#x2191;, ROS/TXNIP/NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and improve cardiac energy metabolism</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6J mice<break/>LADCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">NRVMs and H9c2 cells<break/>H/R-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B158">158</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Loganin</td>
<td valign="top" align="left" style="background-color:#ffffff">GLP-1R&#x2191;, NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LADCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells<break/>OGD/R-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B159">159</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Artemisinin</td>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2193;, autophagy&#x2193;, OS&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and fibrosis, improve mitochondrial function, and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B160">160</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Betulin</td>
<td valign="top" align="left" style="background-color:#ffffff">SIRT1&#x2191;, NLRP3/NF-&#x3ba;B&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and improve electrical signal conduction</td>
<td valign="top" align="left" style="background-color:#ffffff">Wistar rats<break/>LADCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B161">161</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="2" align="left" style="background-color:#ffffff">Triptolide</td>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3/TGF-&#x3b2;1/Smad3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation, fibrosis and hypertrophy</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57/BL6 mice<break/>TAC-induced cardiac remodeling model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B162">162</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">MyD88&#x2193;, JNK&#x2193;, ERK1/2&#x2193;, NLRP3/TGF-&#x3b2;1/Smad&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and fibrosis</td>
<td valign="top" align="left" style="background-color:#ffffff">male C57 WT, NLRP3-KO mice<break/>ISO subcutaneous injection-induced myocardial fibrosis model</td>
<td valign="top" align="left" style="background-color:#ffffff">CFs<break/>Ang II-simulated fibrosis model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B163">163</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Ginsenoside Rg3</td>
<td valign="top" align="left" style="background-color:#ffffff">SIRT1&#x2191;, NF-&#x3ba;B/NLRP3&#x2193;, OS&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation, fibrosis and hypertrophy</td>
<td valign="top" align="left" style="background-color:#ffffff">SD rats<break/>TAC-induced cardiac hypertrophy model</td>
<td valign="top" align="left" style="background-color:#ffffff">AC16 cells and HCMs<break/>Ang II-induced cell hypertrophy model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B164">164</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="2" align="left" style="background-color:#ffffff">Ginsenoside Rb1</td>
<td valign="top" align="left" style="background-color:#ffffff">DUSP-1/TMBIM-6/VDAC1&#x2191;, NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation, fibrosis and hypertrophy, improve cardiac energy metabolism, and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6 WT, DUSP-1-KO, DUSP-1-KI, VDAC1-KO and VDAC1-KI mice<break/>TAC-induced HF model</td>
<td valign="top" align="left" style="background-color:#ffffff">Ventricular myocytes<break/>H/R-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B165">165</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2193;, calcium overload<break/>&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation, improve electrical signal conduction and mitochondrial structure, and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>Aconitine gavage administration-induced cardiac toxicity model</td>
<td valign="top" align="left" style="background-color:#ffffff">HiPSC-CMs and ARVMs<break/>Aconitine-induced cell toxicity model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B166">166</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Ginsenoside Rg1</td>
<td valign="top" align="left" style="background-color:#ffffff">TLR4/NF-kB/NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6J mice<break/>LPS intraperitoneal injection-induced<break/>cardiac dysfunction model</td>
<td valign="top" align="left" style="background-color:#ffffff">NRCMs<break/>LPS-induced cell inflammation model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B167">167</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Shikonin</td>
<td valign="top" align="left" style="background-color:#ffffff">SIRT1&#x2191;, NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6J mice<break/>LPS intraperitoneal injection-induced<break/>cardiac dysfunction model</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells<break/>LPS-induced cell inflammation model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B168">168</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="7" align="left" style="background-color:#ffffff">Phenolic acids</td>
<td valign="top" rowspan="2" align="left" style="background-color:#ffffff">resveratrol</td>
<td valign="top" align="left" style="background-color:#ffffff">SIRT1&#x2191;, p53&#x2193;, NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and fibrosis, and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6J mice<break/>a. LCA ligation-induced MI model<break/>b. LADCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">a. NRCMs and CFs<break/>H/R-induced cell damage model<break/>b. Macrophages<break/>LPS-induced cell inflammation model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B170">170</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Akt1/NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6J mice<break/>ISO subcutaneous injection-induced acute sympathetic stress model</td>
<td valign="top" align="left" style="background-color:#ffffff">NMCMs<break/>ISO-simulated acute sympathetic stress model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B171">171</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="2" align="left" style="background-color:#ffffff">Salvianolic acid B</td>
<td valign="top" align="left" style="background-color:#ffffff">SIRT1/AMPK/PGC-1&#x3b1;&#x2191;, NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation, improve cardiac energy metabolism, and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LADCA ligation-induced MI model</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells<break/>Hypoxia-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B172">172</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Mitophagy&#x2191;, NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation, improve mitochondrial function, and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>ISO subcutaneous injection-induced acute myocardial ischemia model</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells<break/>LPS and ATP-induced cell inflammation model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B173">173</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Cichoric acid</td>
<td valign="top" align="left" style="background-color:#ffffff">HK1/NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and fibrosis, improve cardiac energy metabolism, and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male Kunming mice<break/>ISO subcutaneous injection-induced myocardial fibrosis model</td>
<td valign="top" align="left" style="background-color:#ffffff">
<bold>-</bold>
</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B174">174</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Curcumin</td>
<td valign="top" align="left" style="background-color:#ffffff">Akt/mTOR&#x2191;, NLRP3&#x2193;, Autophagy&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation, improve mitochondrial structure, and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male Kunming mice<break/>DOX intraperitoneal injection-induced myocardial toxicity model</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells<break/>DOX-induced cell toxicity model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B175">175</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Carvacrol</td>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3/caspase-1/GSDMD&#x2193;, OS&#x2193;, Autophagy&#x2191;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation</td>
<td valign="top" align="left" style="background-color:#ffffff">Male Balb/C mice<break/>LPS intraperitoneal injection-induced cardiac dysfunction model</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells<break/>LPS-induced cell inflammation model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B176">176</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="5" align="left" style="background-color:#ffffff">Quinones</td>
<td valign="top" align="left" style="background-color:#ffffff">Tanshinone IIA</td>
<td valign="top" align="left" style="background-color:#ffffff">TLR4/NF-&#x3ba;B p65/NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and fibrosis, improve mitochondrial structure, and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LADCA ligation-induced AMI model</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells<break/>H/R-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B177">177</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Salvianolate</td>
<td valign="top" align="left" style="background-color:#ffffff">TGF-&#x3b2;1/Smad2/3&#x2193;,TXNIP/NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and fibrosis, and improve electrical signal conduction</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SPF SD rats<break/>LADCA ligation-induced MI model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B178">178</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Emodin</td>
<td valign="top" align="left" style="background-color:#ffffff">TLR4/MyD88/NF-&#x3ba;B/NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial <break/>inflammation</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LADCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">NRCMs<break/>H/R-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B179">179</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Emodin</td>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial <break/>inflammation</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6 mice<break/>LPS intraperitoneal injection-induced cardiac dysfunction model</td>
<td valign="top" align="left" style="background-color:#ffffff">H9c2 cells and CMs<break/>LPS-induced cell inflammation model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B180">180</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Sodium tanshinone IIA sulfonate</td>
<td valign="top" align="left" style="background-color:#ffffff">Autophagy&#x2191;, NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and reduce cardiomyocyte <break/>apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6 WT mice<break/>LPS intraperitoneal injection-induced cardiac dysfunction model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B181">181</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="4" align="left" style="background-color:#ffffff">Phenylpropanoids</td>
<td valign="top" align="left" style="background-color:#ffffff">Beta-asarone</td>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LADCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B182">182</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Cinnamaldehyde</td>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LADCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B183">183</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Aesculin</td>
<td valign="top" align="left" style="background-color:#ffffff">Akt&#x2191;, GSK3&#x3b2;&#x2191;, NF-&#x3ba;B/NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation, improve electrical signal conduction and mitochondrial function, and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LADCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">NRCMs<break/>OGD/R-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B184">184</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Cinnamic acid</td>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3/caspase-1/GSDMD&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation, improve mitochondrial structure, and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SPF SD rats<break/>LADCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B185">185</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="3" align="left" style="background-color:#ffffff">Others</td>
<td valign="top" align="left" style="background-color:#ffffff">Gastrodin</td>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation, stimulate angiogenesis, and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male C57BL/6J mice<break/>LADCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">HCMECs<break/>H/R-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B186">186</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">Panaxynol</td>
<td valign="top" align="left" style="background-color:#ffffff">HMGB1/TLR4/NF-&#x3ba;B/NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation and reduce cardiomyocyte apoptosis</td>
<td valign="top" align="left" style="background-color:#ffffff">Male mice<break/>LADCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">NRVMs<break/>H/R-induced cell damage model</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B187">187</xref>)</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#ffffff">ethyl acetate extract of <italic>Cinnamomi Ramulus</italic>
</td>
<td valign="top" align="left" style="background-color:#ffffff">NLRP3&#x2193;</td>
<td valign="top" align="left" style="background-color:#ffffff">Alleviate myocardial inflammation</td>
<td valign="top" align="left" style="background-color:#ffffff">Male SD rats<break/>LADCA ligation and release-induced MI/R model</td>
<td valign="top" align="left" style="background-color:#ffffff">-</td>
<td valign="top" align="left" style="background-color:#ffffff">(<xref ref-type="bibr" rid="B188">188</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>&#x2191; indicates activation; &#x2193; indicates inhibition.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="s4_1">
<label>4.1</label>
<title>Flavonoids and their glycosides</title>
<p>Astragaloside IV (AS-IV) demonstrates significant therapeutic potential for HFpEF (<xref ref-type="bibr" rid="B17">17</xref>). Specifically, AS-IV intervention markedly decreased NLRP3, IL-1&#x3b2;, and caspase-1 levels in the myocardium of HFpEF mice, with this reduction of biomarkers significantly linked to the amelioration of myocardial inflammation and enhancement of cardiac function (<xref ref-type="bibr" rid="B17">17</xref>). Additionally, AS-IV exerted a beneficial effect on maintaining cardiac metabolic homeostasis in HFpEF by optimizing cardiac glycolipid metabolism, enhancing mitochondrial function, and regulating energy metabolic pathways (<xref ref-type="bibr" rid="B17">17</xref>). AS-IV also effectively alleviated cardiac remodeling caused by MI (<xref ref-type="bibr" rid="B137">137</xref>). By inhibiting the ROS/caspase-1/GSDMD signaling pathway, As-IV reduces cardiomyocyte pyroptosis and lowers the expression levels of collagen I, collagen III, &#x3b1;-SMA, and fibronectin (<xref ref-type="bibr" rid="B137">137</xref>). This process effectively reduces post-MI cardiac fibrosis and hypertrophy, consequently enhancing the heart function (<xref ref-type="bibr" rid="B137">137</xref>). As-IV exerts protective effects against pressure overload-induced cardiac dysfunction (<xref ref-type="bibr" rid="B138">138</xref>). Through the upregulation of LC3II levels and inhibition of p62 expression, As-IV activated autophagy, subsequently inhibiting the ROS/NLRP3 inflammasome pathway and reducing the expression levels of IL-1&#x3b2; and IL-18 (<xref ref-type="bibr" rid="B138">138</xref>). This action effectively alleviates pressure overload-induced myocardial hypertrophy (<xref ref-type="bibr" rid="B138">138</xref>). In addition, As-IV mitigates DOX-induced myocardial toxicity (<xref ref-type="bibr" rid="B139">139</xref>). It exerts cardioprotective effects by reversing the DOX-induced downregulation of SIRT1 protein expression, upregulation of NLRP3 expression, and reduction in cardiomyocyte pyroptosis (<xref ref-type="bibr" rid="B139">139</xref>). Phloretin mitigates the electrical remodeling process in the heart post-MI (<xref ref-type="bibr" rid="B122">122</xref>). By inhibiting the NLRP3/caspase-1/IL-1&#x3b2; pathway, it diminished p38 phosphorylation, facilitating the restoration of Cx43 expression and mitigating cardiac electrical remodeling post-MI, consequently lowering cardiac susceptibility to VAs and the occurrence of HF (<xref ref-type="bibr" rid="B122">122</xref>). Furthermore, Phloretin also decreased the expression of fibrotic markers including collagen 1, collagen 3, TGF-&#x3b2;, and &#x3b1;-SMA post-MI by suppressing inflammatory responses orchestrated by NLRP3 inflammasome activation, consequently alleviating detrimental cardiac remodeling (<xref ref-type="bibr" rid="B122">122</xref>). The cardioprotective effects of scutellarin are mediated by its regulation of the Akt/mTORC1/NLRP3 signaling pathway (<xref ref-type="bibr" rid="B140">140</xref>). More&#xa0;precisely, scutellarin inhibits mTORC phosphorylation by upregulating Akt expression (<xref ref-type="bibr" rid="B140">140</xref>). This action subsequently diminishes the activation of the NLRP3 inflammasome, thus mitigating inflammatory injury and dysfunction in the heart induced by MI/R (<xref ref-type="bibr" rid="B140">140</xref>). Hydroxylsafflower yellow A (HSYA) was recognized for its ability to mitigate myocardial ischemia and hypoxic injury (<xref ref-type="bibr" rid="B141">141</xref>&#x2013;<xref ref-type="bibr" rid="B143">143</xref>). In MI/R injury, HSYA suppressed the NLRP3 inflammasome by modulating the AMPK/mTOR signaling pathway, thereby reducing myocardial infarct size and decreasing cardiomyocyte apoptosis, ultimately improving heart function (<xref ref-type="bibr" rid="B143">143</xref>). In an H/R-induced H9c2 cell study, the AMPK inhibitor compound C nullified the suppressive impact of HSYA on NLRP3 inflammasome activation, as demonstrated by elevated levels of NLRP3, caspase-1, and IL-1&#x3b2; expression (<xref ref-type="bibr" rid="B142">142</xref>). This observation further corroborates that the inhibition of the AMPK/NLRP3 inflammasome signaling pathway is an important mechanism in the anti-MI/R injury effect of HSYA (<xref ref-type="bibr" rid="B142">142</xref>). In a study on oxygen-glucose deprivation/reoxygenation (OGD/R)-induced HUVECs, NLRP3 inflammasome-mediated pyroptosis was heightened (<xref ref-type="bibr" rid="B141">141</xref>). Treatment with HSYA mitigated pyroptosis by inhibiting the NLRP3/caspase-1/GSDMD pathway, thereby mitigating inflammatory damage to HUVECs resulting from OGD/R (<xref ref-type="bibr" rid="B141">141</xref>). Formononetin can alleviate MI/R injury (<xref ref-type="bibr" rid="B144">144</xref>). It restricts the activation of the NLRP3 inflammasome by diminishing the release of ROS, suppressing the expression of TXNIP, and attenuating the interaction between TXNIP and NLRP3, thereby decreasing the secretion of proinflammatory factors and cardiomyocyte apoptosis (<xref ref-type="bibr" rid="B144">144</xref>). Luteolin similarly demonstrated the potential to alleviate MI/R injury, and this protective attribute was associated with its suppression of the TLR4/NF-&#x3ba;B/NLRP3 inflammasome pathway (<xref ref-type="bibr" rid="B145">145</xref>). Luteolin downregulates the expression of TLR4, MyD88, and NF-&#x3ba;B in a dose-dependent manner to inhibit NLRP3 inflammasome activation, consequently diminishing myocardial infarct size and enhancing left ventricular function (<xref ref-type="bibr" rid="B145">145</xref>). Intriguingly, another study identified the SIRT1/NLRP3/NF-&#x3ba;B signaling pathway as the primary regulatory mechanism by which luteolin alleviates MI/R damage (<xref ref-type="bibr" rid="B146">146</xref>). These findings suggest that luteolin may exert cardioprotective effects by inhibiting the NLRP3 inflammasome through multiple molecular signaling pathways. Biochanin A alleviates the cardiac inflammatory response and reduces the infarcted myocardial area resulting from MI/R (<xref ref-type="bibr" rid="B147">147</xref>). Its cardioprotective effect was intricately linked to its inhibition of the TLR4/NF-&#x3ba;B/NLRP3 signaling pathway (<xref ref-type="bibr" rid="B147">147</xref>). By inhibiting NLRP3 inflammasome activation, irisin effectively restrained the expression of GSDMD-N and IL-1&#x3b2;, thereby mitigating the detrimental effects of pressure overload on the heart such as myocardial inflammation, fibrosis, and hypertrophy (<xref ref-type="bibr" rid="B148">148</xref>). By inhibiting the STING/NLRP3 signaling pathway, amentoflavone mitigates cardiomyocyte pyroptosis and cardiac inflammation, consequently ameliorating DOX-induced heart damage and functional impairment (<xref ref-type="bibr" rid="B149">149</xref>). Calycosin also shows promise for the treatment of myocardial toxicity (<xref ref-type="bibr" rid="B150">150</xref>). Mechanistically, it inhibited NLRP3 inflammasome activation by upregulating SIRT1 expression, thereby reducing cardiac inflammatory infiltration, myocardial fibrosis, and cardiomyocyte apoptosis, ultimately mitigating DOX-induced cardiac injury (<xref ref-type="bibr" rid="B150">150</xref>).</p>
</sec>
<sec id="s4_2">
<label>4.2</label>
<title>Terpenoids and their glycosides</title>
<p>AMI triggered intense inflammatory responses and oxidative stress (OS) (<xref ref-type="bibr" rid="B151">151</xref>). Gentiopicroside mitigates cardiac inflammatory responses, OS, and cardiomyocyte apoptosis induced by AMI by regulating the Nrf2/NLRP3 signaling pathway, thereby safeguarding cardiac function (<xref ref-type="bibr" rid="B151">151</xref>). In the pathological progression of chronic HF, Celastrol improves cardiac electrophysiological stability, upregulates Cx43 and ion channel expression, and reduces myocardial fibrosis and inflammatory responses by inhibiting the NLRP3/caspase-1/IL-1&#x3b2; signaling pathway, ultimately reducing susceptibility to ventricular fibrillation (<xref ref-type="bibr" rid="B16">16</xref>). Following MI, a notable increase was observed in macrophage and neutrophil infiltration of myocardial tissues alongside a significant upregulation in the expression of pro-fibrotic proteins such as collagen I, collagen III, and &#x3b1;-SMA (<xref ref-type="bibr" rid="B152">152</xref>). Celastrol mitigates these pathological alterations by inhibiting the NLRP3 inflammasome (<xref ref-type="bibr" rid="B152">152</xref>). Muscone exhibits a promising therapeutic potential against MI (<xref ref-type="bibr" rid="B123">123</xref>). It diminishes ventricular inflammation and fibrosis, while decreasing vulnerability to VAs via the upregulation of Cx43 expression in the infarct border zone (<xref ref-type="bibr" rid="B123">123</xref>). These effects were associated with its inhibitory impact on the NLRP3/IL-1&#x3b2;/p38 MAPK pathway (<xref ref-type="bibr" rid="B123">123</xref>). Furthermore, Muscone mitigated the macrophage-driven cardiac inflammatory response by suppressing NF-&#x3ba;B expression and NLRP3 inflammasome activation in myocardial macrophages, leading to enhanced cardiac function and increased survival rates in mice post-MI (<xref ref-type="bibr" rid="B153">153</xref>). Oridonin can alleviate cardiac remodeling post-MI (<xref ref-type="bibr" rid="B154">154</xref>). By inhibiting the NLRP3 inflammasome, it reduced the expression of fibrosis markers, including collagen-I, collagen-III, collagen-IV, and &#x3b1;-SMA, thereby alleviating myocardial fibrosis and cardiac dysfunction following MI (<xref ref-type="bibr" rid="B154">154</xref>). Moreover, pretreatment with oridonin suppressed the overactivation of OS and NLRP3 inflammasome, consequently mitigating cardiac pathological alterations induced by ischemia reperfusion, including the alleviation of myocardial inflammatory damage and reduction of infarct size (<xref ref-type="bibr" rid="B155">155</xref>). Sweroside inhibits the ROS-mediated NF-&#x3ba;B/NLRP3 inflammasome pathway in cardiomyocytes by directly binding to CaMKII&#x3b4;, alleviating myocardial inflammation and adverse cardiac remodeling, thereby improving HF induced by pressure overload (<xref ref-type="bibr" rid="B156">156</xref>). Sweroside also exerts protective effects on ischemia reperfusion myocardium (<xref ref-type="bibr" rid="B157">157</xref>). Its intervention alleviates myocardial inflammatory damage and reduces the size of the infarcted area, helping to alleviate cardiac dysfunction caused by MI/R (<xref ref-type="bibr" rid="B157">157</xref>). This effect is primarily due to the inhibition of NLRP3 inflammasome-mediated pyroptosis (<xref ref-type="bibr" rid="B157">157</xref>). Geniposide has therapeutic potential for alleviating MI/R injury (<xref ref-type="bibr" rid="B158">158</xref>). It inhibits the ROS/TXNIP/NLRP3 inflammasome pathway by activating the AMPK signaling pathway (<xref ref-type="bibr" rid="B158">158</xref>). This process efficiently suppresses cardiac inflammation, enhances myocardial energy metabolism, and ultimately reduces the damage inflicted on the myocardium by ischemia reperfusion (<xref ref-type="bibr" rid="B158">158</xref>). The glucagon-like peptide-1 receptor (GLP-1R)/NLRP3 pathway plays a pivotal role in mediating the cardioprotective effects of loganins (<xref ref-type="bibr" rid="B159">159</xref>). MI/R induces a notable decline in GLP-1R expression within the myocardial tissue, which promotes the formation of the NLRP3 inflammasome and pyroptosis, exacerbating myocardial damage and cardiomyocyte apoptosis (<xref ref-type="bibr" rid="B159">159</xref>). Conversely, treatment with loganin alleviates these pathological changes (<xref ref-type="bibr" rid="B159">159</xref>). Artemisinin pretreatment mitigates MI/R-induced myocardial inflammation, cardiomyocyte apoptosis, and myocardial fibrosis primarily by inhibiting the NLRP3 inflammasome (<xref ref-type="bibr" rid="B160">160</xref>). Betulin attenuated the cardiac inflammatory response, decreased myocardial infarct size, and enhanced cardiac electrical signaling by modulating the SIRT1/NLRP3/NF-&#x3ba;B signaling pathway. This action ultimately helps mitigate the cardiac pathological damage induced by MI/R (<xref ref-type="bibr" rid="B161">161</xref>). Tretinoin has proven advantageous in alleviating negative cardiac repercussions induced by pressure overload (<xref ref-type="bibr" rid="B162">162</xref>). Mechanistically, tretinoin impeded the TGF-&#x3b2;1/Smad3 pathway by dampening the activation of the NLRP3 inflammasome, which in turn attenuated TAC-induced myocardial fibrosis and hypertrophy and improved cardiac function (<xref ref-type="bibr" rid="B162">162</xref>). Another study demonstrated that the mechanism by which tretinoin mitigates myocardial fibrosis involves the inhibition of the NLRP3 inflammasome. By diminishing MyD88-mediated JNK and ERK1/2 activity, tretinoin suppressed the NLRP3 inflammasome, subsequently inhibiting the TGF-&#x3b2;1/Smad signaling pathway (<xref ref-type="bibr" rid="B163">163</xref>). This cascade of events aids in reducing ECM deposition caused by pressure overload, thus exerting an anti-myocardial fibrotic effect (<xref ref-type="bibr" rid="B163">163</xref>). Ginsenoside Rg3 inhibited pathological myocardial hypertrophy induced by pressure overload (<xref ref-type="bibr" rid="B164">164</xref>). It achieved its anti-inflammatory and antioxidant effects by regulating the SIRT1/NF-&#x3ba;B/NLRP3 inflammasome signaling pathway, thereby reducing myocardial fibrosis and hypertrophy (<xref ref-type="bibr" rid="B164">164</xref>). Ginsenoside Rb1 attenuated HF induced by MI/R injury by targeting the DUSP-1/TMBIM-6/VDAC1 pathway, regulating intestinal microbiota homeostasis and the equilibrium of the mitochondrial quality control network, as well as suppressing the NLRP3-mediated inflammatory response and pyroptosis (<xref ref-type="bibr" rid="B165">165</xref>). Cardiac injury is a common adverse effect of aconitine. Following aconitine intervention, there is an increase in the expression of NLRP3-dependent pyroptosis-related proteins in myocardial tissue, accompanied by disruptions in electrophysiology, significant myocardial apoptosis, and cardiac dysfunction (<xref ref-type="bibr" rid="B166">166</xref>). Ginsenoside Rb1 effectively ameliorated aconitine-induced cardiac pathological alterations (<xref ref-type="bibr" rid="B167">167</xref>). Ginsenoside Rg1 effectively mitigated LPS-induced cardiotoxicity by reducing cardiac inflammation and cardiomyocyte apoptosis (<xref ref-type="bibr" rid="B167">167</xref>). This was achieved by lowering the Bax/Bcl2 ratio and the quantity of TUNEL-positive cells in myocardial tissues via the inhibition of the TLR4/NF-&#x3ba;B/NLRP3 pathway (<xref ref-type="bibr" rid="B167">167</xref>). Shikonin also attenuates LPS-induced cardiac dysfunction by inhibiting the NLRP3 inflammasome through upregulation of the SIRT1 pathway (<xref ref-type="bibr" rid="B168">168</xref>). This process reduces the release of inflammatory factors and&#xa0;macrophage infiltration into cardiac tissues, thereby alleviating&#xa0;LPS-induced myocardial injury and improving cardiac function (<xref ref-type="bibr" rid="B168">168</xref>).</p>
</sec>
<sec id="s4_3">
<label>4.3</label>
<title>Phenolic acids</title>
<p>Resveratrol shows promise in HF treatment (<xref ref-type="bibr" rid="B169">169</xref>). After a 3-month treatment with resveratrol, patients with systolic HF experienced significant reductions in IL-1, IL-6, NT-proBNP, galectin-3, total cholesterol, and low-density lipoprotein cholesterol levels, along with substantial enhancements in cardiac function and quality of life (<xref ref-type="bibr" rid="B169">169</xref>). Resveratrol can mitigate MI/R injury (<xref ref-type="bibr" rid="B170">170</xref>). It mitigates cardiac inflammation, fibrosis, and apoptosis by modulating the SIRT1/p53 signaling pathway and inhibiting the NLRP3 inflammasome, thereby ameliorating MI/R-induced cardiac dysfunction (<xref ref-type="bibr" rid="B170">170</xref>). Furthermore, resveratrol reduced acute sympathetic stress-induced cardiac inflammation by inhibiting the Akt1/NLRP3 inflammasome pathway (<xref ref-type="bibr" rid="B171">171</xref>). Salvianolic acid B inhibited the activation of the NLRP3 inflammasome by regulating the SIRT1/AMPK/PGC-1&#x3b1; signaling pathway (<xref ref-type="bibr" rid="B172">172</xref>). This action leads to decreased cardiac inflammation, mitigation of mitochondrial dysfunction, and a reduction in cardiomyocyte apoptosis, ultimately exerting a cardioprotective effect in ischemic and hypoxic conditions (<xref ref-type="bibr" rid="B172">172</xref>). Salvianolic acid B can also ameliorate myocardial inflammation and enhance mitochondrial function by promoting mitochondrial autophagy and inhibiting the NLRP3 inflammasome, thus alleviating ISO-induced acute myocardial ischemic injury (<xref ref-type="bibr" rid="B173">173</xref>). Chicoric acid effectively mitigates the detrimental effects of cardiac overload (<xref ref-type="bibr" rid="B174">174</xref>). Specifically, it reduced ISO-induced cardiac inflammation, fibrosis, apoptosis, and mitochondrial structural damage by inhibiting the hexokinase 1(HK1)/NLRP3 inflammasome signaling pathway (<xref ref-type="bibr" rid="B174">174</xref>). When exposed to DOX, cardiomyocytes exhibit impaired contractile function (<xref ref-type="bibr" rid="B175">175</xref>). Curcumin activates the AKT/mTOR pathway, leading to a reduction in DOX-induced pyroptosis and autophagy, thereby contributing to the alleviation of cardiomyocyt\e apoptosis and cardiac dysfunction (<xref ref-type="bibr" rid="B175">175</xref>). Carvacrol is beneficial in attenuating LPS-induced cardiac dysfunction, and its protective effect against myocardial injury is linked to the inhibition of pyroptosis mediated by the NLRP3/caspase1/GSDMD pathway (<xref ref-type="bibr" rid="B176">176</xref>).</p>
</sec>
<sec id="s4_4">
<label>4.4</label>
<title>Quinones</title>
<p>After AMI, the expression of TLR4, NF-&#x3ba;B p65, NLRP3, IL-1&#x3b2;, and IL-18 increased in cardiac tissue (<xref ref-type="bibr" rid="B177">177</xref>). These changes lead to adverse cardiac effects such as myocardial inflammation, fibrosis, cardiomyocyte apoptosis, and cardiac dysfunction (<xref ref-type="bibr" rid="B177">177</xref>). Tanshinone IIA mitigated these adverse changes by inhibiting the TLR4/NF-&#x3ba;B p65/NLRP3 inflammasome signaling pathway, thus enhancing cardiac structure and restoring left ventricular function (<xref ref-type="bibr" rid="B177">177</xref>). After MI, treatment with salvianolate ameliorated interstitial fibrosis in the atria, decreased the susceptibility of the heart to atrial fibrillation, and reduced the duration of atrial fibrillation (<xref ref-type="bibr" rid="B178">178</xref>). Salvianolate&#x2019;s cardioprotective effect was attributed to its capacity to&#xa0;reduce collagen deposition and attenuate inflammatory responses by inhibiting the TGF-&#x3b2;1/Smad2/3 and TXNIP/NLRP3 inflammasome signaling pathways (<xref ref-type="bibr" rid="B178">178</xref>). Emodin decreased the expression of GSDMD-NT and IL-1&#x3b2; by inhibiting the TLR4/MyD88/NF-&#x3ba;B/NLRP3 inflammasome signaling pathway, thereby mitigating myocardial inflammatory injury induced by MI/R (<xref ref-type="bibr" rid="B179">179</xref>). Furthermore, Emodin potentially ameliorated LPS-induced cardiac injury and dysfunction (<xref ref-type="bibr" rid="B180">180</xref>). This is primarily achieved by inhibiting the NLRP3 inflammasome, decreasing the levels of inflammatory cytokines, and inducing cardiomyocyte pyroptosis (<xref ref-type="bibr" rid="B180">180</xref>). Sodium tanshinone IIA sulfonate has demonstrated potential for the treatment of sepsis-induced myocardial dysfunction (<xref ref-type="bibr" rid="B181">181</xref>). In mice with LPS-induced cardiomyopathy, sodium tanshinone IIA sulfonate mitigates myocardial inflammation and enhances cardiac function by promoting autophagy and inhibiting NLRP3 inflammasome activation, leading to increased survival rates (<xref ref-type="bibr" rid="B181">181</xref>).</p>
</sec>
<sec id="s4_5">
<label>4.5</label>
<title>Phenylpropanoids</title>
<p>Beta-asarone reduces cardiac inflammation and diminishes the size of MI by inhibiting the NLRP3 inflammasome, thus enhancing cardiac recovery after ischemia reperfusion (<xref ref-type="bibr" rid="B182">182</xref>). The cardioprotective effect of cinnamaldehyde also depends on its inhibitory effects on the NLRP3 inflammasome (<xref ref-type="bibr" rid="B183">183</xref>). Pretreatment with Cinnamaldehyde attenuated cardiomyocyte pyroptosis and the number of TUNEL-positive cells by suppressing the expression of NLRP3, ASC, pro-caspase-1, caspase-1, and GSDMD, as well as the release of IL-18 and IL-1&#x3b2;, thereby alleviating MI/R injury (<xref ref-type="bibr" rid="B183">183</xref>). Aesculin also confers protective effects against ischemia reperfusion in the myocardium (<xref ref-type="bibr" rid="B184">184</xref>). It hindered the activation of the NF-&#x3ba;B/NLRP3 inflammasome signaling pathway by enhancing Akt and GSK3&#x3b2; expression, leading to reduced cardiac inflammation, enhanced mitochondrial function, reduced cardiomyocyte apoptosis, and decreased vulnerability to ventricular arrhythmias, ultimately enhancing cardiac function (<xref ref-type="bibr" rid="B184">184</xref>). Cinnamic acid alleviates MI/R injury by reducing the infarct size, preventing myocardial cell apoptosis, and improving cardiac diastolic function (<xref ref-type="bibr" rid="B185">185</xref>). The cardioprotective effects of cinnamic acid have been attributed to the suppression of NLRP3 inflammasome activation-induced pyroptosis (<xref ref-type="bibr" rid="B185">185</xref>).</p>
</sec>
<sec id="s4_6">
<label>4.6</label>
<title>Other active ingredients</title>
<p>In addition to the aforementioned compounds, gastrodin (<xref ref-type="bibr" rid="B186">186</xref>), panaxynol (<xref ref-type="bibr" rid="B187">187</xref>), and the ethyl acetate extract of cinnamomi ramulus (<xref ref-type="bibr" rid="B188">188</xref>) had been identified as having the potential to ameliorate symptoms and enhance the prognosis of HF by inhibiting the NLRP3 inflammasome. By inhibiting NLRP3/caspase-1 signaling, Gastrodin reduced the production of IL-1&#x3b2; (<xref ref-type="bibr" rid="B186">186</xref>). This mechanism alleviates the inflammatory responses in the heart and microvasculature, reduces myocardial apoptosis, and promotes capillary formation, thereby offering protection against myocardial and cardiac microvascular damage induced by MI/R (<xref ref-type="bibr" rid="B186">186</xref>). Panaxynol exhibits anti-inflammatory and anti-apoptotic properties (<xref ref-type="bibr" rid="B187">187</xref>). It demonstrated beneficial effects in mitigating MI/R injury by suppressing the HMGB1/TLR4/NF-&#x3ba;B/NLRP3 inflammasome signaling pathway, leading to a significant reduction in MI size and enhancement of cardiac function (<xref ref-type="bibr" rid="B187">187</xref>). <italic>Cinnamomi Ramulus</italic> also has the potential to ameliorate adverse cardiac outcomes resulting from MI/R (<xref ref-type="bibr" rid="B188">188</xref>). It attenuates cardiac inflammation and enhances cardiac function by reducing NLRP3 inflammasome activation and pyroptosis, thereby exerting cardioprotective effects (<xref ref-type="bibr" rid="B188">188</xref>).</p>
</sec>
</sec>
<sec id="s5" sec-type="conclusions">
<label>5</label>
<title>Conclusions and prospects</title>
<p>The activation of the NLRP3 inflammasome is a complex process involving three distinct pathways: canonical, non-canonical, and alternative NLRP3 inflammasome activation. These activated pathways adversely affect cardiac function by promoting the progression of various pathological processes, including the exacerbation of myocardial inflammatory injury, adverse myocardial fibrosis, pathological myocardial hypertrophy, and abnormal cardiomyocyte apoptosis; inhibition of angiogenesis; and disruption of cardiac electrical signaling and energy metabolism. These factors synergistically accelerate the onset and progression of HF. In the prevention and treatment of HF, the active ingredients of TCM demonstrate significant potential. They inhibit the NLRP3 inflammasome through multiple pathways, effectively attenuating the aforementioned pathological changes and thereby improving both the structure and function of the heart. Furthermore, we found that these active ingredients are primarily concentrated in flavonoids and their glycosides, terpenes and their glycosides, phenolic acids, quinones, and phenylpropanoids. Based on these findings, we posit that there is both theoretical value and clinical significance in reviewing studies on TCM active ingredients for preventing and treating HF, with a focus on the inhibition of the NLRP3 inflammasome. This endeavor aims to lay the foundation for future research and the development of novel therapeutic agents.</p>
<p>Despite some progress in investigating the inhibition of the NLRP3 inflammasome by the active ingredients of TCM for the prevention and treatment of HF, various limitations and challenges persist. First, some studies lack in-depth exploration of the upstream signaling molecules that regulate the NLRP3 inflammasome. It remains unclear which specific signaling pathways the active components of TCM utilize to inhibit the NLRP3 inflammasome. Second, active ingredients of TCM may engage multiple signaling pathways to suppress the NLRP3 inflammasome, such as Astragaloside IV, Luteolin, and Resveratrol. However, there remains a shortage of comprehensive investigations into the interplay between molecular signals. Third, most current research is confined to animal and cell experiments and lacks robust clinical studies that offer evidential support, particularly high-quality randomized controlled trials. Fourth, the etiology of HF is multifaceted and includes myocardial ischemia, cardiac overload, and myocardial toxicity. Further research is necessary to verify whether there are variations in the mechanism of action and the effects of the same active ingredients in TCM on HF with different etiologies. Fifth, although the active ingredients of TCM exhibit minimal side effects and low drug resistance, HF is characterized by a protracted course of illness that may require extended dosing periods. Therefore, the safety profiles of the active ingredients in Chinese medicines require evaluation through meticulously designed clinical studies.</p>
<p>Considering the aforementioned limitations and challenges, future studies should conduct multidimensional validations using HF models derived from various etiological sources both <italic>in vitro</italic> and <italic>in vivo</italic>. Simultaneously, emphasis should be placed on exploring upstream signaling molecules that suppress the NLRP3 inflammasome and investigating the interactions among diverse molecular mechanisms. Furthermore, after verifying the efficacy and safety of the active ingredients in TCM in basic research, clinical trials should be conducted to assess the therapeutic potential of these components in preventing and treating HF, thereby enabling the translation of research findings into clinical applications.</p>
</sec>
</body>
<back>
<sec id="s6" sec-type="author-contributions">
<title>Author contributions</title>
<p>RL: Conceptualization, Investigation, Software, Visualization, Writing &#x2013; original draft. YY: Investigation, Writing &#x2013; review &amp; editing. LD: Visualization, Writing &#x2013; review &amp; editing. ZD: Writing &#x2013; review &amp; editing. ZW: Writing &#x2013; review &amp; editing. JW: Conceptualization, Funding acquisition, Project administration, Supervision, Writing &#x2013; review &amp; editing. ZG: Conceptualization, Funding acquisition, Project administration, Supervision, Writing &#x2013; review &amp; editing.</p>
</sec>
<sec id="s7" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China (82174343, 82405372), Key Subject of Scientific Research Projects of Traditional Chinese Medicine in Hunan Province (A2023017), Hunan Provincial Health Commission Research Project (D202303017861), Key Research and Development Plan of Hunan Province (2022SK2012), Changsha Science and Technology Bureau Project (kq2402175), Scientific Research Project of Hunan University of Chinese Medicine (Z2023XJYB05), Graduate Innovation Project of&#xa0;Hunan University of Chinese Medicine (2024CX036, 2024CX008, 2024CX019).</p>
</sec>
<sec id="s8" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s9" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p>
</sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2025.1520482/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2025.1520482/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Table1.docx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baman</surname> <given-names>JR</given-names>
</name>
<name>
<surname>Ahmad</surname> <given-names>FS</given-names>
</name>
</person-group>. <article-title>Heart failure</article-title>. <source>Jama</source>. (<year>2020</year>) <volume>324</volume>:<fpage>1015</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/jama.2020.13310</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Savarese</surname> <given-names>G</given-names>
</name>
<name>
<surname>Becher</surname> <given-names>PM</given-names>
</name>
<name>
<surname>Lund</surname> <given-names>LH</given-names>
</name>
<name>
<surname>Seferovic</surname> <given-names>P</given-names>
</name>
<name>
<surname>Rosano</surname> <given-names>G</given-names>
</name>
<name>
<surname>Coats</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Global burden of heart failure: a comprehensive and updated review of epidemiology</article-title>. <source>Cardiovasc Res</source>. (<year>2023</year>) <volume>118</volume>:<page-range>3272&#x2013;87</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/cvr/cvac013</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nedkoff</surname> <given-names>L</given-names>
</name>
<name>
<surname>Weber</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Heart failure: not just a disease of the elderly</article-title>. <source>Heart</source>. (<year>2022</year>) <volume>108</volume>:<page-range>249&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/heartjnl-2021-320273</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heidenreich</surname> <given-names>PA</given-names>
</name>
<name>
<surname>Bozkurt</surname> <given-names>B</given-names>
</name>
<name>
<surname>Aguilar</surname> <given-names>D</given-names>
</name>
<name>
<surname>Allen</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Byun</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Colvin</surname> <given-names>MM</given-names>
</name>
<etal/>
</person-group>. <article-title>AHA/ACC/HFSA guideline for the management of heart failure: A report of the american college of cardiology/american heart association joint committee on clinical practice guidelines</article-title>. <source>J Am Coll Cardiol</source>. (<year>2022</year>) <volume>79</volume>:<page-range>e263&#x2013;421</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jacc.2021.12.012</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Li</surname> <given-names>G</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>NLRP3-inflammasome inhibition by MCC950 attenuates cardiac and pulmonary artery remodelling in heart failure with preserved ejection fraction</article-title>. <source>Life Sci</source>. (<year>2023</year>) <volume>333</volume>:<elocation-id>122185</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.lfs.2023.122185</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hua</surname> <given-names>X</given-names>
</name>
<name>
<surname>Shu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Single-cell RNA sequencing in donor and end-stage heart failure patients identifies NLRP3 as a therapeutic target for arrhythmogenic right ventricular cardiomyopathy</article-title>. <source>BMC Med</source>. (<year>2024</year>) <volume>22</volume>:<elocation-id>11</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12916-023-03232-8</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>M</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>MCC950, a selective NLRP3 inhibitor, attenuates adverse cardiac remodeling following heart failure through improving the cardiometabolic dysfunction in obese mice</article-title>. <source>Front Cardiovasc Med</source>. (<year>2022</year>) <volume>9</volume>:<elocation-id>727474</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcvm.2022.727474</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>YX</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>RY</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>XY</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>XJ</given-names>
</name>
</person-group>. <article-title>MicroRNA-30a-5p promotes chronic heart failure in rats by targeting sirtuin-1 to activate the nuclear factor-kappaB/NOD-like receptor 3 signaling pathway</article-title>. <source>Cardiovasc Drugs Ther</source>. (<year>2023</year>) <volume>37</volume>:<page-range>1065&#x2013;76</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10557-021-07304-w</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname> <given-names>H</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>JX</given-names>
</name>
</person-group>. <article-title>Microvascular rarefaction and heart failure with preserved ejection fraction</article-title>. <source>Front Cardiovasc Med</source>. (<year>2019</year>) <volume>6</volume>:<elocation-id>15</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcvm.2019.00015</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Lian</surname> <given-names>K</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Yi</surname> <given-names>F</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia/reperfusion injury</article-title>. <source>Basic Res Cardiol</source>. (<year>2014</year>) <volume>109</volume>:<elocation-id>415</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00395-014-0415-z</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>C</given-names>
</name>
<name>
<surname>Fu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Yuan</surname> <given-names>P</given-names>
</name>
<name>
<surname>Ge</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>To investigate the correlation of serum NLRP3 level with endothelial function, severity of disease and prognosis in elderly patients with chronic heart failure</article-title>. <source>Minerva Med</source>. (<year>2024</year>) <volume>115</volume>:<page-range>1&#x2013;3</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.23736/S0026-4806.24.09322-4</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petrilli</surname> <given-names>V</given-names>
</name>
<name>
<surname>Dostert</surname> <given-names>C</given-names>
</name>
<name>
<surname>Muruve</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Tschopp</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>The inflammasome: a danger sensing complex triggering innate immunity</article-title>. <source>Curr Opin Immunol</source>. (<year>2007</year>) <volume>19</volume>:<page-range>615&#x2013;22</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.coi.2007.09.002</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>A</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>W</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>K</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>P</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Mechanisms and efficacy of traditional chinese medicine in heart failure</article-title>. <source>Front Pharmacol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>810587</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fphar.2022.810587</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Song</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Traditional Chinese medicine for heart failure with preserved ejection fraction: clinical evidence and potential mechanisms</article-title>. <source>Front Pharmacol</source>. (<year>2023</year>) <volume>14</volume>:<elocation-id>1154167</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fphar.2023.1154167</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fang</surname> <given-names>HY</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>XN</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>YY</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Beneficial effects of flavonoids on cardiovascular diseases by influencing NLRP3 inflammasome</article-title>. <source>Inflammopharmacology</source>. (<year>2023</year>) <volume>31</volume>:<page-range>1715&#x2013;29</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10787-023-01249-2</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname> <given-names>W</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>S</given-names>
</name>
<name>
<surname>Qiu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>M</given-names>
</name>
<name>
<surname>Song</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Celastrol exerts antiarrhythmic effects in chronic heart failure via NLRP3/Caspase-1/IL-1beta signaling pathway</article-title>. <source>BioMed Pharmacother</source>. (<year>2024</year>) <volume>177</volume>:<elocation-id>117121</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.biopha.2024.117121</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>He</surname> <given-names>X</given-names>
</name>
<name>
<surname>Li</surname> <given-names>L</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Astragaloside IV alleviates inflammation and improves myocardial metabolism in heart failure mice with preserved ejection fraction</article-title>. <source>Front Pharmacol</source>. (<year>2024</year>) <volume>15</volume>:<elocation-id>1467132</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fphar.2024.1467132</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>P</given-names>
</name>
<name>
<surname>Li</surname> <given-names>W</given-names>
</name>
<name>
<surname>Shao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Hong</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases</article-title>. <source>Acta Pharm Sin B</source>. (<year>2023</year>) <volume>13</volume>:<page-range>678&#x2013;93</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.apsb.2022.09.014</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rahman</surname> <given-names>T</given-names>
</name>
<name>
<surname>Nagar</surname> <given-names>A</given-names>
</name>
<name>
<surname>Duffy</surname> <given-names>EB</given-names>
</name>
<name>
<surname>Okuda</surname> <given-names>K</given-names>
</name>
<name>
<surname>Silverman</surname> <given-names>N</given-names>
</name>
<name>
<surname>Harton</surname> <given-names>JA</given-names>
</name>
</person-group>. <article-title>NLRP3 sensing of diverse inflammatory stimuli requires distinct structural features</article-title>. <source>Front Immunol</source>. (<year>2020</year>) <volume>11</volume>:<elocation-id>1828</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2020.01828</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hochheiser</surname> <given-names>IV</given-names>
</name>
<name>
<surname>Behrmann</surname> <given-names>H</given-names>
</name>
<name>
<surname>Hagelueken</surname> <given-names>G</given-names>
</name>
<name>
<surname>Rodriguez-Alcazar</surname> <given-names>JF</given-names>
</name>
<name>
<surname>Kopp</surname> <given-names>A</given-names>
</name>
<name>
<surname>Latz</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Directionality of PYD filament growth determined by the transition of NLRP3 nucleation seeds to ASC elongation</article-title>. <source>Sci Adv</source>. (<year>2022</year>) <volume>8</volume>:<fpage>eabn7583</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/sciadv.abn7583</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nambayan</surname> <given-names>R</given-names>
</name>
<name>
<surname>Sandin</surname> <given-names>SI</given-names>
</name>
<name>
<surname>Quint</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Satyadi</surname> <given-names>DM</given-names>
</name>
<name>
<surname>de Alba</surname> <given-names>E</given-names>
</name>
</person-group>. <article-title>The inflammasome adapter ASC assembles into filaments with integral participation of its two Death Domains</article-title>. <source>J Biol Chem</source>. (<year>2019</year>) <volume>294</volume>:<page-range>439&#x2013;52</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/jbc.RA118.004407</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Segovia</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Tsai</surname> <given-names>SY</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>TH</given-names>
</name>
<name>
<surname>Shil</surname> <given-names>NK</given-names>
</name>
<name>
<surname>Weintraub</surname> <given-names>ST</given-names>
</name>
<name>
<surname>Short</surname> <given-names>JD</given-names>
</name>
<etal/>
</person-group>. <article-title>Nedd8 regulates inflammasome-dependent caspase-1 activation</article-title>. <source>Mol Cell Biol</source>. (<year>2015</year>) <volume>35</volume>:<page-range>582&#x2013;97</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/MCB.00775-14</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seok</surname> <given-names>JK</given-names>
</name>
<name>
<surname>Kang</surname> <given-names>HC</given-names>
</name>
<name>
<surname>Cho</surname> <given-names>YY</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>HS</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>JY</given-names>
</name>
</person-group>. <article-title>Regulation of the NLRP3 inflammasome by post-translational modifications and small molecules</article-title>. <source>Front Immunol</source>. (<year>2020</year>) <volume>11</volume>:<elocation-id>618231</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2020.618231</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toldo</surname> <given-names>S</given-names>
</name>
<name>
<surname>Mezzaroma</surname> <given-names>E</given-names>
</name>
<name>
<surname>McGeough</surname> <given-names>MD</given-names>
</name>
<name>
<surname>Pena</surname> <given-names>CA</given-names>
</name>
<name>
<surname>Marchetti</surname> <given-names>C</given-names>
</name>
<name>
<surname>Sonnino</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Independent roles of the priming and the triggering of the NLRP3 inflammasome in the heart</article-title>. <source>Cardiovasc Res</source>. (<year>2015</year>) <volume>105</volume>:<page-range>203&#x2013;12</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/cvr/cvu259</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wan</surname> <given-names>F</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kou</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Targeting microglial alpha-synuclein/TLRs/NF-kappaB/NLRP3 inflammasome axis in parkinson's disease</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<elocation-id>719807</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.719807</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sano</surname> <given-names>S</given-names>
</name>
<name>
<surname>Oshima</surname> <given-names>K</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>MacLauchlan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Katanasaka</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Sano</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1beta/NLRP3 inflammasome</article-title>. <source>J Am Coll Cardiol</source>. (<year>2018</year>) <volume>71</volume>:<page-range>875&#x2013;86</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jacc.2017.12.037</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGeough</surname> <given-names>MD</given-names>
</name>
<name>
<surname>Wree</surname> <given-names>A</given-names>
</name>
<name>
<surname>Inzaugarat</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Haimovich</surname> <given-names>A</given-names>
</name>
<name>
<surname>Johnson</surname> <given-names>CD</given-names>
</name>
<name>
<surname>Pena</surname> <given-names>CA</given-names>
</name>
<etal/>
</person-group>. <article-title>TNF regulates transcription of NLRP3 inflammasome components and inflammatory molecules in cryopyrinopathies</article-title>. <source>J Clin Invest</source>. (<year>2017</year>) <volume>127</volume>:<page-range>4488&#x2013;97</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1172/JCI90699</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname> <given-names>N</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>ZS</given-names>
</name>
<name>
<surname>Xue</surname> <given-names>W</given-names>
</name>
<name>
<surname>Bai</surname> <given-names>ZF</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>QY</given-names>
</name>
<name>
<surname>Dai</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>NLRP3 phosphorylation is an essential priming event for inflammasome activation</article-title>. <source>Mol Cell</source>. (<year>2017</year>) <volume>68</volume>:<page-range>185&#x2013;97</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.molcel.2017.08.017</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Fang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Chi</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Ubiquitination of NLRP3 by gp78/Insig-1 restrains NLRP3 inflammasome activation</article-title>. <source>Cell Death Differ</source>. (<year>2022</year>) <volume>29</volume>:<page-range>1582&#x2013;95</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41418-022-00947-8</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname> <given-names>H</given-names>
</name>
<name>
<surname>Kwon</surname> <given-names>S</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>X</given-names>
</name>
<name>
<surname>Akther</surname> <given-names>M</given-names>
</name>
<name>
<surname>Han</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Vanillylacetone attenuates NLRP3 inflammasome mediated immune responses in murine bone marrow derived macrophages via NLRP3 alkylation</article-title>. <source>J Funct Foods</source>. (<year>2020</year>) <volume>64</volume>:<elocation-id>103655</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jff.2019.103655</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mishra</surname> <given-names>BB</given-names>
</name>
<name>
<surname>Rathinam</surname> <given-names>VA</given-names>
</name>
<name>
<surname>Martens</surname> <given-names>GW</given-names>
</name>
<name>
<surname>Martinot</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Kornfeld</surname> <given-names>H</given-names>
</name>
<name>
<surname>Fitzgerald</surname> <given-names>KA</given-names>
</name>
<etal/>
</person-group>. <article-title>Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1beta</article-title>. <source>Nat Immunol</source>. (<year>2013</year>) <volume>14</volume>:<fpage>52</fpage>&#x2013;<lpage>60</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ni.2474</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Gai</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Meng</surname> <given-names>D</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Luo</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Tau induces inflammasome activation and microgliosis through acetylating NLRP3</article-title>. <source>Clin Transl Med</source>. (<year>2024</year>) <volume>14</volume>:<fpage>e1623</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/ctm2.1623</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barry</surname> <given-names>R</given-names>
</name>
<name>
<surname>John</surname> <given-names>SW</given-names>
</name>
<name>
<surname>Liccardi</surname> <given-names>G</given-names>
</name>
<name>
<surname>Tenev</surname> <given-names>T</given-names>
</name>
<name>
<surname>Jaco</surname> <given-names>I</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>CH</given-names>
</name>
<etal/>
</person-group>. <article-title>SUMO-mediated regulation of NLRP3 modulates inflammasome activity</article-title>. <source>Nat Commun</source>. (<year>2018</year>) <volume>9</volume>:<fpage>3001</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41467-018-05321-2</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munoz-Planillo</surname> <given-names>R</given-names>
</name>
<name>
<surname>Kuffa</surname> <given-names>P</given-names>
</name>
<name>
<surname>Martinez-Colon</surname> <given-names>G</given-names>
</name>
<name>
<surname>Smith</surname> <given-names>BL</given-names>
</name>
<name>
<surname>Rajendiran</surname> <given-names>TM</given-names>
</name>
<name>
<surname>Nunez</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter</article-title>. <source>Immunity</source>. (<year>2013</year>) <volume>38</volume>:<page-range>1142&#x2013;53</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2013.05.016</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname> <given-names>T</given-names>
</name>
<name>
<surname>Lang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Gong</surname> <given-names>T</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation</article-title>. <source>Nat Commun</source>. (<year>2017</year>) <volume>8</volume>:<fpage>202</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41467-017-00227-x</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname> <given-names>R</given-names>
</name>
<name>
<surname>Yazdi</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Menu</surname> <given-names>P</given-names>
</name>
<name>
<surname>Tschopp</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>A role for mitochondria in NLRP3 inflammasome activation</article-title>. <source>Nature</source>. (<year>2011</year>) <volume>469</volume>:<page-range>221&#x2013;25</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature09663</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimada</surname> <given-names>K</given-names>
</name>
<name>
<surname>Crother</surname> <given-names>TR</given-names>
</name>
<name>
<surname>Karlin</surname> <given-names>J</given-names>
</name>
<name>
<surname>Dagvadorj</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chiba</surname> <given-names>N</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis</article-title>. <source>Immunity</source>. (<year>2012</year>) <volume>36</volume>:<page-range>401&#x2013;14</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2012.01.009</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murakami</surname> <given-names>T</given-names>
</name>
<name>
<surname>Ockinger</surname> <given-names>J</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Byles</surname> <given-names>V</given-names>
</name>
<name>
<surname>McColl</surname> <given-names>A</given-names>
</name>
<name>
<surname>Hofer</surname> <given-names>AM</given-names>
</name>
<etal/>
</person-group>. <article-title>Critical role for calcium mobilization in activation of the NLRP3 inflammasome</article-title>. <source>Proc Natl Acad Sci U.S.A</source>. (<year>2012</year>) <volume>109</volume>:<page-range>11282&#x2013;87</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.1117765109</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>ZJ</given-names>
</name>
</person-group>. <article-title>PtdIns4P on dispersed trans-Golgi network mediates NLRP3 inflammasome activation</article-title>. <source>Nature</source>. (<year>2018</year>) <volume>564</volume>:<page-range>71&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41586-018-0761-3</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Jia</surname> <given-names>L</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Fu</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Su</surname> <given-names>SA</given-names>
</name>
<etal/>
</person-group>. <article-title>Cathepsin B aggravates coxsackievirus B3-induced myocarditis through activating the inflammasome and promoting pyroptosis</article-title>. <source>PloS Pathog</source>. (<year>2018</year>) <volume>14</volume>:<fpage>e1006872</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.ppat.1006872</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swanson</surname> <given-names>KV</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ting</surname> <given-names>JP</given-names>
</name>
</person-group>. <article-title>The NLRP3 inflammasome: molecular activation and regulation to therapeutics</article-title>. <source>Nat Rev Immunol</source>. (<year>2019</year>) <volume>19</volume>:<page-range>477&#x2013;89</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41577-019-0165-0</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname> <given-names>BL</given-names>
</name>
<name>
<surname>Stowe</surname> <given-names>IB</given-names>
</name>
<name>
<surname>Gupta</surname> <given-names>A</given-names>
</name>
<name>
<surname>Kornfeld</surname> <given-names>OS</given-names>
</name>
<name>
<surname>Roose-Girma</surname> <given-names>M</given-names>
</name>
<name>
<surname>Anderson</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Caspase-11 auto-proteolysis is crucial for noncanonical inflammasome activation</article-title>. <source>J Exp Med</source>. (<year>2018</year>) <volume>215</volume>:<page-range>2279&#x2013;88</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.20180589</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>K</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death</article-title>. <source>Nature</source>. (<year>2015</year>) <volume>526</volume>:<page-range>660&#x2013;65</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature15514</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>W</given-names>
</name>
<name>
<surname>Ding</surname> <given-names>J</given-names>
</name>
<name>
<surname>Li</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Inflammatory caspases are innate immune receptors for intracellular LPS</article-title>. <source>Nature</source>. (<year>2014</year>) <volume>514</volume>:<page-range>187&#x2013;92</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature13683</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kayagaki</surname> <given-names>N</given-names>
</name>
<name>
<surname>Stowe</surname> <given-names>IB</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>BL</given-names>
</name>
<name>
<surname>O'Rourke</surname> <given-names>K</given-names>
</name>
<name>
<surname>Anderson</surname> <given-names>K</given-names>
</name>
<name>
<surname>Warming</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling</article-title>. <source>Nature</source>. (<year>2015</year>) <volume>526</volume>:<page-range>666&#x2013;71</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature15541</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmid-Burgk</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Gaidt</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Schmidt</surname> <given-names>T</given-names>
</name>
<name>
<surname>Ebert</surname> <given-names>TS</given-names>
</name>
<name>
<surname>Bartok</surname> <given-names>E</given-names>
</name>
<name>
<surname>Hornung</surname> <given-names>V</given-names>
</name>
</person-group>. <article-title>Caspase-4 mediates non-canonical activation of the NLRP3 inflammasome in human myeloid cells</article-title>. <source>Eur J Immunol</source>. (<year>2015</year>) <volume>45</volume>:<page-range>2911&#x2013;17</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/eji.201545523</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Platnich</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Chung</surname> <given-names>H</given-names>
</name>
<name>
<surname>Lau</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sandall</surname> <given-names>CF</given-names>
</name>
<name>
<surname>Bondzi-Simpson</surname> <given-names>A</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>HM</given-names>
</name>
<etal/>
</person-group>. <article-title>Shiga toxin/lipopolysaccharide activates caspase-4 and gasdermin D to trigger mitochondrial reactive oxygen species upstream of the NLRP3 inflammasome</article-title>. <source>Cell Rep</source>. (<year>2018</year>) <volume>25</volume>:<page-range>1525&#x2013;36</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.celrep.2018.09.071</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname> <given-names>F</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>J</given-names>
</name>
<name>
<surname>Li</surname> <given-names>W</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>X</given-names>
</name>
<name>
<surname>Qian</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>The orphan receptor Nur77 binds cytoplasmic LPS to activate the non-canonical NLRP3 inflammasome</article-title>. <source>Immunity</source>. (<year>2023</year>) <volume>56</volume>:<page-range>753&#x2013;67</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2023.03.003</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruhl</surname> <given-names>S</given-names>
</name>
<name>
<surname>Broz</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Caspase-11 activates a canonical NLRP3 inflammasome by promoting K(+) efflux</article-title>. <source>Eur J Immunol</source>. (<year>2015</year>) <volume>45</volume>:<page-range>2927&#x2013;36</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/eji.201545772</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>D</given-names>
</name>
<name>
<surname>He</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Munoz-Planillo</surname> <given-names>R</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Nunez</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Caspase-11 requires the pannexin-1 channel and the purinergic P2X7 pore to mediate pyroptosis and endotoxic shock</article-title>. <source>Immunity</source>. (<year>2015</year>) <volume>43</volume>:<page-range>923&#x2013;32</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2015.10.009</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moretti</surname> <given-names>J</given-names>
</name>
<name>
<surname>Jia</surname> <given-names>B</given-names>
</name>
<name>
<surname>Hutchins</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Roy</surname> <given-names>S</given-names>
</name>
<name>
<surname>Yip</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Caspase-11 interaction with NLRP3 potentiates the noncanonical activation of the NLRP3 inflammasome</article-title>. <source>Nat Immunol</source>. (<year>2022</year>) <volume>23</volume>:<page-range>705&#x2013;17</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41590-022-01192-4</pub-id>
</citation>
</ref>
<ref id="B52">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zanoni</surname> <given-names>I</given-names>
</name>
<name>
<surname>Tan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Di Gioia</surname> <given-names>M</given-names>
</name>
<name>
<surname>Broggi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ruan</surname> <given-names>J</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>An endogenous caspase-11 ligand elicits interleukin-1 release from living dendritic cells</article-title>. <source>Science</source>. (<year>2016</year>) <volume>352</volume>:<page-range>1232&#x2013;36</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.aaf3036</pub-id>
</citation>
</ref>
<ref id="B53">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chu</surname> <given-names>LH</given-names>
</name>
<name>
<surname>Indramohan</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ratsimandresy</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Gangopadhyay</surname> <given-names>A</given-names>
</name>
<name>
<surname>Morris</surname> <given-names>EP</given-names>
</name>
<name>
<surname>Monack</surname> <given-names>DM</given-names>
</name>
<etal/>
</person-group>. <article-title>The oxidized phospholipid oxPAPC protects from septic shock by targeting the non-canonical inflammasome in macrophages</article-title>. <source>Nat Commun</source>. (<year>2018</year>) <volume>9</volume>:<fpage>996</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41467-018-03409-3</pub-id>
</citation>
</ref>
<ref id="B54">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaidt</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Ebert</surname> <given-names>TS</given-names>
</name>
<name>
<surname>Chauhan</surname> <given-names>D</given-names>
</name>
<name>
<surname>Schmidt</surname> <given-names>T</given-names>
</name>
<name>
<surname>Schmid-Burgk</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Rapino</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Human monocytes engage an alternative inflammasome pathway</article-title>. <source>Immunity</source>. (<year>2016</year>) <volume>44</volume>:<page-range>833&#x2013;46</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2016.01.012</pub-id>
</citation>
</ref>
<ref id="B55">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verma</surname> <given-names>D</given-names>
</name>
<name>
<surname>Fekri</surname> <given-names>SZ</given-names>
</name>
<name>
<surname>Sigurdardottir</surname> <given-names>G</given-names>
</name>
<name>
<surname>Bivik</surname> <given-names>EC</given-names>
</name>
<name>
<surname>Sandin</surname> <given-names>C</given-names>
</name>
<name>
<surname>Enerback</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Enhanced inflammasome activity in patients with psoriasis promotes systemic inflammation</article-title>. <source>J Invest Dermatol</source>. (<year>2021</year>) <volume>141</volume>:<page-range>586&#x2013;95</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jid.2020.07.012</pub-id>
</citation>
</ref>
<ref id="B56">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zewinger</surname> <given-names>S</given-names>
</name>
<name>
<surname>Reiser</surname> <given-names>J</given-names>
</name>
<name>
<surname>Jankowski</surname> <given-names>V</given-names>
</name>
<name>
<surname>Alansary</surname> <given-names>D</given-names>
</name>
<name>
<surname>Hahm</surname> <given-names>E</given-names>
</name>
<name>
<surname>Triem</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation</article-title>. <source>Nat Immunol</source>. (<year>2020</year>) <volume>21</volume>:<fpage>30</fpage>&#x2013;<lpage>41</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41590-019-0548-1</pub-id>
</citation>
</ref>
<ref id="B57">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frangogiannis</surname> <given-names>NG</given-names>
</name>
</person-group>. <article-title>The inflammatory response in myocardial injury, repair, and remodelling</article-title>. <source>Nat Rev Cardiol</source>. (<year>2014</year>) <volume>11</volume>:<page-range>255&#x2013;65</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrcardio.2014.28</pub-id>
</citation>
</ref>
<ref id="B58">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Westman</surname> <given-names>PC</given-names>
</name>
<name>
<surname>Lipinski</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Luger</surname> <given-names>D</given-names>
</name>
<name>
<surname>Waksman</surname> <given-names>R</given-names>
</name>
<name>
<surname>Bonow</surname> <given-names>RO</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction</article-title>. <source>J Am Coll Cardiol</source>. (<year>2016</year>) <volume>67</volume>:<page-range>2050&#x2013;60</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jacc.2016.01.073</pub-id>
</citation>
</ref>
<ref id="B59">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lan</surname> <given-names>T</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>G</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>K</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Xin-Li formula attenuates heart failure induced by a combination of hyperlipidemia and myocardial infarction in rats via Treg immunomodulation and NLRP3 inflammasome inhibition</article-title>. <source>J Tradit Complement Med</source>. (<year>2023</year>) <volume>13</volume>:<page-range>441&#x2013;53</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jtcme.2023.03.009</pub-id>
</citation>
</ref>
<ref id="B60">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marunouchi</surname> <given-names>T</given-names>
</name>
<name>
<surname>Iguchi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Shindo</surname> <given-names>A</given-names>
</name>
<name>
<surname>Shimbo</surname> <given-names>N</given-names>
</name>
<name>
<surname>Yano</surname> <given-names>E</given-names>
</name>
<name>
<surname>Tanonaka</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Involvement of Hsp90 in NLRP3 inflammasome activation in the failing heart following myocardial infarction in rats</article-title>. <source>Biochem Pharmacol</source>. (<year>2023</year>) <volume>212</volume>:<elocation-id>115547</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bcp.2023.115547</pub-id>
</citation>
</ref>
<ref id="B61">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mezzaroma</surname> <given-names>E</given-names>
</name>
<name>
<surname>Toldo</surname> <given-names>S</given-names>
</name>
<name>
<surname>Farkas</surname> <given-names>D</given-names>
</name>
<name>
<surname>Seropian</surname> <given-names>IM</given-names>
</name>
<name>
<surname>Van Tassell</surname> <given-names>BW</given-names>
</name>
<name>
<surname>Salloum</surname> <given-names>FN</given-names>
</name>
<etal/>
</person-group>. <article-title>The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse</article-title>. <source>Proc Natl Acad Sci U.S.A</source>. (<year>2011</year>) <volume>108</volume>:<page-range>19725&#x2013;30</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.1108586108</pub-id>
</citation>
</ref>
<ref id="B62">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>F</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>ZQ</given-names>
</name>
<name>
<surname>Zhong</surname> <given-names>GL</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>JJ</given-names>
</name>
</person-group>. <article-title>Nicorandil inhibits TLR4/MyD88/NF-kappaB/NLRP3 signaling pathway to reduce pyroptosis in rats with myocardial infarction</article-title>. <source>Exp Biol Med (Maywood)</source>. (<year>2021</year>) <volume>246</volume>:<page-range>1938&#x2013;47</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/15353702211013444</pub-id>
</citation>
</ref>
<ref id="B63">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toldo</surname> <given-names>S</given-names>
</name>
<name>
<surname>Marchetti</surname> <given-names>C</given-names>
</name>
<name>
<surname>Mauro</surname> <given-names>AG</given-names>
</name>
<name>
<surname>Chojnacki</surname> <given-names>J</given-names>
</name>
<name>
<surname>Mezzaroma</surname> <given-names>E</given-names>
</name>
<name>
<surname>Carbone</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemia-reperfusion in the mouse</article-title>. <source>Int J Cardiol</source>. (<year>2016</year>) <volume>209</volume>:<page-range>215&#x2013;20</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijcard.2016.02.043</pub-id>
</citation>
</ref>
<ref id="B64">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>D</given-names>
</name>
<name>
<surname>Shali</surname> <given-names>S</given-names>
</name>
<name>
<surname>Li</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>M2 macrophage-derived exosomes carry microRNA-148a to alleviate myocardial ischemia/reperfusion injury via inhibiting TXNIP and the TLR4/NF-kappaB/NLRP3 inflammasome signaling pathway</article-title>. <source>J Mol Cell Cardiol</source>. (<year>2020</year>) <volume>142</volume>:<fpage>65</fpage>&#x2013;<lpage>79</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.yjmcc.2020.02.007</pub-id>
</citation>
</ref>
<ref id="B65">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>X</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Hua</surname> <given-names>F</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Metformin protects against myocardial ischemia-reperfusion injury and cell pyroptosis via AMPK/NLRP3 inflammasome pathway</article-title>. <source>Aging (Albany Ny)</source>. (<year>2020</year>) <volume>12</volume>:<page-range>24270&#x2013;87</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.18632/aging.202143</pub-id>
</citation>
</ref>
<ref id="B66">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>W</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>D</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
<name>
<surname>He</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Fedorova</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>SIRT1 agonism modulates cardiac NLRP3 inflammasome through pyruvate dehydrogenase during ischemia and reperfusion</article-title>. <source>Redox Biol</source>. (<year>2020</year>) <volume>34</volume>:<elocation-id>101538</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.redox.2020.101538</pub-id>
</citation>
</ref>
<ref id="B67">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bi</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Han</surname> <given-names>T</given-names>
</name>
<name>
<surname>Li</surname> <given-names>YE</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>NN</given-names>
</name>
<etal/>
</person-group>. <article-title>The E3 ubiquitin ligase MARCH2 protects against myocardial ischemia-reperfusion injury through inhibiting pyroptosis via negative regulation of PGAM5/MAVS/NLRP3 axis</article-title>. <source>Cell Discovery</source>. (<year>2024</year>) <volume>10</volume>:<fpage>24</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41421-023-00622-3</pub-id>
</citation>
</ref>
<ref id="B68">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>CD</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>YH</given-names>
</name>
<name>
<surname>Sheng</surname> <given-names>LS</given-names>
</name>
<name>
<surname>Song</surname> <given-names>XY</given-names>
</name>
<etal/>
</person-group>. <article-title>Chinese medicinal formula Fu Xin decoction against chronic heart failure by inhibiting the NLRP3/caspase-1/GSDMD pyroptotic pathway</article-title>. <source>BioMed Pharmacother</source>. (<year>2024</year>) <volume>174</volume>:<elocation-id>116548</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.biopha.2024.116548</pub-id>
</citation>
</ref>
<ref id="B69">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>TAOK1-mediated regulation of the YAP/TEAD pathway as a potential therapeutic target in heart failure</article-title>. <source>PloS One</source>. (<year>2024</year>) <volume>19</volume>:<fpage>e308619</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0308619</pub-id>
</citation>
</ref>
<ref id="B70">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ping</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Fangfang</surname> <given-names>T</given-names>
</name>
<name>
<surname>Yuliang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Xinyong</surname> <given-names>C</given-names>
</name>
<name>
<surname>Lang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Oxidative stress and pyroptosis in doxorubicin-induced heart failure and atrial fibrillation</article-title>. <source>Oxid Med Cell Longev</source>. (<year>2023</year>) <volume>2023</volume>:<elocation-id>4938287</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2023/4938287</pub-id>
</citation>
</ref>
<ref id="B71">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Cai</surname> <given-names>X</given-names>
</name>
<name>
<surname>Shao</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>The m(6)A demethylase fat mass and obesity-associated protein mitigates pyroptosis and inflammation in doxorubicin-induced heart failure via the toll-like receptor 4/NF-kappaB pathway</article-title>. <source>Cardiovasc Diagn Ther</source>. (<year>2024</year>) <volume>14</volume>:<page-range>158&#x2013;73</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.21037/cdt-23-326</pub-id>
</citation>
</ref>
<ref id="B72">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname> <given-names>C</given-names>
</name>
<name>
<surname>Duan</surname> <given-names>F</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Luo</surname> <given-names>B</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>B</given-names>
</name>
<name>
<surname>Lou</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy</article-title>. <source>Redox Biol</source>. (<year>2020</year>) <volume>34</volume>:<elocation-id>101523</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.redox.2020.101523</pub-id>
</citation>
</ref>
<ref id="B73">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lafuse</surname> <given-names>WP</given-names>
</name>
<name>
<surname>Wozniak</surname> <given-names>DJ</given-names>
</name>
<name>
<surname>Rajaram</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Role of cardiac macrophages on cardiac inflammation, fibrosis and tissue repair</article-title>. <source>Cells</source>. (<year>2020</year>) <volume>10</volume>:<fpage>51</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cells10010051</pub-id>
</citation>
</ref>
<ref id="B74">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Byrne</surname> <given-names>NJ</given-names>
</name>
<name>
<surname>Matsumura</surname> <given-names>N</given-names>
</name>
<name>
<surname>Maayah</surname> <given-names>ZH</given-names>
</name>
<name>
<surname>Ferdaoussi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Takahara</surname> <given-names>S</given-names>
</name>
<name>
<surname>Darwesh</surname> <given-names>AM</given-names>
</name>
<etal/>
</person-group>. <article-title>Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (Nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure</article-title>. <source>Circ Heart Fail</source>. (<year>2020</year>) <volume>13</volume>:<fpage>e6277</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.119.006277</pub-id>
</citation>
</ref>
<ref id="B75">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suetomi</surname> <given-names>T</given-names>
</name>
<name>
<surname>Willeford</surname> <given-names>A</given-names>
</name>
<name>
<surname>Brand</surname> <given-names>CS</given-names>
</name>
<name>
<surname>Cho</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ross</surname> <given-names>RS</given-names>
</name>
<name>
<surname>Miyamoto</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Inflammation and NLRP3 inflammasome activation initiated in response to pressure overload by ca(2+)/calmodulin-dependent protein kinase II delta signaling in cardiomyocytes are essential for adverse cardiac remodeling</article-title>. <source>Circulation</source>. (<year>2018</year>) <volume>138</volume>:<page-range>2530&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.034621</pub-id>
</citation>
</ref>
<ref id="B76">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Willeford</surname> <given-names>A</given-names>
</name>
<name>
<surname>Suetomi</surname> <given-names>T</given-names>
</name>
<name>
<surname>Nickle</surname> <given-names>A</given-names>
</name>
<name>
<surname>Hoffman</surname> <given-names>HM</given-names>
</name>
<name>
<surname>Miyamoto</surname> <given-names>S</given-names>
</name>
<name>
<surname>Heller</surname> <given-names>BJ</given-names>
</name>
</person-group>. <article-title>CaMKIIdelta-mediated inflammatory gene expression and inflammasome activation in cardiomyocytes initiate inflammation and induce fibrosis</article-title>. <source>JCI Insight</source>. (<year>2018</year>) <volume>3</volume>:<elocation-id>e97054</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1172/jci.insight.97054</pub-id>
</citation>
</ref>
<ref id="B77">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>P</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>IL-30 protects against sepsis-induced myocardial dysfunction by inhibiting pro-inflammatory macrophage polarization and pyroptosis</article-title>. <source>Iscience</source>. (<year>2023</year>) <volume>26</volume>:<elocation-id>107544</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.isci.2023.107544</pub-id>
</citation>
</ref>
<ref id="B78">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Qazazi</surname> <given-names>R</given-names>
</name>
<name>
<surname>Lima</surname> <given-names>P</given-names>
</name>
<name>
<surname>Prisco</surname> <given-names>SZ</given-names>
</name>
<name>
<surname>Potus</surname> <given-names>F</given-names>
</name>
<name>
<surname>Dasgupta</surname> <given-names>A</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>KH</given-names>
</name>
<etal/>
</person-group>. <article-title>Macrophage-NLRP3 activation promotes right ventricle failure in pulmonary arterial hypertension</article-title>. <source>Am J Respir Crit Care Med</source>. (<year>2022</year>) <volume>206</volume>:<page-range>608&#x2013;24</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1164/rccm.202110-2274OC</pub-id>
</citation>
</ref>
<ref id="B79">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname> <given-names>L</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>G</given-names>
</name>
<name>
<surname>Cao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Dai</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Regulation of the immune microenvironment by an NLRP3 inhibitor contributes to attenuation of acute right ventricular failure in rats with pulmonary arterial hypertension</article-title>. <source>J Inflammation Res</source>. (<year>2021</year>) <volume>14</volume>:<page-range>5699&#x2013;711</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2147/JIR.S336964</pub-id>
</citation>
</ref>
<ref id="B80">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Su</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>D</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>G</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Dao</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Carbonic Anhydrase 3 is required for cardiac repair post myocardial infarction via Smad7-Smad2/3 signaling pathway</article-title>. <source>Int J Biol Sci</source>. (<year>2024</year>) <volume>20</volume>:<page-range>1796&#x2013;814</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.7150/ijbs.91396</pub-id>
</citation>
</ref>
<ref id="B81">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gulati</surname> <given-names>A</given-names>
</name>
<name>
<surname>Japp</surname> <given-names>AG</given-names>
</name>
<name>
<surname>Raza</surname> <given-names>S</given-names>
</name>
<name>
<surname>Halliday</surname> <given-names>BP</given-names>
</name>
<name>
<surname>Jones</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Newsome</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Absence of myocardial fibrosis predicts favorable long-term survival in new-onset heart failure</article-title>. <source>Circ Cardiovasc Imaging</source>. (<year>2018</year>) <volume>11</volume>:<fpage>e7722</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/CIRCIMAGING.118.007722</pub-id>
</citation>
</ref>
<ref id="B82">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roy</surname> <given-names>C</given-names>
</name>
<name>
<surname>Slimani</surname> <given-names>A</given-names>
</name>
<name>
<surname>de Meester</surname> <given-names>C</given-names>
</name>
<name>
<surname>Amzulescu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Pasquet</surname> <given-names>A</given-names>
</name>
<name>
<surname>Vancraeynest</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Associations and prognostic significance of diffuse myocardial fibrosis by cardiovascular magnetic resonance in heart failure with preserved ejection fraction</article-title>. <source>J Cardiovasc Magn Reson</source>. (<year>2018</year>) <volume>20</volume>:<fpage>55</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12968-018-0477-4</pub-id>
</citation>
</ref>
<ref id="B83">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Lopez</surname> <given-names>DJAB</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies</article-title>. <source>Adv Drug Delivery Rev</source>. (<year>2021</year>) <volume>173</volume>:<page-range>504&#x2013;19</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.addr.2021.03.021</pub-id>
</citation>
</ref>
<ref id="B84">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lv</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>ZF</given-names>
</name>
<name>
<surname>Gan</surname> <given-names>WQ</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>WQ</given-names>
</name>
<name>
<surname>Li</surname> <given-names>TG</given-names>
</name>
<name>
<surname>Hou</surname> <given-names>YF</given-names>
</name>
<etal/>
</person-group>. <article-title>Lp-PLA2 inhibition prevents Ang II-induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation</article-title>. <source>Acta Pharmacol Sin</source>. (<year>2021</year>) <volume>42</volume>:<page-range>2016&#x2013;32</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41401-021-00703-7</pub-id>
</citation>
</ref>
<ref id="B85">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gan</surname> <given-names>W</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>J</given-names>
</name>
<name>
<surname>Li</surname> <given-names>T</given-names>
</name>
<name>
<surname>Lv</surname> <given-names>S</given-names>
</name>
<name>
<surname>Li</surname> <given-names>C</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>The SGK1 inhibitor EMD638683, prevents Angiotensin II-induced cardiac inflammation and fibrosis by blocking NLRP3 inflammasome activation</article-title>. <source>Biochim Biophys Acta Mol Basis Dis</source>. (<year>2018</year>) <volume>1864</volume>:<fpage>1</fpage>&#x2013;<lpage>10</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbadis.2017.10.001</pub-id>
</citation>
</ref>
<ref id="B86">
<label>86</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname> <given-names>R</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Lv</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction</article-title>. <source>Int Immunopharmacol</source>. (<year>2019</year>) <volume>74</volume>:<fpage>105575</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.intimp.2019.04.022</pub-id>
</citation>
</ref>
<ref id="B87">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Qu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>T</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>D</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>LuQi formula ameliorates myocardial fibrosis by suppressing TLR4/myD88/NF-kappaB pathway and NLRP3 inflammasome activation in mice with myocardial infarction</article-title>. <source>Evid Based Complement Alternat Med</source>. (<year>2022</year>) <volume>2022</volume>:<elocation-id>5867987</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2022/5867987</pub-id>
</citation>
</ref>
<ref id="B88">
<label>88</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>J</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>N</given-names>
</name>
<name>
<surname>Ding</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Calhex231 ameliorates myocardial fibrosis post myocardial infarction in rats through the autophagy-NLRP3 inflammasome pathway in macrophages</article-title>. <source>J Cell Mol Med</source>. (<year>2020</year>) <volume>24</volume>:<page-range>13440&#x2013;53</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/jcmm.15969</pub-id>
</citation>
</ref>
<ref id="B89">
<label>89</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname> <given-names>S</given-names>
</name>
<name>
<surname>Duan</surname> <given-names>J</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Qi</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Kang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Colchicine alleviates inflammation and improves diastolic dysfunction in heart failure rats with preserved ejection fraction</article-title>. <source>Eur J Pharmacol</source>. (<year>2022</year>) <volume>929</volume>:<elocation-id>175126</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ejphar.2022.175126</pub-id>
</citation>
</ref>
<ref id="B90">
<label>90</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice</article-title>. <source>Cardiovasc Drugs Ther</source>. (<year>2020</year>) <volume>34</volume>:<page-range>629&#x2013;40</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10557-020-06995-x</pub-id>
</citation>
</ref>
<ref id="B91">
<label>91</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>LS</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Hou</surname> <given-names>YL</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>WW</given-names>
</name>
<name>
<surname>Ni</surname> <given-names>XQ</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Intermedin(1-53) inhibits NLRP3 inflammasome activation by targeting IRE1alpha in cardiac fibrosis</article-title>. <source>Inflammation</source>. (<year>2022</year>) <volume>45</volume>:<page-range>1568&#x2013;84</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10753-022-01642-z</pub-id>
</citation>
</ref>
<ref id="B92">
<label>92</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>N</given-names>
</name>
<name>
<surname>Gong</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>CTRP3 inhibits myocardial fibrosis through the P2X7R-NLRP3 inflammasome pathway in SHR rats</article-title>. <source>J Hypertens</source>. (<year>2024</year>) <volume>42</volume>:<page-range>315&#x2013;28</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/HJH.0000000000003591</pub-id>
</citation>
</ref>
<ref id="B93">
<label>93</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>S</given-names>
</name>
<name>
<surname>Withaar</surname> <given-names>C</given-names>
</name>
<name>
<surname>Rodrigues</surname> <given-names>PG</given-names>
</name>
<name>
<surname>Zijlstra</surname> <given-names>SN</given-names>
</name>
<name>
<surname>de Boer</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Sillje</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>The NLRP3-inflammasome inhibitor MCC950 improves cardiac function in a HFpEF mouse model</article-title>. <source>BioMed Pharmacother</source>. (<year>2024</year>) <volume>181</volume>:<elocation-id>117711</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.biopha.2024.117711</pub-id>
</citation>
</ref>
<ref id="B94">
<label>94</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ye</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Selective inhibition of NLRP3 inflammasome reverses pressure overload-induced pathological cardiac remodeling by attenuating hypertrophy, fibrosis, and inflammation</article-title>. <source>Int Immunopharmacol</source>. (<year>2021</year>) <volume>99</volume>:<elocation-id>108046</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.intimp.2021.108046</pub-id>
</citation>
</ref>
<ref id="B95">
<label>95</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname> <given-names>XH</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>WJ</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Lan</surname> <given-names>TH</given-names>
</name>
<name>
<surname>Pan</surname> <given-names>H</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>MY</given-names>
</name>
<etal/>
</person-group>. <article-title>XinLi formula, a traditional Chinese decoction, alleviates chronic heart failure via regulating the interaction of AGTR1 and AQP1</article-title>. <source>Phytomedicine</source>. (<year>2023</year>) <volume>113</volume>:<elocation-id>154722</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.phymed.2023.154722</pub-id>
</citation>
</ref>
<ref id="B96">
<label>96</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caceres</surname> <given-names>FT</given-names>
</name>
<name>
<surname>Gaspari</surname> <given-names>TA</given-names>
</name>
<name>
<surname>Samuel</surname> <given-names>CS</given-names>
</name>
<name>
<surname>Pinar</surname> <given-names>AA</given-names>
</name>
</person-group>. <article-title>Serelaxin inhibits the profibrotic TGF-beta1/IL-1beta axis by targeting TLR-4 and the NLRP3 inflammasome in cardiac myofibroblasts</article-title>. <source>FASEB J</source>. (<year>2019</year>) <volume>33</volume>:<page-range>14717&#x2013;33</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1096/fj.201901079RR</pub-id>
</citation>
</ref>
<ref id="B97">
<label>97</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bracey</surname> <given-names>NA</given-names>
</name>
<name>
<surname>Gershkovich</surname> <given-names>B</given-names>
</name>
<name>
<surname>Chun</surname> <given-names>J</given-names>
</name>
<name>
<surname>Vilaysane</surname> <given-names>A</given-names>
</name>
<name>
<surname>Meijndert</surname> <given-names>HC</given-names>
</name>
<name>
<surname>Wright</surname> <given-names>JJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Mitochondrial NLRP3 protein induces reactive oxygen species to promote Smad protein signaling and fibrosis independent from the inflammasome</article-title>. <source>J Biol Chem</source>. (<year>2014</year>) <volume>289</volume>:<page-range>19571&#x2013;84</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/jbc.M114.550624</pub-id>
</citation>
</ref>
<ref id="B98">
<label>98</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oka</surname> <given-names>T</given-names>
</name>
<name>
<surname>Akazawa</surname> <given-names>H</given-names>
</name>
<name>
<surname>Naito</surname> <given-names>AT</given-names>
</name>
<name>
<surname>Komuro</surname> <given-names>I</given-names>
</name>
</person-group>. <article-title>Angiogenesis and cardiac hypertrophy: maintenance of cardiac function and causative roles in heart failure</article-title>. <source>Circ Res</source>. (<year>2014</year>) <volume>114</volume>:<page-range>565&#x2013;71</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.300507</pub-id>
</citation>
</ref>
<ref id="B99">
<label>99</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duan</surname> <given-names>F</given-names>
</name>
<name>
<surname>Li</surname> <given-names>H</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>B</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>X</given-names>
</name>
</person-group>. <article-title>Loss of trim31 worsens cardiac remodeling in a mouse model of heart failure by enhancing the activation of the NLRP3 inflammasome</article-title>. <source>Inflammation</source>. (<year>2024</year>) <volume>47</volume>:<page-range>1&#x2013;13</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10753-024-02217-w</pub-id>
</citation>
</ref>
<ref id="B100">
<label>100</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schlegel</surname> <given-names>P</given-names>
</name>
<name>
<surname>Reinkober</surname> <given-names>J</given-names>
</name>
<name>
<surname>Meinhardt</surname> <given-names>E</given-names>
</name>
<name>
<surname>Tscheschner</surname> <given-names>H</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>E</given-names>
</name>
<name>
<surname>Schumacher</surname> <given-names>SM</given-names>
</name>
<etal/>
</person-group>. <article-title>G protein-coupled receptor kinase 2 promotes cardiac hypertrophy</article-title>. <source>PloS One</source>. (<year>2017</year>) <volume>12</volume>:<fpage>e182110</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0182110</pub-id>
</citation>
</ref>
<ref id="B101">
<label>101</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>M</given-names>
</name>
<name>
<surname>Wen</surname> <given-names>G</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Paroxetine attenuates cardiac hypertrophy via blocking GRK2 and ADRB1 interaction in hypertension</article-title>. <source>J Am Heart Assoc</source>. (<year>2021</year>) <volume>10</volume>:<fpage>e16364</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/JAHA.120.016364</pub-id>
</citation>
</ref>
<ref id="B102">
<label>102</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Ding</surname> <given-names>L</given-names>
</name>
<name>
<surname>Li</surname> <given-names>W</given-names>
</name>
<name>
<surname>Niu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>GRK2 participation in cardiac hypertrophy induced by isoproterenol through the regulation of Nrf2 signaling and the promotion of NLRP3 inflammasome and oxidative stress</article-title>. <source>Int Immunopharmacol</source>. (<year>2023</year>) <volume>117</volume>:<elocation-id>109957</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.intimp.2023.109957</pub-id>
</citation>
</ref>
<ref id="B103">
<label>103</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lim</surname> <given-names>S</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Jeong</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>J</given-names>
</name>
<name>
<surname>Cho</surname> <given-names>S</given-names>
</name>
<name>
<surname>Seo</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>sRAGE attenuates angiotensin II-induced cardiomyocyte hypertrophy by inhibiting RAGE-NFkappaB-NLRP3 activation</article-title>. <source>Inflammation Res</source>. (<year>2018</year>) <volume>67</volume>:<fpage>691</fpage>&#x2013;<lpage>701</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00011-018-1160-9</pub-id>
</citation>
</ref>
<ref id="B104">
<label>104</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Li</surname> <given-names>W</given-names>
</name>
</person-group>. <article-title>PRMT5 up-regulation improves myocardial hypertrophy by mediating E2F-1/NF-kappaB/NLRP3 pathway</article-title>. <source>Prev Med</source>. (<year>2023</year>) <volume>172</volume>:<elocation-id>107553</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ypmed.2023.107553</pub-id>
</citation>
</ref>
<ref id="B105">
<label>105</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>B</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Qiu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>JX</given-names>
</name>
<name>
<surname>Li</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Inhibition of Sema4D attenuates pressure overload-induced pathological myocardial hypertrophy via the MAPK/NF-kappaB/NLRP3 pathways</article-title>. <source>Biochim Biophys Acta Mol Basis Dis</source>. (<year>2024</year>) <volume>1870</volume>:<elocation-id>166944</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbadis.2023.166944</pub-id>
</citation>
</ref>
<ref id="B106">
<label>106</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>M</given-names>
</name>
<name>
<surname>Li</surname> <given-names>T</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Silica nanoparticles induce pyroptosis and cardiac hypertrophy <italic>via</italic> ROS/NLRP3/Caspase-1 pathway</article-title>. <source>Free Radic Biol Med</source>. (<year>2022</year>) <volume>182</volume>:<page-range>171&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2022.02.027</pub-id>
</citation>
</ref>
<ref id="B107">
<label>107</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Pan</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>S</given-names>
</name>
<name>
<surname>Dai</surname> <given-names>F</given-names>
</name>
<name>
<surname>Chao</surname> <given-names>M</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>SNO-MLP (S-nitrosylation of muscle LIM protein) facilitates myocardial hypertrophy through TLR3 (Toll-like receptor 3)-mediated RIP3 (Receptor-interacting protein kinase 3) and NLRP3 (NOD-like receptor pyrin domain containing 3) inflammasome activation</article-title>. <source>Circulation</source>. (<year>2020</year>) <volume>141</volume>:<fpage>984</fpage>&#x2013;<lpage>1000</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.119.042336</pub-id>
</citation>
</ref>
<ref id="B108">
<label>108</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferraro</surname> <given-names>B</given-names>
</name>
<name>
<surname>Leoni</surname> <given-names>G</given-names>
</name>
<name>
<surname>Hinkel</surname> <given-names>R</given-names>
</name>
<name>
<surname>Ormanns</surname> <given-names>S</given-names>
</name>
<name>
<surname>Paulin</surname> <given-names>N</given-names>
</name>
<name>
<surname>Ortega-Gomez</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Pro-angiogenic macrophage phenotype to promote myocardial repair</article-title>. <source>J Am Coll Cardiol</source>. (<year>2019</year>) <volume>73</volume>:<fpage>2990</fpage>&#x2013;<lpage>3002</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jacc.2019.03.503</pub-id>
</citation>
</ref>
<ref id="B109">
<label>109</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shiojima</surname> <given-names>I</given-names>
</name>
<name>
<surname>Sato</surname> <given-names>K</given-names>
</name>
<name>
<surname>Izumiya</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Schiekofer</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ito</surname> <given-names>M</given-names>
</name>
<name>
<surname>Liao</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure</article-title>. <source>J Clin Invest</source>. (<year>2005</year>) <volume>115</volume>:<page-range>2108&#x2013;18</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1172/JCI24682</pub-id>
</citation>
</ref>
<ref id="B110">
<label>110</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname> <given-names>YH</given-names>
</name>
<name>
<surname>Li</surname> <given-names>LF</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Lv</surname> <given-names>YL</given-names>
</name>
<etal/>
</person-group>. <article-title>Microtubule associated protein 4 (MAP4) phosphorylation reduces cardiac microvascular density through NLRP3-related pyroptosis</article-title>. <source>Cell Death Discovery</source>. (<year>2021</year>) <volume>7</volume>:<fpage>213</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41420-021-00606-w</pub-id>
</citation>
</ref>
<ref id="B111">
<label>111</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname> <given-names>T</given-names>
</name>
<name>
<surname>Xiang</surname> <given-names>DK</given-names>
</name>
<name>
<surname>Li</surname> <given-names>SN</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>LH</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>LF</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>MicroRNA-495 ameliorates cardiac microvascular endothelial cell injury and inflammatory reaction by suppressing the NLRP3 inflammasome signaling pathway</article-title>. <source>Cell Physiol Biochem</source>. (<year>2018</year>) <volume>49</volume>:<fpage>798</fpage>&#x2013;<lpage>815</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1159/000493042</pub-id>
</citation>
</ref>
<ref id="B112">
<label>112</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>H</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>ST</given-names>
</name>
<name>
<surname>Roman</surname> <given-names>RJ</given-names>
</name>
<name>
<surname>Aschner</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Didion</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Endothelial specific SIRT3 deletion impairs glycolysis and angiogenesis and causes diastolic dysfunction</article-title>. <source>J Mol Cell Cardiol</source>. (<year>2017</year>) <volume>112</volume>:<page-range>104&#x2013;13</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.yjmcc.2017.09.007</pub-id>
</citation>
</ref>
<ref id="B113">
<label>113</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>XH</given-names>
</name>
<name>
<surname>Ran</surname> <given-names>L</given-names>
</name>
<name>
<surname>Lang</surname> <given-names>HD</given-names>
</name>
<name>
<surname>Yi</surname> <given-names>L</given-names>
</name>
<name>
<surname>Mi</surname> <given-names>MT</given-names>
</name>
</person-group>. <article-title>Trimethylamine-N-oxide induces vascular inflammation by activating the NLRP3 inflammasome through the SIRT3-SOD2-mtROS signaling pathway</article-title>. <source>J Am Heart Assoc</source>. (<year>2017</year>) <volume>6</volume>:<elocation-id>e006347</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/JAHA.117.006347</pub-id>
</citation>
</ref>
<ref id="B114">
<label>114</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Aynaszyan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Holm</surname> <given-names>K</given-names>
</name>
<name>
<surname>Goldhaber</surname> <given-names>JI</given-names>
</name>
<name>
<surname>Marban</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Ventricular arrhythmias underlie sudden death in rats with heart failure and preserved ejection fraction</article-title>. <source>Circ Arrhythm Electrophysiol</source>. (<year>2018</year>) <volume>11</volume>:<fpage>e6452</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/CIRCEP.118.006452</pub-id>
</citation>
</ref>
<ref id="B115">
<label>115</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Ou</surname> <given-names>D</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Li</surname> <given-names>H</given-names>
</name>
<name>
<surname>Lang</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>MCC950 ameliorates ventricular arrhythmia vulnerability induced by heart failure</article-title>. <source>Bioengineered</source>. (<year>2022</year>) <volume>13</volume>:<page-range>8593&#x2013;604</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/21655979.2022.2053813</pub-id>
</citation>
</ref>
<ref id="B116">
<label>116</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>B</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Silenced SOX2-OT alleviates ventricular arrhythmia associated with heart failure by inhibiting NLRP3 expression via regulating miR-2355-3p</article-title>. <source>Immun Inflammation Dis</source>. (<year>2021</year>) <volume>9</volume>:<page-range>255&#x2013;64</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/iid3.388</pub-id>
</citation>
</ref>
<ref id="B117">
<label>117</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Kong</surname> <given-names>B</given-names>
</name>
<name>
<surname>Shuai</surname> <given-names>W</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Knockout of MD1 contributes to sympathetic hyperactivity and exacerbates ventricular arrhythmias following heart failure with preserved ejection fraction via NLRP3 inflammasome activation</article-title>. <source>Exp Physiol</source>. (<year>2020</year>) <volume>105</volume>:<page-range>966&#x2013;78</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1113/EP088390</pub-id>
</citation>
</ref>
<ref id="B118">
<label>118</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Kong</surname> <given-names>B</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Shuai</surname> <given-names>W</given-names>
</name>
</person-group>. <article-title>Low-intensity pulsed ultrasound treatment mitigates ventricular arrhythmias via inhibiting microglia-mediated neuroinflammation in heart failure rat model</article-title>. <source>Int Immunopharmacol</source>. (<year>2024</year>) <volume>126</volume>:<elocation-id>111317</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.intimp.2023.111317</pub-id>
</citation>
</ref>
<ref id="B119">
<label>119</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Fu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Shuai</surname> <given-names>W</given-names>
</name>
</person-group>. <article-title>Dapansutrile ameliorates atrial inflammation and vulnerability to atrial fibrillation in HFpEF rats</article-title>. <source>Heart Lung Circ</source>. (<year>2024</year>) <volume>33</volume>:<fpage>65</fpage>&#x2013;<lpage>77</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.hlc.2023.09.017</pub-id>
</citation>
</ref>
<ref id="B120">
<label>120</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xue</surname> <given-names>M</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>P2X(7) receptor inhibition attenuated sympathetic nerve sprouting after myocardial infarction via the NLRP3/IL-1beta pathway</article-title>. <source>J Cell Mol Med</source>. (<year>2017</year>) <volume>21</volume>:<page-range>2695&#x2013;710</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/jcmm.13185</pub-id>
</citation>
</ref>
<ref id="B121">
<label>121</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Fei</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Hou</surname> <given-names>J</given-names>
</name>
<name>
<surname>Cai</surname> <given-names>X</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Loss of Camk2n1 aggravates cardiac remodeling and Malignant ventricular arrhythmia after myocardial infarction in mice via NLRP3 inflammasome activation</article-title>. <source>Free Radic Biol Med</source>. (<year>2021</year>) <volume>167</volume>:<page-range>243&#x2013;57</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2021.03.014</pub-id>
</citation>
</ref>
<ref id="B122">
<label>122</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>B</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>M</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>X</given-names>
</name>
</person-group>. <article-title>Phloretin ameliorates heart function after myocardial infarction via NLRP3/Caspase-1/IL-1beta signaling</article-title>. <source>BioMed Pharmacother</source>. (<year>2023</year>) <volume>165</volume>:<elocation-id>115083</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.biopha.2023.115083</pub-id>
</citation>
</ref>
<ref id="B123">
<label>123</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bi</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>W</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Mao</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Muscone attenuates susceptibility to ventricular arrhythmia by inhibiting NLRP3 inflammasome activation in rats after myocardial infarction</article-title>. <source>J Biochem Mol Toxicol</source>. (<year>2023</year>) <volume>37</volume>:<fpage>e23458</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jbt.23458</pub-id>
</citation>
</ref>
<ref id="B124">
<label>124</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopaschuk</surname> <given-names>GD</given-names>
</name>
<name>
<surname>Karwi</surname> <given-names>QG</given-names>
</name>
<name>
<surname>Tian</surname> <given-names>R</given-names>
</name>
<name>
<surname>Wende</surname> <given-names>AR</given-names>
</name>
<name>
<surname>Abel</surname> <given-names>ED</given-names>
</name>
</person-group>. <article-title>Cardiac energy metabolism in heart failure</article-title>. <source>Circ Res</source>. (<year>2021</year>) <volume>128</volume>:<page-range>1487&#x2013;513</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.121.318241</pub-id>
</citation>
</ref>
<ref id="B125">
<label>125</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>H</given-names>
</name>
<name>
<surname>Ding</surname> <given-names>W</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>Nlrp3 deficiency alleviates angiotensin II-induced cardiomyopathy by inhibiting mitochondrial dysfunction</article-title>. <source>Oxid Med Cell Longev</source>. (<year>2021</year>) <volume>2021</volume>:<elocation-id>6679100</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2021/6679100</pub-id>
</citation>
</ref>
<ref id="B126">
<label>126</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname> <given-names>B</given-names>
</name>
<name>
<surname>Li</surname> <given-names>B</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model</article-title>. <source>PloS One</source>. (<year>2014</year>) <volume>9</volume>:<fpage>e104771</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0104771</pub-id>
</citation>
</ref>
<ref id="B127">
<label>127</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mastrocola</surname> <given-names>R</given-names>
</name>
<name>
<surname>Penna</surname> <given-names>C</given-names>
</name>
<name>
<surname>Tullio</surname> <given-names>F</given-names>
</name>
<name>
<surname>Femmino</surname> <given-names>S</given-names>
</name>
<name>
<surname>Nigro</surname> <given-names>D</given-names>
</name>
<name>
<surname>Chiazza</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Pharmacological inhibition of NLRP3 inflammasome attenuates myocardial ischemia/reperfusion injury by activation of RISK and mitochondrial pathways</article-title>. <source>Oxid Med Cell Longev</source>. (<year>2016</year>) <volume>2016</volume>:<elocation-id>5271251</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2016/5271251</pub-id>
</citation>
</ref>
<ref id="B128">
<label>128</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kerr</surname> <given-names>JF</given-names>
</name>
<name>
<surname>Wyllie</surname> <given-names>AH</given-names>
</name>
<name>
<surname>Currie</surname> <given-names>AR</given-names>
</name>
</person-group>. <article-title>Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics</article-title>. <source>Br J Cancer</source>. (<year>1972</year>) <volume>26</volume>:<page-range>239&#x2013;57</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/bjc.1972.33</pub-id>
</citation>
</ref>
<ref id="B129">
<label>129</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Litvinukova</surname> <given-names>M</given-names>
</name>
<name>
<surname>Talavera-Lopez</surname> <given-names>C</given-names>
</name>
<name>
<surname>Maatz</surname> <given-names>H</given-names>
</name>
<name>
<surname>Reichart</surname> <given-names>D</given-names>
</name>
<name>
<surname>Worth</surname> <given-names>CL</given-names>
</name>
<name>
<surname>Lindberg</surname> <given-names>EL</given-names>
</name>
<etal/>
</person-group>. <article-title>Cells of the adult human heart</article-title>. <source>Nature</source>. (<year>2020</year>) <volume>588</volume>:<page-range>466&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41586-020-2797-4</pub-id>
</citation>
</ref>
<ref id="B130">
<label>130</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chunhacha</surname> <given-names>P</given-names>
</name>
<name>
<surname>Pinkaew</surname> <given-names>D</given-names>
</name>
<name>
<surname>Sinthujaroen</surname> <given-names>P</given-names>
</name>
<name>
<surname>Bowles</surname> <given-names>DE</given-names>
</name>
<name>
<surname>Fujise</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Fortilin inhibits p53, halts cardiomyocyte apoptosis, and protects the heart against heart failure</article-title>. <source>Cell Death Discovery</source>. (<year>2021</year>) <volume>7</volume>:<fpage>310</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41420-021-00692-w</pub-id>
</citation>
</ref>
<ref id="B131">
<label>131</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>QQ</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>TT</given-names>
</name>
<name>
<surname>Wan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>QW</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>JH</given-names>
</name>
<etal/>
</person-group>. <article-title>Tax1 banding protein 1 exacerbates heart failure in mice by activating ITCH-P73-BNIP3-mediated cardiomyocyte apoptosis</article-title>. <source>Acta Pharmacol Sin</source>. (<year>2022</year>) <volume>43</volume>:<page-range>2562&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41401-022-00950-2</pub-id>
</citation>
</ref>
<ref id="B132">
<label>132</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>K</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>M</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Chi</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Calcium-sensing receptor on neutrophil promotes myocardial apoptosis and fibrosis after acute myocardial infarction via NLRP3 inflammasome activation</article-title>. <source>Can J Cardiol</source>. (<year>2020</year>) <volume>36</volume>:<fpage>893</fpage>&#x2013;<lpage>905</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cjca.2019.09.026</pub-id>
</citation>
</ref>
<ref id="B133">
<label>133</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Long</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zong</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>ZNF561-AS1 regulates cell proliferation and apoptosis in myocardial infarction through miR-223-3p/NLRP3 axis</article-title>. <source>Cell Transplant</source>. (<year>2022</year>) <volume>31</volume>:<fpage>73831512</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/09636897221077928</pub-id>
</citation>
</ref>
<ref id="B134">
<label>134</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>D</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Pioglitazone protects against hypoxia-induced cardiomyocyte apoptosis through inhibiting NLRP3/caspase-1 pathway <italic>in vivo and in vitro</italic>
</article-title>. <source>Int Heart J</source>. (<year>2022</year>) <volume>63</volume>:<fpage>893</fpage>&#x2013;<lpage>903</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1536/ihj.21-404</pub-id>
</citation>
</ref>
<ref id="B135">
<label>135</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Li</surname> <given-names>F</given-names>
</name>
<name>
<surname>Li</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Du</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Overexpression of lncRNA HULC Attenuates Myocardial Ischemia/reperfusion Injury in Rat Models and Apoptosis of Hypoxia/reoxygenation Cardiomyocytes via Targeting miR-377-5p through NLRP3/Caspase&#x2212;1/IL&#x2212;1beta Signaling Pathway Inhibition</article-title>. <source>Immunol Invest</source>. (<year>2021</year>) <volume>50</volume>:<page-range>925&#x2013;38</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/08820139.2020.1791178</pub-id>
</citation>
</ref>
<ref id="B136">
<label>136</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>N</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Duan</surname> <given-names>M</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>STING-IRF3 contributes to lipopolysaccharide-induced cardiac dysfunction, inflammation, apoptosis and pyroptosis by activating NLRP3</article-title>. <source>Redox Biol</source>. (<year>2019</year>) <volume>24</volume>:<elocation-id>101215</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.redox.2019.101215</pub-id>
</citation>
</ref>
<ref id="B137">
<label>137</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Qu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>T</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Astragaloside IV attenuate MI-induced myocardial fibrosis and cardiac remodeling by inhibiting ROS/caspase-1/GSDMD signaling pathway</article-title>. <source>Cell Cycle</source>. (<year>2022</year>) <volume>21</volume>:<page-range>2309&#x2013;22</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/15384101.2022.2093598</pub-id>
</citation>
</ref>
<ref id="B138">
<label>138</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>T</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>K</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>J</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Astragaloside IV prevents myocardial hypertrophy induced by mechanical stress by activating autophagy and reducing inflammation</article-title>. <source>Am J Transl Res</source>. (<year>2020</year>) <volume>12</volume>:<page-range>5332&#x2013;42</page-range>.</citation>
</ref>
<ref id="B139">
<label>139</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tian</surname> <given-names>W</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>P</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Song</surname> <given-names>P</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Astragaloside IV alleviates doxorubicin-induced cardiotoxicity by inhibiting cardiomyocyte pyroptosis through the SIRT1/NLRP3 pathway</article-title>. <source>Am J Chin Med</source>. (<year>2024</year>) <volume>52</volume>:<page-range>453&#x2013;69</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1142/S0192415X24500198</pub-id>
</citation>
</ref>
<ref id="B140">
<label>140</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname> <given-names>LJ</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>RC</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>XY</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>GB</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>XB</given-names>
</name>
</person-group>. <article-title>Scutellarin protects against myocardial ischemia-reperfusion injury by suppressing NLRP3 inflammasome activation</article-title>. <source>Phytomedicine</source>. (<year>2020</year>) <volume>68</volume>:<elocation-id>153169</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.phymed.2020.153169</pub-id>
</citation>
</ref>
<ref id="B141">
<label>141</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname> <given-names>F</given-names>
</name>
<name>
<surname>Han</surname> <given-names>X</given-names>
</name>
<name>
<surname>You</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>YH</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>YY</given-names>
</name>
<etal/>
</person-group>. <article-title>Hydroxysafflor yellow A inhibits pyroptosis and protecting HUVECs from OGD/R via NLRP3/caspase-1/GSDMD pathway</article-title>. <source>Chin J Integr Med</source>. (<year>2024</year>) <volume>30</volume>:<page-range>1027&#x2013;34</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s11655-023-3716-y</pub-id>
</citation>
</ref>
<ref id="B142">
<label>142</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ye</surname> <given-names>JX</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>RY</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>HT</given-names>
</name>
<name>
<surname>Qi</surname> <given-names>YD</given-names>
</name>
<name>
<surname>Fu</surname> <given-names>JH</given-names>
</name>
<etal/>
</person-group>. <article-title>Hydroxysafflor yellow A inhibits hypoxia/reoxygenation-induced cardiomyocyte injury via regulating the AMPK/NLRP3 inflammasome pathway</article-title>. <source>Int Immunopharmacol</source>. (<year>2020</year>) <volume>82</volume>:<elocation-id>106316</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.intimp.2020.106316</pub-id>
</citation>
</ref>
<ref id="B143">
<label>143</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ye</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ge</surname> <given-names>W</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Qi</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Hydroxysafflor yellow A protects against myocardial ischemia/reperfusion injury via suppressing NLRP3 inflammasome and activating autophagy</article-title>. <source>Front Pharmacol</source>. (<year>2020</year>) <volume>11</volume>:<elocation-id>1170</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fphar.2020.01170</pub-id>
</citation>
</ref>
<ref id="B144">
<label>144</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>DS</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>LY</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>DZ</given-names>
</name>
<name>
<surname>Lyu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Fang</surname> <given-names>LH</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>SB</given-names>
</name>
<etal/>
</person-group>. <article-title>Formononetin ameliorates myocardial ischemia/reperfusion injury in rats by suppressing the ROS-TXNIP-NLRP3 pathway</article-title>. <source>Biochem Biophys Res Commun</source>. (<year>2020</year>) <volume>525</volume>:<page-range>759&#x2013;66</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbrc.2020.02.147</pub-id>
</citation>
</ref>
<ref id="B145">
<label>145</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Du</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Dou</surname> <given-names>S</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>The protective effect of Luteolin on myocardial ischemia/reperfusion (I/R) injury through TLR4/NF-kappaB/NLRP3 inflammasome pathway</article-title>. <source>BioMed Pharmacother</source>. (<year>2017</year>) <volume>91</volume>:<page-range>1042&#x2013;52</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.biopha.2017.05.033</pub-id>
</citation>
</ref>
<ref id="B146">
<label>146</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Fu</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Luteolin alleviates myocardial ischemia reperfusion injury in rats via Siti1/NLRP3/NF-kappaB pathway</article-title>. <source>Int Immunopharmacol</source>. (<year>2020</year>) <volume>85</volume>:<elocation-id>106680</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.intimp.2020.106680</pub-id>
</citation>
</ref>
<ref id="B147">
<label>147</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bai</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>D</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Biochanin A attenuates myocardial ischemia/reperfusion injury through the TLR4/NF-kappaB/NLRP3 signaling pathway</article-title>. <source>Acta Cir Bras</source>. (<year>2019</year>) <volume>34</volume>:<fpage>e201901104</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1590/s0102-865020190110000004</pub-id>
</citation>
</ref>
<ref id="B148">
<label>148</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yue</surname> <given-names>R</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Luo</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Lv</surname> <given-names>M</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>NLRP3-mediated pyroptosis aggravates pressure overload-induced cardiac hypertrophy, fibrosis, and dysfunction in mice: cardioprotective role of irisin</article-title>. <source>Cell Death Discovery</source>. (<year>2021</year>) <volume>7</volume>:<fpage>50</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41420-021-00434-y</pub-id>
</citation>
</ref>
<ref id="B149">
<label>149</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fang</surname> <given-names>G</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>T</given-names>
</name>
<name>
<surname>Qiu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Amentoflavone mitigates doxorubicin-induced cardiotoxicity by suppressing cardiomyocyte pyroptosis and inflammation through inhibition of the STING/NLRP3 signalling pathway</article-title>. <source>Phytomedicine</source>. (<year>2023</year>) <volume>117</volume>:<elocation-id>154922</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.phymed.2023.154922</pub-id>
</citation>
</ref>
<ref id="B150">
<label>150</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhai</surname> <given-names>J</given-names>
</name>
<name>
<surname>Tao</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Calycosin ameliorates doxorubicin-induced cardiotoxicity by suppressing oxidative stress and inflammation via the sirtuin 1-NOD-like receptor protein 3 pathway</article-title>. <source>Phytother Res</source>. (<year>2020</year>) <volume>34</volume>:<page-range>649&#x2013;59</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/ptr.6557</pub-id>
</citation>
</ref>
<ref id="B151">
<label>151</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>F</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Gentiopicroside alleviates acute myocardial infarction injury in rats by disrupting Nrf2/NLRP3 signaling</article-title>. <source>Exp Biol Med (Maywood)</source>. (<year>2023</year>) <volume>248</volume>:<page-range>1254&#x2013;66</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/15353702231199076</pub-id>
</citation>
</ref>
<ref id="B152">
<label>152</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>M</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>W</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>H</given-names>
</name>
<name>
<surname>He</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Celastrol relieves myocardial infarction-induced cardiac fibrosis by inhibiting NLRP3 inflammasomes in rats</article-title>. <source>Int Immunopharmacol</source>. (<year>2023</year>) <volume>121</volume>:<elocation-id>110511</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.intimp.2023.110511</pub-id>
</citation>
</ref>
<ref id="B153">
<label>153</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Meng</surname> <given-names>H</given-names>
</name>
<name>
<surname>Aa</surname> <given-names>N</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Muscone improves cardiac function in mice after myocardial infarction by alleviating cardiac macrophage-mediated chronic inflammation through inhibition of NF-kappaB and NLRP3 inflammasome</article-title>. <source>Am J Transl Res</source>. (<year>2018</year>) <volume>10</volume>:<page-range>4235&#x2013;46</page-range>.</citation>
</ref>
<ref id="B154">
<label>154</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname> <given-names>RF</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xiang</surname> <given-names>HY</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Lv</surname> <given-names>CY</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>XL</given-names>
</name>
<etal/>
</person-group>. <article-title>The covalent NLRP3-inflammasome inhibitor Oridonin relieves myocardial infarction induced myocardial fibrosis and cardiac remodeling in mice</article-title>. <source>Int Immunopharmacol</source>. (<year>2021</year>) <volume>90</volume>:<elocation-id>107133</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.intimp.2020.107133</pub-id>
</citation>
</ref>
<ref id="B155">
<label>155</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>C</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>A</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Oridonin attenuates myocardial ischemia/reperfusion injury via downregulating oxidative stress and NLRP3 inflammasome pathway in mice</article-title>. <source>Evid Based Complement Alternat Med</source>. (<year>2020</year>) <volume>2020</volume>:<elocation-id>7395187</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2020/7395187</pub-id>
</citation>
</ref>
<ref id="B156">
<label>156</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>D</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>K</given-names>
</name>
<name>
<surname>Li</surname> <given-names>F</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Pu</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Sweroside alleviates pressure overload-induced heart failure through targeting CaMKIIdelta to inhibit ROS-mediated NF-kappaB/NLRP3 in cardiomyocytes</article-title>. <source>Redox Biol</source>. (<year>2024</year>) <volume>74</volume>:<elocation-id>103223</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.redox.2024.103223</pub-id>
</citation>
</ref>
<ref id="B157">
<label>157</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>G</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Sweroside protects against myocardial ischemia-reperfusion injury by inhibiting oxidative stress and pyroptosis partially via modulation of the keap1/nrf2 axis</article-title>. <source>Front Cardiovasc Med</source>. (<year>2021</year>) <volume>8</volume>:<elocation-id>650368</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcvm.2021.650368</pub-id>
</citation>
</ref>
<ref id="B158">
<label>158</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>H</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>DH</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>F</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>F</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Geniposide suppresses NLRP3 inflammasome-mediated pyroptosis <italic>via</italic> the AMPK signaling pathway to mitigate myocardial ischemia/reperfusion injury</article-title>. <source>Chin Med</source>. (<year>2022</year>) <volume>17</volume>:<fpage>73</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13020-022-00616-5</pub-id>
</citation>
</ref>
<ref id="B159">
<label>159</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>W</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>P</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Loganin alleviates myocardial ischemia-reperfusion injury through GLP-1R/NLRP3-mediated pyroptosis pathway</article-title>. <source>Environ Toxicol</source>. (<year>2023</year>) <volume>38</volume>:<page-range>2730&#x2013;40</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/tox.23908</pub-id>
</citation>
</ref>
<ref id="B160">
<label>160</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Cao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Artemisinin suppresses myocardial ischemia-reperfusion injury via NLRP3 inflammasome mechanism</article-title>. <source>Mol Cell Biochem</source>. (<year>2020</year>) <volume>474</volume>:<page-range>171&#x2013;80</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s11010-020-03842-3</pub-id>
</citation>
</ref>
<ref id="B161">
<label>161</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Cai</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>Betulin alleviates myocardial ischemia-reperfusion injury in rats via regulating the siti1/NLRP3/NF-kappaB signaling pathway</article-title>. <source>Inflammation</source>. (<year>2021</year>) <volume>44</volume>:<page-range>1096&#x2013;107</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10753-020-01405-8</pub-id>
</citation>
</ref>
<ref id="B162">
<label>162</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>R</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>K</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Triptolide attenuates pressure overload-induced myocardial remodeling in mice via the inhibition of NLRP3 inflammasome expression</article-title>. <source>Biochem Biophys Res Commun</source>. (<year>2017</year>) <volume>485</volume>:<fpage>69</fpage>&#x2013;<lpage>75</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbrc.2017.02.021</pub-id>
</citation>
</ref>
<ref id="B163">
<label>163</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pan</surname> <given-names>XC</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Cen</surname> <given-names>YY</given-names>
</name>
<name>
<surname>Xiong</surname> <given-names>YL</given-names>
</name>
<name>
<surname>Li</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Ding</surname> <given-names>YY</given-names>
</name>
<etal/>
</person-group>. <article-title>Dual role of triptolide in interrupting the NLRP3 inflammasome pathway to attenuate cardiac fibrosis</article-title>. <source>Int J Mol Sci</source>. (<year>2019</year>) <volume>20</volume>:<fpage>360</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms20020360</pub-id>
</citation>
</ref>
<ref id="B164">
<label>164</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname> <given-names>B</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>J</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>N</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>C</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>Q</given-names>
</name>
</person-group>. <article-title>Ginsenoside Rg3 attenuates angiotensin II-induced myocardial hypertrophy through repressing NLRP3 inflammasome and oxidative stress via modulating SIRT1/NF-kappaB pathway</article-title>. <source>Int Immunopharmacol</source>. (<year>2021</year>) <volume>98</volume>:<elocation-id>107841</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.intimp.2021.107841</pub-id>
</citation>
</ref>
<ref id="B165">
<label>165</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Guan</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Q</given-names>
</name>
<etal/>
</person-group>. <article-title>Ginsenoside Rb1 ameliorates heart failure through DUSP-1-TMBIM-6-mediated mitochondrial quality control and gut flora interactions</article-title>. <source>Phytomedicine</source>. (<year>2024</year>) <volume>132</volume>:<elocation-id>155880</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.phymed.2024.155880</pub-id>
</citation>
</ref>
<ref id="B166">
<label>166</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>H</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>G</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>X</given-names>
</name>
</person-group>. <article-title>Ginsenoside Rb1 ameliorates cardiotoxicity triggered by aconitine via inhibiting calcium overload and pyroptosis</article-title>. <source>Phytomedicine</source>. (<year>2021</year>) <volume>83</volume>:<elocation-id>153468</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.phymed.2021.153468</pub-id>
</citation>
</ref>
<ref id="B167">
<label>167</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname> <given-names>M</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>D</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Tao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Ginsenoside Rg1 attenuates cardiomyocyte apoptosis and inflammation via the TLR4/NF-kB/NLRP3 pathway</article-title>. <source>J Cell Biochem</source>. (<year>2020</year>) <volume>121</volume>:<fpage>2994</fpage>&#x2013;<lpage>3004</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jcb.29556</pub-id>
</citation>
</ref>
<ref id="B168">
<label>168</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname> <given-names>T</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>ZB</given-names>
</name>
<name>
<surname>Tong</surname> <given-names>ZY</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Chai</surname> <given-names>XP</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>XZ</given-names>
</name>
</person-group>. <article-title>Shikonin ameliorates LPS-induced cardiac dysfunction by SIRT1-dependent inhibition of NLRP3 inflammasome</article-title>. <source>Front Physiol</source>. (<year>2020</year>) <volume>11</volume>:<elocation-id>570441</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fphys.2020.570441</pub-id>
</citation>
</ref>
<ref id="B169">
<label>169</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gal</surname> <given-names>R</given-names>
</name>
<name>
<surname>Deres</surname> <given-names>L</given-names>
</name>
<name>
<surname>Horvath</surname> <given-names>O</given-names>
</name>
<name>
<surname>Eros</surname> <given-names>K</given-names>
</name>
<name>
<surname>Sandor</surname> <given-names>B</given-names>
</name>
<name>
<surname>Urban</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Resveratrol improves heart function by moderating inflammatory processes in patients with systolic heart failure</article-title>. <source>Antioxidants (Basel)</source>. (<year>2020</year>) <volume>9</volume>:<fpage>1108</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/antiox9111108</pub-id>
</citation>
</ref>
<ref id="B170">
<label>170</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname> <given-names>H</given-names>
</name>
<name>
<surname>Mou</surname> <given-names>SQ</given-names>
</name>
<name>
<surname>Li</surname> <given-names>WJ</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>N</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>ZY</given-names>
</name>
<name>
<surname>Ding</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Resveratrol inhibits ischemia-induced myocardial senescence signals and NLRP3 inflammasome activation</article-title>. <source>Oxid Med Cell Longev</source>. (<year>2020</year>) <volume>2020</volume>:<elocation-id>2647807</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2020/2647807</pub-id>
</citation>
</ref>
<ref id="B171">
<label>171</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Resveratrol targets AKT1 to inhibit inflammasome activation in cardiomyocytes under acute sympathetic stress</article-title>. <source>Front Pharmacol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>818127</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fphar.2022.818127</pub-id>
</citation>
</ref>
<ref id="B172">
<label>172</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zuo</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Pan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Salvianolic acid B alleviates myocardial ischemia injury by suppressing NLRP3 inflammasome activation via SIRT1-AMPK-PGC-1alpha signaling pathway</article-title>. <source>Cardiovasc Toxicol</source>. (<year>2022</year>) <volume>22</volume>:<page-range>842&#x2013;57</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12012-022-09760-8</pub-id>
</citation>
</ref>
<ref id="B173">
<label>173</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Pan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Salvianolic acid B alleviates myocardial ischemic injury by promoting mitophagy and inhibiting activation of the NLRP3 inflammasome</article-title>. <source>Mol Med Rep</source>. (<year>2020</year>) <volume>22</volume>:<page-range>5199&#x2013;208</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3892/mmr.2020.11589</pub-id>
</citation>
</ref>
<ref id="B174">
<label>174</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>H</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Song</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Cichoric acid improves isoproterenol-induced myocardial fibrosis via inhibition of HK1/NLRP3 inflammasome-mediated signaling pathways by reducing oxidative stress, inflammation, and apoptosis</article-title>. <source>Food Sci Nutr</source>. (<year>2024</year>) <volume>12</volume>:<page-range>180&#x2013;91</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/fsn3.3758</pub-id>
</citation>
</ref>
<ref id="B175">
<label>175</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Qiu</surname> <given-names>P</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zha</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Curcumin suppresses doxorubicin-induced cardiomyocyte pyroptosis <italic>via</italic> a PI3K/Akt/mTOR-dependent manner</article-title>. <source>Cardiovasc Diagn Ther</source>. (<year>2020</year>) <volume>10</volume>:<page-range>752&#x2013;69</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.21037/cdt-19-707</pub-id>
</citation>
</ref>
<ref id="B176">
<label>176</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joshi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kundu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Priya</surname> <given-names>VV</given-names>
</name>
<name>
<surname>Kulhari</surname> <given-names>U</given-names>
</name>
<name>
<surname>Mugale</surname> <given-names>MN</given-names>
</name>
<name>
<surname>Sahu</surname> <given-names>BD</given-names>
</name>
</person-group>. <article-title>Anti-inflammatory activity of carvacrol protects the heart from lipopolysaccharide-induced cardiac dysfunction by inhibiting pyroptosis via NLRP3/Caspase1/Gasdermin D signaling axis</article-title>. <source>Life Sci</source>. (<year>2023</year>) <volume>324</volume>:<elocation-id>121743</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.lfs.2023.121743</pub-id>
</citation>
</ref>
<ref id="B177">
<label>177</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chai</surname> <given-names>R</given-names>
</name>
<name>
<surname>Ye</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Xue</surname> <given-names>W</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Tanshinone IIA inhibits cardiomyocyte pyroptosis through TLR4/NF-kappaB p65 pathway after acute myocardial infarction</article-title>. <source>Front Cell Dev Biol</source>. (<year>2023</year>) <volume>11</volume>:<elocation-id>1252942</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcell.2023.1252942</pub-id>
</citation>
</ref>
<ref id="B178">
<label>178</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qiu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Lan</surname> <given-names>T</given-names>
</name>
<name>
<surname>Pan</surname> <given-names>W</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Salvianolate reduces atrial fibrillation through suppressing atrial interstitial fibrosis by inhibiting TGF-beta1/Smad2/3 and TXNIP/NLRP3 inflammasome signaling pathways in post-MI rats</article-title>. <source>Phytomedicine</source>. (<year>2018</year>) <volume>51</volume>:<page-range>255&#x2013;65</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.phymed.2018.09.238</pub-id>
</citation>
</ref>
<ref id="B179">
<label>179</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ye</surname> <given-names>B</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Dai</surname> <given-names>S</given-names>
</name>
<name>
<surname>Han</surname> <given-names>J</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Emodin alleviates myocardial ischemia/reperfusion injury by inhibiting gasdermin D-mediated pyroptosis in cardiomyocytes</article-title>. <source>Drug Des Devel Ther</source>. (<year>2019</year>) <volume>13</volume>:<page-range>975&#x2013;90</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2147/DDDT.S195412</pub-id>
</citation>
</ref>
<ref id="B180">
<label>180</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ye</surname> <given-names>B</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>L</given-names>
</name>
<name>
<surname>Hong</surname> <given-names>G</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>G</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>Z</given-names>
</name>
</person-group>. <article-title>Emodin alleviates LPS-induced myocardial injury through inhibition of NLRP3 inflammasome activation</article-title>. <source>Phytother Res</source>. (<year>2021</year>) <volume>35</volume>:<page-range>5203&#x2013;13</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/ptr.7191</pub-id>
</citation>
</ref>
<ref id="B181">
<label>181</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>P</given-names>
</name>
<name>
<surname>An</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Mao</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Prevention of endotoxin-induced cardiomyopathy using sodium tanshinone IIA sulfonate: Involvement of augmented autophagy and NLRP3 inflammasome suppression</article-title>. <source>Eur J Pharmacol</source>. (<year>2021</year>) <volume>909</volume>:<elocation-id>174438</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ejphar.2021.174438</pub-id>
</citation>
</ref>
<ref id="B182">
<label>182</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname> <given-names>B</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Beta-asarone alleviates myocardial ischemia-reperfusion injury by inhibiting inflammatory response and NLRP3 inflammasome mediated pyroptosis</article-title>. <source>Biol Pharm Bull</source>. (<year>2020</year>) <volume>43</volume>:<page-range>1046&#x2013;51</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1248/bpb.b19-00926</pub-id>
</citation>
</ref>
<ref id="B183">
<label>183</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luan</surname> <given-names>F</given-names>
</name>
<name>
<surname>Lei</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>X</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>L</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>L</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Cardioprotective effect of cinnamaldehyde pretreatment on ischemia/ reperfusion injury via inhibiting NLRP3 inflammasome activation and gasdermin D mediated cardiomyocyte pyroptosis</article-title>. <source>Chem Biol Interact</source>. (<year>2022</year>) <volume>368</volume>:<elocation-id>110245</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cbi.2022.110245</pub-id>
</citation>
</ref>
<ref id="B184">
<label>184</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname> <given-names>XN</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>LY</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>SY</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>YH</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>SB</given-names>
</name>
<etal/>
</person-group>. <article-title>Aesculin suppresses the NLRP3 inflammasome-mediated pyroptosis via the Akt/GSK3beta/NF-kappaB pathway to mitigate myocardial ischemia/reperfusion injury</article-title>. <source>Phytomedicine</source>. (<year>2021</year>) <volume>92</volume>:<elocation-id>153687</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.phymed.2021.153687</pub-id>
</citation>
</ref>
<ref id="B185">
<label>185</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luan</surname> <given-names>F</given-names>
</name>
<name>
<surname>Rao</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>L</given-names>
</name>
<name>
<surname>Lei</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>J</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Cinnamic acid preserves against myocardial ischemia/reperfusion injury via suppression of NLRP3/Caspase-1/GSDMD signaling pathway</article-title>. <source>Phytomedicine</source>. (<year>2022</year>) <volume>100</volume>:<elocation-id>154047</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.phymed.2022.154047</pub-id>
</citation>
</ref>
<ref id="B186">
<label>186</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname> <given-names>W</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Lyu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>P</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Li</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Gastrodin ameliorates microvascular reperfusion injury-induced pyroptosis by regulating the NLRP3/caspase-1 pathway</article-title>. <source>J Physiol Biochem</source>. (<year>2019</year>) <volume>75</volume>:<page-range>531&#x2013;47</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s13105-019-00702-7</pub-id>
</citation>
</ref>
<ref id="B187">
<label>187</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname> <given-names>HS</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Qu</surname> <given-names>JF</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>YJ</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>ZY</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>FY</given-names>
</name>
<etal/>
</person-group>. <article-title>Panaxynol ameliorates cardiac ischemia/reperfusion injury by suppressing NLRP3-induced pyroptosis and apoptosis via HMGB1/TLR4/NF-kappaB axis</article-title>. <source>Int Immunopharmacol</source>. (<year>2023</year>) <volume>121</volume>:<elocation-id>110222</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.intimp.2023.110222</pub-id>
</citation>
</ref>
<ref id="B188">
<label>188</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peng</surname> <given-names>L</given-names>
</name>
<name>
<surname>Lei</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Rao</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>L</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Cardioprotective activity of ethyl acetate extract of Cinnamomi Ramulus against myocardial ischemia/reperfusion injury in rats via inhibiting NLRP3 inflammasome activation and pyroptosis</article-title>. <source>Phytomedicine</source>. (<year>2021</year>) <volume>93</volume>:<elocation-id>153798</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.phymed.2021.153798</pub-id>
</citation>
</ref>
</ref-list>
<glossary>
<title>Glossary</title>
<def-list>
<def-item>
<term>Akt</term>
<def>
<p>serine/threonine protein kinase B</p>
</def>
</def-item>
<def-item>
<term>AMI</term>
<def>
<p>acute myocardial infarction</p>
</def>
</def-item>
<def-item>
<term>AMPK</term>
<def>
<p>adenosine 5&#x2019;-monophosphate (AMP)-activated protein kinase</p>
</def>
</def-item>
<def-item>
<term>AMVMs</term>
<def>
<p>adult mouse ventricular myocytes</p>
</def>
</def-item>
<def-item>
<term>Ang II</term>
<def>
<p>angiotensin II</p>
</def>
</def-item>
<def-item>
<term>ASC</term>
<def>
<p>apoptosis speck-like protein containing a caspase recruitment domain</p>
</def>
</def-item>
<def-item>
<term>As-IV</term>
<def>
<p>Astragaloside IV</p>
</def>
</def-item>
<def-item>
<term>&#x3b1;-SMA</term>
<def>
<p>&#x3b1;-smooth muscle actin</p>
</def>
</def-item>
<def-item>
<term>ATP</term>
<def>
<p>adenosine triphosphate</p>
</def>
</def-item>
<def-item>
<term>BMDMs</term>
<def>
<p>bone marrow-derived macrophages</p>
</def>
</def-item>
<def-item>
<term>CARD</term>
<def>
<p>caspase activation and recruitment domain</p>
</def>
</def-item>
<def-item>
<term>CFs</term>
<def>
<p>cardiac fibroblasts</p>
</def>
</def-item>
<def-item>
<term>CMECs</term>
<def>
<p>cardiac microvascular endothelial cells</p>
</def>
</def-item>
<def-item>
<term>H/R</term>
<def>
<p>hypoxia/reoxygenation</p>
</def>
</def-item>
<def-item>
<term>Cx43</term>
<def>
<p>Connexin 43</p>
</def>
</def-item>
<def-item>
<term>DCM</term>
<def>
<p>dilated cardiomyopathy</p>
</def>
</def-item>
<def-item>
<term>DOX</term>
<def>
<p>Doxorubicin</p>
</def>
</def-item>
<def-item>
<term>ECM</term>
<def>
<p>Extracellular matrix</p>
</def>
</def-item>
<def-item>
<term>ECs</term>
<def>
<p>endothelial cells</p>
</def>
</def-item>
<def-item>
<term>GSDMD</term>
<def>
<p>gasderminD</p>
</def>
</def-item>
<def-item>
<term>GSDMD-NT</term>
<def>
<p>GSDMD N-terminal</p>
</def>
</def-item>
<def-item>
<term>HCMs</term>
<def>
<p>human cardiomyocytes</p>
</def>
</def-item>
<def-item>
<term>HF</term>
<def>
<p>heart failure</p>
</def>
</def-item>
<def-item>
<term>HFpEF</term>
<def>
<p>heart failure with preserved ejection fraction</p>
</def>
</def-item>
<def-item>
<term>HK1</term>
<def>
<p>hexokinase 1</p>
</def>
</def-item>
<def-item>
<term>HUVECs</term>
<def>
<p>human umbilical vein endothelial cells</p>
</def>
</def-item>
<def-item>
<term>IFN&#x2010;&#x3b3;</term>
<def>
<p>interferon-gamma</p>
</def>
</def-item>
<def-item>
<term>IL</term>
<def>
<p>interleukin</p>
</def>
</def-item>
<def-item>
<term>ISO</term>
<def>
<p>isoproterenol</p>
</def>
</def-item>
<def-item>
<term>KI</term>
<def>
<p>knock-in</p>
</def>
</def-item>
<def-item>
<term>KO</term>
<def>
<p>knockout</p>
</def>
</def-item>
<def-item>
<term>K<sup>+</sup>
</term>
<def>
<p>potassium ion</p>
</def>
</def-item>
<def-item>
<term>LADCA</term>
<def>
<p>left anterior descending coronary artery</p>
</def>
</def-item>
<def-item>
<term>LCA</term>
<def>
<p>left coronary artery</p>
</def>
</def-item>
<def-item>
<term>LPS</term>
<def>
<p>lipopolysaccharide</p>
</def>
</def-item>
<def-item>
<term>LRR</term>
<def>
<p>leucine rich repeat</p>
</def>
</def-item>
<def-item>
<term>MAPK</term>
<def>
<p>mitogen-activated protein kinase</p>
</def>
</def-item>
<def-item>
<term>MCFs</term>
<def>
<p>mouse cardiac fibroblasts</p>
</def>
</def-item>
<def-item>
<term>MCP-1</term>
<def>
<p>monocyte chemoattractant protein-1</p>
</def>
</def-item>
<def-item>
<term>MI</term>
<def>
<p>myocardial infarction</p>
</def>
</def-item>
<def-item>
<term>MI/R</term>
<def>
<p>myocardial ischemia/reperfusion</p>
</def>
</def-item>
<def-item>
<term>mtROS</term>
<def>
<p>mitochondrial reactive oxygen species</p>
</def>
</def-item>
<def-item>
<term>mtDNA</term>
<def>
<p>mitochondrial DNA</p>
</def>
</def-item>
<def-item>
<term>MyD88</term>
<def>
<p>myeloid differentiation primary response protein 88</p>
</def>
</def-item>
<def-item>
<term>NF-&#x3ba;B</term>
<def>
<p>nuclear factor-&#x3ba;B</p>
</def>
</def-item>
<def-item>
<term>NLRP3</term>
<def>
<p>NOD-like receptor protein 3</p>
</def>
</def-item>
<def-item>
<term>NMCMs</term>
<def>
<p>neonatal mouse cardiomyocytes</p>
</def>
</def-item>
<def-item>
<term>NMVMs</term>
<def>
<p>neonatal mouse ventricular cardiomyocytes</p>
</def>
</def-item>
<def-item>
<term>NRCFs</term>
<def>
<p>neonatal rat cardiac fibroblasts</p>
</def>
</def-item>
<def-item>
<term>NRCMs</term>
<def>
<p>neonatal rat cardiomyocytes;NRVMs, neonatal rat ventricular myocytes</p>
</def>
</def-item>
<def-item>
<term>OGD/R</term>
<def>
<p>oxygen-glucose deprivation/reoxygenation</p>
</def>
</def-item>
<def-item>
<term>OS</term>
<def>
<p>oxidative stress</p>
</def>
</def-item>
<def-item>
<term>pro-caspase-1</term>
<def>
<p>caspase-1 precursor</p>
</def>
</def-item>
<def-item>
<term>PYD</term>
<def>
<p>pyrin domain</p>
</def>
</def-item>
<def-item>
<term>P2X7R</term>
<def>
<p>P2X7 receptor</p>
</def>
</def-item>
<def-item>
<term>RV</term>
<def>
<p>right ventricular</p>
</def>
</def-item>
<def-item>
<term>SD</term>
<def>
<p>sprague dawley</p>
</def>
</def-item>
<def-item>
<term>SHRs</term>
<def>
<p>spontaneously hypertensive rats</p>
</def>
</def-item>
<def-item>
<term>SIRT</term>
<def>
<p>silent information regulator of transcription</p>
</def>
</def-item>
<def-item>
<term>TAC</term>
<def>
<p>transverse aortic constriction</p>
</def>
</def-item>
<def-item>
<term>TGF-&#x3b2;</term>
<def>
<p>transforming growth factor-&#x3b2;</p>
</def>
</def-item>
<def-item>
<term>TLR</term>
<def>
<p>toll-like receptor</p>
</def>
</def-item>
<def-item>
<term>TNF-&#x3b1;</term>
<def>
<p>tumor necrosis factor-&#x3b1;;VAs, ventricular arrhythmias</p>
</def>
</def-item>
<def-item>
<term>WKY</term>
<def>
<p>Wistar-Kyoto</p>
</def>
</def-item>
<def-item>
<term>WT</term>
<def>
<p>wild type.</p>
</def>
</def-item>
</def-list>
</glossary>
</back>
</article>